hosted by
publicationslist.org
    

Hans J Schlitt


hans.schlitt@klinik.uni-regensburg.de

Journal articles

2011
I Iesalnieks, S Deimel, K Kienle, H J Schlitt, C Zülke (2011)  [Pit-picking surgery for pilonidal disease].   Chirurg 82: 10. 927-931 Oct  
Abstract: The pit-picking method was first described by J. Bascom in 1980, however, this minimally invasive technique is used only by a minority of surgeons yet.
Notes:
Karl-Hermann Schlingensiepen, Frank Jaschinski, Sven Arke Lang, Christian Moser, Edward Kenneth Geissler, Hans Jürgen Schlitt, Marcus Kielmanowicz, Anneliese Schneider (2011)  Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.   Cancer Sci 102: 6. 1193-1200 Jun  
Abstract: Pancreatic cancer is one of the most aggressive human cancers with a 5-year survival rate of <5%. Overexpression of transforming growth factor-beta 2 (TGF-β2) in pancreatic malignancies is suggested to be a pivotal factor for malignant progression by inducing immunosuppression, metastasis, angiogenesis and proliferation. Trabedersen (AP 12009) is a phosphorothioate antisense oligodeoxynucleotide specific for human TGF-β2 mRNA and was successfully tested in a randomized, active-controlled phase IIb clinical study in patients with high-grade glioma. Here, we report on the antitumor activity of trabedersen in human pancreatic cancer cells and in an orthotopic xenograft mouse model of human metastatic pancreatic cancer. Trabedersen reduced TGF-β2 secretion in human pancreatic cell lines with an IC50 in the low μM range without transfection reagent, clearly inhibited cell proliferation, and completely blocked migration of pancreatic cancer cells. Additionally, trabedersen reversed TGF-β2-mediated immunosuppression of pancreatic cancer cells targeted by lymphokine activated killer (LAK) cells, resulting in considerably increased LAK cell-mediated cytotoxicity. Moreover, in an orthotopic mouse model of metastatic pancreatic cancer, intraperitoneal (i.p.) treatment with trabedersen significantly reduced tumor growth, lymph node metastasis and angiogenesis. These promising results warrant further clinical development of trabedersen.
Notes:
V Benseler, H J Schlitt (2011)  [The liver as an immunological organ].   Z Gastroenterol 49: 1. 54-62 Jan  
Abstract: In many species, liver transplants induce antigen-specific immunological tolerance. Furthermore, the liver seems to play an important role in oral tolerance although the exact mechanisms as to how the liver induces immunological tolerance still need to be defined. Apart from the presence of an unusual subset of effector cells of the innate immune system, the liver is rich in CD 8+ T cells with an activated and preapoptotic phenotype. In this article, we discuss the suggested hypothesis to explain this phenotype. In addition, we discuss the different cell types that have been suggested to serve as antigen-presenting cells (APC) for naïve T cells. Interestingly, different APCs seem to use different mechanisms to induce tolerance while hepatic stellate cells were reported to induce an effective immune response.
Notes:
Thomas Bein, Markus Zimmermann, Alois Philipp, Michael Ramming, Barbara Sinner, Christof Schmid, Thomas Müller, Bernhard Graf, Hans Jürgen Schlitt, Steffen Weber-Carstens (2011)  Addition of acetylsalicylic acid to heparin for anticoagulation management during pumpless extracorporeal lung assist.   ASAIO J 57: 3. 164-168 May/Jun  
Abstract: Pump-driven extracorporeal membrane oxygenation (ECMO) or pumpless arterio-venous interventional lung assist (iLA) is associated with possible complications, mainly consisting of bleeding or thrombosis/clotting by cellular deposits on the membrane or extracorporeal circuit surfaces, which may reduce gas-exchange capacity. In this study, we report our experiences with the addition of low-dose acetylsalicylic acid (ASA 1.5 mg/kg body weight/d) to heparin for anticoagulation of a pumpless low-resistance gas-exchange membrane (Novalung GmbH, Talheim, Germany). We assessed changes in coagulation parameters and the demand for transfusion of blood components. Furthermore, we compared the function of the artificial membranes (oxygen transfer and capacity of CO2 removal) of the ASA group (n = 15) with that of a matched-pair control group treated with heparin alone. The mean duration of iLA treatment was 6.6 ± 3.7 days. The addition of ASA did not increase bleeding activity or the demand for transfusion. Relative changes of CO2 removal on day 3 expressed as a percentage in the ASA group were (mean value) -11.8% in comparison with control (-3.0%, p = 0.266), but the relative amount of oxygen transfer tended to be increased in the ASA group (+3.9%) and to be decreased in the control group (-14.7%, p = 0.214). PaO2/FiO2 ratio was significantly improved in the ASA group compared with the control group at day 5. The use of membranes per patient (membrane/patient ratio) tended to be decreased in patients treated with ASA (1.12 ± 0.34) in comparison with control (1.33 ± 0.62, p = 0.157). In the ASA group, one patient died due to multiple organ failure, whereas in the control group, five patients died. We conclude that supplementation of low-dose ASA during pumpless extracorporeal lung support is safe and might preserve the function of oxygen transfer.
Notes:
Andreas A Schnitzbauer, Hans J Schlitt, Edward K Geissler (2011)  Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence.   Transplantation 91: 11. 1173-1176 Jun  
Abstract: Effects of immunosuppressive drug on tumor development in transplantation are understudied. Tumors are especially concerning when liver transplantation recipients have a pretransplant hepatocellular carcinoma (HCC). Because immunosuppressive drugs likely influence HCC recurrence, with mammalian target of rapamycin inhibitors showing antineoplastic properties especially experimentally, we sought for practical medical guidance from published clinical studies. Although the current literature review revealed 14 studies regarding immunosuppression in this context, suggesting antitumor effects for mammalian target of rapamycin inhibitors, the quality of evidence is low. Therefore, randomized controlled trials investigating effects of immunosuppression on HCC recurrence in liver transplantation are lacking, exposing a gap between basic science knowledge and clinical evidence.
Notes:
Thomas Bohrer, Michael Koller, Hans Juergen Schlitt, Hartwig Bauer (2011)  Workload and quality of life of surgeons. Results and implications of a large-scale survey by the German Society of Surgery.   Langenbecks Arch Surg 396: 5. 669-676 Jun  
Abstract: Quality of life is of vital importance for patients undergoing surgery. However, little is known about the quality of life of surgeons who are facing a stressful and dramatically changing working environment. For this reason, this large-scale study investigated the quality of life (QL) of surgeons in Germany in the context of occupational, private, and system-related risk factors.
Notes:
H J Schlitt, M Loss, M N Scherer, T Becker, K - W Jauch, B Nashan, H Schmidt, U Settmacher, X Rogiers, P Neuhaus, C Strassburg (2011)  [Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres].   Z Gastroenterol 49: 1. 30-38 Jan  
Abstract: Liver transplantation represents a successful and well-established therapeutic concept for patients with advanced liver diseases. Organ donor shortage continues to pose a significant problem. To ensure fair and transparent allocation of too few post-mortem grafts, the model of end-stage liver disease (MELD)-based allocation was implemented in December 2006. This has decreased waiting list mortality from 20 to 10 % but at the same time has reduced post OLT survival (1-year survival from almost 90% to below 80%), which is largely due to patients with a labMELD score > 30. Following MELD introduction the regular allocation threshold has increased from a matchMELD of initially 25 to meanwhile 34. At the same time the quality of donor organs has seen a continuous deterioration over the last 10 - 15 years: 63% of organs are "suboptimal" with a donor risk index of > 1.5. Moreover, the numbers of living-related liver transplantations have decreased. In Germany incentives for transplant centres are inappropriate: patients with decompensated cirrhosis, high MELD scores and high post-transplant mortality as well as marginal liver grafts are accepted for transplantation without the necessary consideration of outcomes, and against a background of the still absent publication and transparency of outcome results. The outlined development calls for measures for improvement: (i) the increase of donor grafts (e. g., living donation, opt-out solutions, non-heart beating donors), (ii) the elimination of inappropriate incentives for transplant centres, (iii) changes of allocation guidelines, that take the current situation and suboptimal donor grafts into account, and (iv) the systematic and complete collection of transplant-related data in order to allow for the development of improved prognostic scores.
Notes:
E Eggenhofer, J F Steinmann, P Renner, P Slowik, P Piso, E K Geissler, H J Schlitt, M H Dahlke, F C Popp (2011)  Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts.   Transpl Immunol 24: 3. 157-163 Apr  
Abstract: Donor-derived mesenchymal stem cells (MSC) can induce long-term acceptance in a rat heart transplantation model when injected prior to transplantation in combination with mycophenolate mofetil (MMF). In contrast, MSC alone cause accelerated graft rejection. To better understand these conflicting data we studied the effects of MSC and MMF on lymphocyte populations in heart allografts and secondary lymphatic organs. Allogeneic MSC injected prior to transplantation are immunogenic in this model because activated CD4+ and CD8+ cells emerged earlier in secondary lymphatic organs of MSC- and MSC/MMF-treated animals, compared to animals not treated with MSC. Consequently T cells infiltrated the grafts of MSC-only treated animals promptly causing accelerated graft rejection. However, few T cells or antigen-presenting cells (APC) infiltrated the grafts of animals treated with MSC and MMF. Consistent with this finding, intercellular adhesion molecule 1 (ICAM-1) and E-selectin was down-regulated exclusively in MSC/MMF-treated grafts, indicating that MSC together with MMF interfere with endothelial activation. Additionally, the presence of interferon-gamma (IFN-γ) enhanced MSC capabilities to suppress T cell proliferation in vitro. Interestingly, MMF did not influence serum IFN-γ levels in vivo. Together, our data indicate that MSC pre-activate T cells, but co-treatment with MMF eliminates these T cells, decreases intragraft APC and T cell trafficking by inhibiting endothelial activation, and allows IFN-γ stimulation of suppressive MSC.
Notes:
Gabriel Glockzin, Philipp Renner, Felix C Popp, Marc H Dahlke, Philipp von Breitenbuch, Hans J Schlitt, Pompiliu Piso (2011)  Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.   Ann Surg Oncol 18: 4. 1052-1059 Apr  
Abstract: The long-term prognosis of patients with peritoneal malignancies has greatly improved since the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Nevertheless, CRS can be associated with high postoperative morbidity. In this retrospective study, we analyzed the influence of hepatobiliary surgery as part of CRS on postoperative short-term patient outcome.
Notes:
Tobias J Weismüller, Panagiotis Fikatas, Jan Schmidt, Ana P Barreiros, Gerd Otto, Susanne Beckebaum, Andreas Paul, Markus N Scherer, Hartmut H Schmidt, Hans J Schlitt, Peter Neuhaus, Jürgen Klempnauer, Johann Pratschke, Michael P Manns, Christian P Strassburg (2011)  Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept.   Transpl Int 24: 1. 91-99 Jan  
Abstract: Since the introduction of model for end-stage liver disease (MELD) in 2006, post-orthotopic liver transplantation (OLT) survival in Germany has declined. The aim of this study was to evaluate risk factors and prognostic scores for outcome. All adult OLT recipients in seven German transplant centers after MELD implementation (December 2006-December 2007) were included. Recipient data were analyzed for their influence on 1-year outcome. A total of 462 patients (mean calculated MELD = 20.5, follow-up: 1 year) were transplanted for alcoholic cirrhosis (33.1%), hepatocellular carcinoma (26.6%), Hepatitis-C (17.1%), Hepatitis-B (9.5%), primary sclerosing cholangitis (5.6%) and late graft-failure after first OLT before December 2006 (8.7%). 1-year patient survival was 75.8% (graft survival 71.2%) correlating with MELD parameters and serum choline esterase. MELD score >30 [odds ratio (OR) = 4.17, confidence interval: 2.57-6.78, 12-month survival = 52.6%, c-statistic = 0.669], hyponatremia (OR = 2.07), and pre-OLT hemodialysis (OR = 2.35) were the main death risk factors. In alcoholic cirrhosis (n = 153, mean MELD = 21.1) and hepatocellular carcinoma (n = 123, mean MELD = 13.5), serum bilirubin and the survival after liver transplantation score were independent outcome parameters, respectively. MELD >30 currently represents a major risk factor for outcome. Risk factors differ in individual patient subgroups. In the current German practice of organ allocation to sicker patients, outcome prediction should be considered to prevent results below acceptable standards.
Notes:
Igors Iesalnieks, Alexandra Kilger, Barbara Kalisch, Florian Obermeier, Hans J Schlitt, Ayman Agha (2011)  Treatment of the anastomotic complications in patients with Crohn's disease.   Int J Colorectal Dis 26: 2. 239-244 Feb  
Abstract: Postoperative anastomotic complications in patients with Crohn's disease undergoing bowel resections have a detrimental influence on the long-term outcome. The aim of this study was to evaluate whether patients' prognosis is affected by various treatment strategies of anastomotic complications.
Notes:
Tung Yu Tsui, Hans Jürgen Schlitt, Aiman Obed (2011)  Prospective evaluation of biliary reconstruction with duct-to-duct continuous suture in adult live donor liver transplantation.   Langenbecks Arch Surg 396: 2. 209-215 Feb  
Abstract: Biliary reconstruction remains the Achilles' heel of adult live donor liver transplantation (LDLT). The study aims to investigate the feasibility of duct-to-duct hepaticocholedochostomy in LDLT.
Notes:
Philipp Renner, Klaus Kienle, Marc H Dahlke, Peter Heiss, Karin Pfister, Christian Stroszczynski, Pompiliu Piso, Hans J Schlitt (2011)  Intestinal ischemia: current treatment concepts.   Langenbecks Arch Surg 396: 1. 3-11 Jan  
Abstract: Mesenteric ischemia is a condition well-known among physicians treating patients with abdominal symptoms. Even so, mortality rates have not decreased significantly over the last decades. The purpose of this article is to review current treatment concepts of acute and chronic mesenteric ischemia.
Notes:
Rania Dayoub, Hannah Wagner, Frauke Bataille, Oliver Stöltzing, Thilo Spruss, Christa Buechler, Hans-Jürgen Schlitt, Thomas S Weiss (2011)  Liver regeneration associated protein (ALR) exhibits antimetastatic potential in hepatocellular carcinoma.   Mol Med 17: 3-4. 221-228 Mar/Apr  
Abstract: Augmenter of liver regeneration (ALR), which is critically important in liver regeneration and hepatocyte proliferation, is highly expressed in cirrhotic livers and hepatocellular carcinomas (HCC). In the current study, the functional role of ALR in hepatocancerogenesis was analyzed in more detail. HepG2 cells, in which the cytosolic 15 kDa ALR isoform was reexpressed stably, (HepG2-ALR) were used in migration and invasion assays using modified Boyden chambers. Epithelial-mesenchymal transition (EMT) markers were determined in HepG2-ALR cells in vitro and in HepG2-ALR tumors grown in nude mice. ALR protein was quantified in HCC and nontumorous tissues by immunohistochemistry. HepG2-ALR, compared with HepG2 cells, demonstrated reduced cell motility and increased expression of the epithelial cell markers E-cadherin and Zona occludens-1 (ZO-1), whereas SNAIL, a negative regulator of E-cadherin, was diminished. Matrix metalloproteinase MMP1 and MMP3 mRNA expression and activity were reduced. HepG2-ALR cell-derived subcutaneously grown tumors displayed fewer necrotic areas, more epithelial-like cell growth and fewer polymorphisms and atypical mitotic figures than tumors derived from HepG2 cells. Analysis of tumor tissues of 53 patients with HCC demonstrated an inverse correlation of ALR protein with histological angioinvasion and grading. The 15 kDa ALR isoform was found mainly in HCC tissues without histological angioinvasion 0. In summary the present data indicate that cytosolic ALR reduces hepatoma cell migration, augments epithelial growth and, therefore, may act as an antimetastatic and EMT reversing protein.
Notes:
Janine Hartl, Marcus N Scherer, Martin Loss, Andreas Schnitzbauer, Stefan Farkas, Lucia Baier, Alexander Szecsey, Juergen Schoelmerich, Hans-Juergen Schlitt, Gabriele I Kirchner (2011)  Strong predictors for alcohol recidivism after liver transplantation: non-acceptance of the alcohol problem and abstinence of <3 months.   Scand J Gastroenterol 46: 10. 1257-1266 Oct  
Abstract: Alcohol-toxic liver cirrhosis (ALC) is one of the main indications for liver transplantation (LT). The aim of the study is to define predictors for alcohol recidivism and to identify the outcome and quality of life of such patients.
Notes:
Gabi I Kirchner, Marcus N Scherer, Aiman Obed, Petra Ruemmele, Reiner Wiest, Matthias Froh, Martin Loss, Hans-Juergen Schlitt, Juergen Schölmerich, Cornelia M Gelbmann (2011)  Outcome of patients with ischemic-like cholangiopathy with secondary sclerosing cholangitis after liver transplantation.   Scand J Gastroenterol 46: 4. 471-478 Apr  
Abstract: Sclerosing cholangitis in critically ill patients (SC-CIP) with sepsis and acute respiratory distress syndrome (ARDS) is a cholestatic liver disease with a rapid progression to liver cirrhosis and hepatic failure. Data on outcome of these patients after liver transplantation (LT) are sparse.
Notes:
Gabriela Schiechl, Bernhard Bauer, Ivan Fuss, Sven A Lang, Christian Moser, Petra Ruemmele, Stefan Rose-John, Markus F Neurath, Edward K Geissler, Hans-Jürgen Schlitt, Warren Strober, Stefan Fichtner-Feigl (2011)  Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages.   J Clin Invest 121: 5. 1692-1708 May  
Abstract: Patients with prolonged ulcerative colitis (UC) frequently develop colorectal adenocarcinoma for reasons that are not fully clear. To analyze inflammation-associated colonic tumorigenesis, we developed a chronic form of oxazolone-induced colitis in mice that, similar to UC, was distinguished by the presence of IL-13-producing NKT cells. In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production. Importantly, this subset of macrophages was a source of tumor-promoting factors, including IL-6. Similar to dextran sodium sulfate-induced colitis, F4/80+CD11b(high)Gr1(intermediate) macrophages were present in the mouse model of chronic oxazolone-induced colitis and may influence tumor development through production of TGF-β1, a cytokine that inhibits tumor immunosurveillance. Finally, while robust chronic oxazolone-induced colitis developed in myeloid differentiation primary response gene 88-deficient (Myd88-/-) mice, these mice did not support tumor development. The inhibition of tumor development in Myd88-/- mice correlated with cessation of IL-6 and TGF-β1 production by M2 and F4/80+CD11b(high)Gr1(intermediate) macrophages, respectively, and was reversed by exogenous IL-6. These data show that an UC-like inflammation may facilitate tumor development by providing a milieu favoring development of MyD88-dependent tumor-supporting macrophages.
Notes:
A A Schnitzbauer, P E Lamby, I Mutzbauer, J von Hassel, E K Geissler, H J Schlitt (2011)  [Challenges in the organization of investigator initiated trials: in transplantation medicine].   Chirurg 82: 3. 249-254 Mar  
Abstract: Transplantation medicine offers multiple translational questions which should preferably be transferred to clinical evidence. The current gold standard for testing such questions and hypotheses is by prospective randomized controlled trials (RCT). The trials should be performed independently from the medical industry to avoid conflicts of interests and to guarantee a strict scientific approach. A good model is an investigator initiated trial (IIT) in which academic institutions function as the sponsor and in which normally a scientific idea stands before marketing interests of a certain medical product.
Notes:
Matthias Hornung, Jens M Werner, Stefan Farkas, Hans J Schlitt, Edward K Geissler (2011)  Migration and chemokine receptor pattern of colitis-preventing DX5+NKT cells.   Int J Colorectal Dis 26: 11. 1423-1433 Nov  
Abstract: DX5(+)NKT cells are a subpopulation of NKT cells expressing both T cell receptor and NK cell markers that show an immune-regulating function. Transferred DX5(+)NKT cells from immune competent Balb/c mice can prevent or reduce induced colitis in severe combined immunodeficient (SCID) mice. Here, we investigated the in vivo migration of DX5(+)NKT cells and their corresponding chemokine receptor patterns.
Notes:
Jens M Werner, Corinna Lang, Marcus N Scherer, Stefan A Farkas, Edward K Geissler, Hans J Schlitt, Matthias Hornung (2011)  Distribution of intrahepatic T, NK and CD3(+)CD56(+)NKT cells alters after liver transplantation: Shift from innate to adaptive immunity?   Transpl Immunol 25: 1. 27-33 Jul  
Abstract: The liver is an immunological organ containing a large number of T, NK and NKT cells, but little is known about intrahepatic immunity after LTx. Here, we investigated whether the distribution of T, NK and CD3(+)CD56(+)NKT cells is altered in transplanted livers under different circumstances.
Notes:
Jens M Werner, Elisabeth Busl, Stefan A Farkas, Hans J Schlitt, Edward K Geissler, Matthias Hornung (2011)  DX5+NKT cells display phenotypical and functional differences between spleen and liver as well as NK1.1-Balb/c and NK1.1+ C57Bl/6 mice.   BMC Immunol 12: 04  
Abstract: Natural killer T cells represent a linkage between innate and adaptive immunity. They are a heterogeneous population of specialized T lymphocytes composed of different subsets. DX5+NKT cells are characterized by expression of the NK cell marker DX5 in the context of CD3. However, little is known about the phenotype and functional capacity of this unique cell population. Therefore, we investigated the expression of several T cell and NK cell markers, as well as functional parameters in spleen and liver subsets of DX5+NKT cells in NK1.1- Balb/c mice and compared our findings to NK1.1+ C57Bl/6 mice.
Notes:
Hans J Schlitt, Andreas A Schnitzbauer (2011)  Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment.   Liver Transpl 17 Suppl 3: S10-S12 Nov  
Abstract: Key Points: 1. Adjuvant/neoadjuvant chemotherapy. 2. Neoadjuvant transarterial chemoembolization. 3. Kinase inhibitors (eg, sorafenib). 4. Antiviral treatment. 5.Immunosuppressive treatment after liver transplantation. 6. Disseminated tumor cells: the basis for innovative treatment options?
Notes:
Christina Hackl, Michael Gerken, Martin Loss, Monika Klinkhammer-Schalke, Pompiliu Piso, Hans J Schlitt (2011)  A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany.   Int J Colorectal Dis 26: 11. 1475-1481 Nov  
Abstract: Early detection and multidisciplinary treatment of colorectal liver metastases (CLM), preferably resection, can significantly prolong the survival of colorectal cancer patients. The purpose of this study was to analyze the incidence, management and long-term clinical outcome of CLM patients using data from a regional German tumour registry.
Notes:
James A Hutchinson, Paloma Riquelme, Birgit Sawitzki, Stefan Tomiuk, Patrick Miqueu, Maaz Zuhayra, Hans H Oberg, Andreas Pascher, Ulf Lützen, Uwe Janssen, Christiane Broichhausen, Lutz Renders, Friedrich Thaiss, Ernst Scheuermann, Eberhard Henze, Hans-Dieter Volk, Lucienne Chatenoud, Robert I Lechler, Kathryn J Wood, Dieter Kabelitz, Hans J Schlitt, Edward K Geissler, Fred Fändrich (2011)  Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients.   J Immunol 187: 5. 2072-2078 Sep  
Abstract: Regulatory macrophages (M regs) were administered to two living-donor renal transplant recipients. Both patients were minimized to low-dose tacrolimus monotherapy within 24 wk of transplantation and subsequently maintained excellent graft function. After central venous administration, most M regs remained viable and were seen to traffic from the pulmonary vasculature via the blood to liver, spleen, and bone marrow. By 1 y posttransplantation, both patients displayed patterns of peripheral blood gene expression converging upon the IOT-RISET signature. Furthermore, both patients maintained levels of peripheral blood FOXP3 and TOAG-1 mRNA expression within the range consistent with nonrejection. It is concluded that M regs warrant further study as a potential immune-conditioning therapy for use in solid-organ transplantation. The results of this work are being used to inform the design of The ONE Study, a multinational clinical trial of immunomodulatory cell therapy in renal transplantation.
Notes:
Felix C Popp, Barbara Fillenberg, Elke Eggenhofer, Philipp Renner, Johannes Dillmann, Volker Benseler, Andreas A Schnitzbauer, James Hutchinson, Robert Deans, Deborah Ladenheim, Cheryl A Graveen, Florian Zeman, Michael Koller, Martin J Hoogduijn, Edward K Geissler, Hans J Schlitt, Marc H Dahlke (2011)  Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).   J Transl Med 9: 07  
Abstract: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to be reduced. In the current protocol, we propose to complement immunosuppressive pharmacotherapy with third-party multipotent adult progenitor cells (MAPCs), a culture-selected population of adult adherent stem cells derived from bone marrow that has been shown to display potent immunomodulatory and regenerative properties. In animal models, MAPCs reduce the need for pharmacological immunosuppression after experimental solid organ transplantation and regenerate damaged organs.
Notes:
Stefan M Brunner, Gabriela Schiechl, Werner Falk, Hans J Schlitt, Edward K Geissler, Stefan Fichtner-Feigl (2011)  Interleukin-33 prolongs allograft survival during chronic cardiac rejection.   Transpl Int 24: 10. 1027-1039 Oct  
Abstract: Interleukin-33 (IL-33) stimulates the generation of cells and cytokines characteristic of a Th2 immune response. We examined the effects of IL-33 on allografted heart tissue in a chronic cardiac rejection model, including analysis of the peripheral myeloid and lymphoid compartments. B6.C-H2bm12/KhEg hearts were transplanted into MHC class II-mismatched C57Bl/6J mice; IL-33 was administered daily. Cells from allografts and spleens were isolated for flow cytometry and cultured for cytokine production; some tissues were used for immunohistochemistry. Animals treated with IL-33 showed significantly longer allograft survival, which was associated with a distinct cytokine profile produced by graft-infiltrating cells. Proinflammatory IL-17A production was decreased with IL-33 treatment, while increased levels of IL-5, IL-10, and IL-13 were observed. After IL-33 therapy, flow cytometry showed a direct induction of CD4(+) Foxp3(+) Treg, whereas the number of B220(+) CD19(+) B cells, and circulating, as well as allograft deposited, alloantibodies was reduced. Following IL-33 treatment, a significant decrease in graft-infiltrating CD11b(high) Gr1(high) granulocytes coincided with a significant increase in CD11b(high) Gr1(intermediate) myeloid-derived suppressor cells (MDSC). In conclusion, IL-33 treatment in the setting of chronic rejection promotes the development of a Th2-type immune response that favors MDSC and Treg expansion, reduces antibody-mediated rejection (AMR), and ultimately, prolongs allograft survival.
Notes:
T Bohrer, M Koller, H - J Schlitt, H Bauer (2011)  [Quality of life of German surgeons: results of a survey of 3,652 attendees of the annual meetings of the German Surgical Societies ].   Dtsch Med Wochenschr 136: 42. 2140-2144 Oct  
Abstract: Quality of life is of vital importance for patients undergoing surgery. However, little is known about the quality of life of surgeons who are facing a stressful and dramatically changing working environment. For this reason, this large scale study investigated the quality of life (QL) of surgeons in Germany in the context of occupational, private, and system-related risk factors with a standardized QL measurement instrument.
Notes:
Elke Eggenhofer, Philipp Renner, Yorick Soeder, Felix C Popp, Martin J Hoogduijn, Edward K Geissler, Hans J Schlitt, Marc H Dahlke (2011)  Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model.   Transpl Immunol 25: 2-3. 141-147 Sep  
Abstract: Mesenchymal stem cells (MSCs) can be used for immunomodulation therapy after solid organ transplantation. Here, we focus on the immunoregulatory potential of combination therapies of MSCs and classic pharmacotherapy to mediate acceptance of solid organ grafts.
Notes:
Tobias J Weismüller, Gabriele I Kirchner, Marcus N Scherer, Ahmed A Negm, Andreas A Schnitzbauer, Frank Lehner, Jürgen Klempnauer, Hans J Schlitt, Michael P Manns, Christian P Strassburg (2011)  Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival.   Hepatology 54: 6. 2114-2124 Dec  
Abstract: Serum ferritin (SF) concentration is a widely available parameter used to assess iron homeostasis. It has been described as a marker to identify high-risk patients awaiting liver transplantation (LT) but is also elevated in systemic immune-mediated diseases, metabolic syndrome, and in hemodialysis where it is associated with an inferior prognosis. This study analyzed whether SF is not only a predictor of liver-related mortality prior to LT but also an independent marker of survival following LT. In a dual-center, retrospective study, a cohort of 328 consecutive first-LT patients from Hannover Medical School, Germany (2003-2008, follow-up 1260 days), and 82 consecutive LT patients from Regensburg University Hospital, Germany (2003-2007, follow-up 1355 days) as validation cohort were analyzed. In patients exhibiting SF ≥365 μg/L versus <365 μg/L prior to LT, 1-, 3-, and 5-year post-LT survival was 73.3% versus 81.1%, 64.4% versus 77.3%, and 61.1% versus 74.4%, respectively (overall survival P = 0.0097), which was confirmed in the validation cohort (overall survival of 55% versus 83.3%, P = 0.005). Multivariate analyses identified SF ≥365 μg/L combined with transferrin saturation (TFS) <55%, hepatocellular carcinoma, and the survival after LT (SALT) score as independent risk factors for death. In patients with SF concentrations ≥365 μg/L and TFS <55%, overall survival was 54% versus 74.8% in the remaining group (P = 0.003). In the validation cohort, it was 28.6% versus 72% (P = 0.017), respectively. Conclusion: SF concentration ≥365 μg/L in combination with TFS <55% before LT is an independent risk factor for mortality following LT. Lower TFS combined with elevated SF concentrations indicate that acute phase mechanisms beyond iron overload may play a prognostic role. SF concentration therefore not only predicts pre-LT mortality but also death following LT. (HEPATOLOGY 2011;).
Notes:
W Uller, E M Jung, M Hornung, C Ross, W Jung, H J Schlitt, C Stroszczynski, A Agha (2011)  Evaluation of the microvascularization of pathologic parathyroid glands in patients with primary hyperparathyroidism using conventional ultrasound and contrast-enhanced ultrasound.   Clin Hemorheol Microcirc 48: 1. 95-103  
Abstract: The objective was to characterize the microcirculation of parathyroid adenomas using contrast-enhanced ultrasound (CEUS) and to evaluate if it can be used for diagnosis and localization of pathologic glands.
Notes:
Ayman Agha, Martin Loss, Hans Jürgen Schlitt, Marcus N Scherer (2011)  Recurrence of secondary hyperparathyroidism in patients after total parathyroidectomy with autotransplantation: technical and therapeutic aspects.   Eur Arch Otorhinolaryngol Oct  
Abstract: Recurrence of secondary hyperparathyroidism (rSHPT) in patients after total parathyroidectomy (TPTX) with autotransplantation (AT) represents a major diagnostic and therapeutic challenge. The aim of this retrospective cohort study was to evaluate rSHPT in patients after TPTX with AT and the subsequent surgical treatment. 112 patients with secondary hyperparathyroidism (surgery 1998-2008) were evaluated. In 16 patients, rSHPT was detected, while all of them had been originally operated with TPTX, cervical thymectomy and AT. The recurrence rate of TPTX with AT in our patient cohort was 14.2% (16/112). All the 16 patients with rSHPT suffered from forearm-autotransplant(s) hyperparathyroidism (AT-HPT). AT-HPT was diagnosed after a median of 5.6 years (1.5-11 years). All "forearm" AT-HPT operations were performed using the method of intra-operative parathyroid-hormone measurement. The histopathologic result showed hyperplasia or an adenoma of the reimplanted parathyroid gland (PTG) particles. The parathyroid hormone measurement (PTH) showed normal values in all cases 2 weeks after surgery. In none of the patients persistent hypocalcemia was observed. Our data demonstrates that the high rate of rSHPT in patients after TPTX with AT with renal-insufficiency represents an unsolved problem, often leading to re-operation including possible morbidity. Although we are not showing direct data, we propose, that the alternative method of TPTX without AT, simultaneous cryopreservation and potential metachronous reimplantation could offer an excellent alternative. However, this therapy option needs to be validated in further clinical trials.
Notes:
Johannes Taeger, Christian Moser, Claus Hellerbrand, Maria E Mycielska, Gabriel Glockzin, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing, Sven A Lang (2011)  Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.   Mol Cancer Ther 10: 11. 2157-2167 Nov  
Abstract: Activation of receptor tyrosine kinases, such as fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and VEGF receptor (VEGFR), has been implicated in tumor progression and metastasis in human pancreatic cancer. In this study, we investigated the effects of TKI258, a tyrosine kinase inhibitor to FGFR, PDGFR, and VEGFR on pancreatic cancer cell lines (HPAF-II, BxPC-3, MiaPaCa2, and L3.6pl), endothelial cells, and vascular smooth muscle cells (VSMC). Results showed that treatment with TKI258 impaired activation of signaling intermediates in pancreatic cancer cells, endothelial cells, and VSMCs, even upon stimulation with FGF-1, FGF-2, VEGF-A, and PDGF-B. Furthermore, blockade of FGFR/PDGFR/VEGFR reduced survivin expression and improved activity of gemcitabine in MiaPaCa2 pancreatic cancer cells. In addition, motility of cancer cells, endothelial cells, and VSMCs was reduced upon treatment with TKI258. In vivo, therapy with TKI258 led to dose-dependent inhibition of subcutaneous (HPAF-II) and orthotopic (L3.6pl) tumor growth. Immunohistochemical analysis revealed effects on tumor cell proliferation [bromodeoxyuridine (BrdUrd)] and tumor vascularization (CD31). Moreover, lymph node metastases were significantly reduced in the orthotopic tumor model when treatment was initiated early with TKI258 (30 mg/kg/d). In established tumors, TKI258 (30 mg/kg/d) led to significant growth delay and improved survival in subcutaneous and orthotopic models, respectively. These data provide evidence that targeting FGFR/PDFGR/VEGFR with TKI258 may be effective in human pancreatic cancer and warrants further clinical evaluation.
Notes:
Thomas Bein, Markus Zimmermann, Frank Schiewe-Langgartner, Roland Strobel, Kathrin Hackner, Hans J Schlitt, Michael N Nerlich, Florian Zeman, Bernhard M Graf, Michael Gruber (2011)  Continuous lateral rotational therapy and systemic inflammatory response in posttraumatic acute lung injury: Results from a prospective randomised study.   Injury Sep  
Abstract: BACKGROUND: The incidence of posttraumatic acute lung injury is high and may result in increased mortality. Changes in the body position are additional measures to improve pulmonary gas exchange and to prevent pulmonary complications. We investigated the effect of a continuous lateral rotational therapy (CLRT) on the inflammatory response in patients with posttraumatic lung failure. METHODS: After admission to the intensive care unit (ICU) and after randomisation, 13 patients were placed in a special motor-driven bed and CLRT was performed for 5 days. In the control group (n=14), patients were positioned conventionally. Samples from blood and from broncho-alveolar lavage fluid (BAL) were collected in both groups before study began and on day 5. The levels of cytokines (Tumour Necrosis Factor, Interleukin 6, Interleukin 8 or Intercellular Adhesion Molecule-1) were assessed and haemodynamic, pulmonary, and laboratory values were documented. RESULTS: On day 5, no significant differences were found in cytokine levels between groups, but a significant decrease in IL-8 (p<0.01) and TNF-α (p<0.05) serum levels and an increase in IL-8 BAL levels was found in the CLRT-group, but not for conventionally managed patients. In general cytokine BAL levels tended to be increased in both groups, but more pronounced during CLRT. Daily assessment of the severity of disease (SAPS-II, SOFA) was significantly reduced in the study group on days 2-4 (p<0.05) in comparison to control group. CONCLUSIONS: CLRT may attenuate the inflammatory response to posttraumatic acute lung injury. The exact mechanism of such an effect is unknown.
Notes:
Volker Benseler, Alessandra Warren, Michelle Vo, Lauren E Holz, Szun S Tay, David G Le Couteur, Eamon Breen, Anthony C Allison, Nico van Rooijen, Claire McGuffog, Hans J Schlitt, David G Bowen, Geoffrey W McCaughan, Patrick Bertolino (2011)  Hepatocyte entry leads to degradation of autoreactive CD8 T cells.   Proc Natl Acad Sci U S A 108: 40. 16735-16740 Oct  
Abstract: Although most self-reactive T cells are eliminated in the thymus, mechanisms to inactivate or control T cells specific for extrathymic antigens are required and exist in the periphery. By investigating the site in which autoreactive T cells are tolerized, we identify a unique mechanism of peripheral deletion in which naïve autoreactive CD8 T cells are rapidly eliminated in the liver after intrahepatic activation. T cells actively invade hepatocytes, enter endosomal/lysosomal compartments, and are degraded. Blockade of this process leads to accumulation of autoreactive CD8 T cells in the liver and breach of tolerance, with the development of autoimmune hepatitis. Cell into cell invasion, or emperipolesis, is a long-observed phenomenon for which a physiological role has not been previously demonstrated. We propose that this "suicidal emperipolesis" is a unique mechanism of autoreactive T-cell deletion, a process critical for the maintenance of tolerance.
Notes:
Ayman Agha, Matthias Hornung, Janine Rennert, Wibke Uller, Hamid Lighvani, Hans J Schlitt, Ernst Michael Jung (2011)  Contrast-enhanced ultrasonography for localization of pathologic glands in patients with primary hyperparathyroidism.   Surgery Oct  
Abstract: BACKGROUND: The localization of enlarged parathyroid glands might, depending on size, histology, and concomitant goiter, be difficult in some patients. In the presented study, contrast-enhanced ultrasonography (CEUS) was applied as a new diagnostic tool to detect the site of parathyroid lesions. METHODS: Thirty patients underwent operation for primary hyperparathyroidism (pHPT) between 8/2009 and 6/2010. Contrast-enhanced ultrasonography (CEUS) using a linear probe (6-9 MHz, LOGIQE9/GE), fundamental B scan, and Doppler ultrasonography, (99m)Technetium-sestamibi scintigraphy and magnetic resonance imaging (MRI) were performed in all patients preoperatively. The diagnostic sensitivity of the procedures, time requirements, and overall costs were analyzed. RESULTS: Using CEUS, all 31 pathologic glands could be detected, compared with 23 using conventional ultrasonography, 25 using (99m)Technetium-sestamibi scintigraphy and 22 using MRI (P = .015). Costs and time requirement were less using CEUS as compared with (99m)Technetium-scintigraphy and MRI examinations (P = .002). Minimally invasive, video-assisted parathyroidectomy could be performed successfully based on CEUS findings in all but 7 patients who required concomitant thyroid surgery or had underwent previous thyroid operations. All patients showed normal serum levels of calcium and parathyroid hormone serum levels 3 months after parathyroidectomy. CONCLUSION: CEUS represents a highly sensitive and cost-efficient method for localization of pathologic parathyroid glands in patients with pHPT. Future studies should confirm these findings in order to establish CEUS as a standard diagnostic procedure.
Notes:
Dominik Jauch, Maria Martin, Gabriela Schiechl, Rebecca Kesselring, Hans Jürgen Schlitt, Edward K Geissler, Stefan Fichtner-Feigl (2011)  Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice.   Gut 60: 12. 1678-1686 Dec  
Abstract: Colitis-associated tumorigenesis is a balance between proliferation of tumour cells and tumour immunosurveillance. The role of T-helper-cell-derived cytokines in tumour growth is not fully understood. In this study the authors investigated the influence of interleukin (IL) 21 on intestinal tumorigenesis.
Notes:
2010
M Loss, E M Jung, M N Scherer, S A Farkas, H J Schlitt (2010)  [Surgical treatment of liver metastases].   Chirurg 81: 6. 533-541 Jun  
Abstract: The treatment of liver metastases has become more and more complex in recent years. More individualized therapeutic concepts have become feasible by the increase in different treatment options (surgical, interventional and oncological). In the field of surgery the definition of resectability could be broadened. More extensive liver resections are being performed, which are partly carried out as staged resections after neoadjuvant chemotherapy in combination with portal vein embolization (PVE), radio frequency ablation (RFA) or other procedures in order to increase complete resection rates and patient survival. Consequently the overall 5 year survival rate of patients with resected colorectal liver metastases has doubled from 30% to nearly 60% in the past decade. Due to the complexity of the different treatment approaches an interdisciplinary assessment of the individual patient in experienced centers is necessary.
Notes:
Rania Dayoub, Peter Groitl, Thomas Dobner, Anja Katrin Bosserhoff, Hans-Jürgen Schlitt, Thomas S Weiss (2010)  Foxa2 (HNF-3beta) regulates expression of hepatotrophic factor ALR in liver cells.   Biochem Biophys Res Commun 395: 4. 465-470 May  
Abstract: Liver regeneration is a multistep and well-orchestrated process which is initiated by injuries such as tissue loss, infectious or toxic insults. Augmenter of liver regeneration (ALR) is a hepatotrophic growth factor which has been shown to stimulate hepatic regeneration after partial hepatectomy and therefore seems to be regulated during the regenerative process in the liver. Our aim was to analyze how ALR is regulated in hepatic tissues and which transcription factors might regulate its tissue-specific expression. Promoter studies of ALR (-733/+527 bp) revealed potential regulatory elements for various transcription factors like Foxa2, IL-6 RE-BP and C/EBPbeta. Analysis of the promoter activity by performing luciferase assays revealed that co-transfection with Foxa2 significantly induced the activity of ALR promoter in HepG2 cells. EMSA and Supershift analysis using anti-Foxa2 antibody confirmed the specific binding of Foxa2 to ALR promoter and this binding was inducible when the cells were simultaneously stimulated with IL-6. The increased binding after activation with IL-6 and/or Foxa2 was confirmed by elevated ALR protein levels using Western blot technique. In addition, we could not detect any binding of C/EBPbeta and IL-6 RE-BP to the promoter of ALR. In conclusion, these results indicate that ALR is regulated by Foxa2, and this regulation may be amplified by IL-6.
Notes:
Thomas Bein, Franz Ploner, Markus Ritzka, Michael Pfeifer, Hans J Schlitt, Bernhard M Graf (2010)  No change in the regional distribution of tidal volume during lateral posture in mechanically ventilated patients assessed by electrical impedance tomography.   Clin Physiol Funct Imaging 30: 4. 234-240 Jul  
Abstract: We assessed the distribution of regional lung ventilation during moderate and steep lateral posture using electrical impedance tomography (EIT) in mechanically ventilated patients. Seven patients were placed on a kinetic treatment table. An elastic belt containing 16 electrodes was placed around the chest and was connected to the EIT device. Patients were moved to left and right lateral positions in a stepwise (10 degrees ) mode up to 60 degrees. EIT images [arbitrary units (AU)] were generated and scanned for assessment of relative ventilation distribution changes [tidal volume (V(T))]. A calibration procedure of arbitrary units (AUs) versus ventilator-derived V(T) performed in all patients during three predefined positions (supine, 60 degrees-left dependent and 60 degrees-right-dependent) showed a significant correlation between V(T) in supine, left and right lateral positions with the corresponding AUs (r(2) = 0.356, P<0.05). Changes in V(T) were calculated and compared to supine position, and specific regions of interest (ROIs) were analysed. In our study, in contrast to recent findings, a change in lateral positions did not induce a significant change in regional tidal volume distribution. In right lateral positions, a broader variation of V(T) with a trend towards an increase in the dependently positioned lung was observed in comparison with supine. Lateral positioning promotes the redistribution of ventilation to the ventral regions of the lung. The use of EIT technology might become a helpful tool for understanding and guiding posture therapy in mechanically ventilated patients.
Notes:
Markus K Diener, Thomas Bruckner, Pietro Contin, Christopher Halloran, Matthias Glanemann, Hans Jürgen Schlitt, Joachim Mössner, Meinhard Kieser, Jens Werner, Markus W Büchler, Christoph M Seiler (2010)  ChroPac-trial: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for chronic pancreatitis. Trial protocol of a randomised controlled multicentre trial.   Trials 11: 04  
Abstract: A recently published systematic review indicated superiority of duodenum-preserving techniques when compared with pancreatoduodenectomy, for the treatment of patients with chronic pancreatitis in the head of the gland. A multicentre randomised trial to confirm these results is needed.
Notes:
Ulrich Bolder, Marcus N Scherer, Thorsten Schmidt, Matthias Hornung, Hans-Jürgen Schlitt, Peter Vogel (2010)  Percutaneous laparoscopic assisted gastrostomy (PLAG)--a new technique for cases of pharyngoesophageal obstruction.   Langenbecks Arch Surg 395: 8. 1107-1113 Nov  
Abstract: Percutaneous endoscopic gastrostomy (PEG) is the preferable method to provide enteral nutrition for a longer time period. Safe placement of a PEG tube requires passage of the esophagus and transillumination of the stomach through the abdominal wall. Surgical placement of a PEG tube has been shown to be feasible although the local complication rate ranges above the endoscopic procedure. We are presenting a new technique (percutaneous laparoscopically assisted gastrostomy, PLAG) to provide enteral access for patients with pharyngoesophageal obstruction not suitable for PEG placement.
Notes:
Andreas A Schnitzbauer, Carl Zuelke, Christian Graeb, Justine Rochon, Itxarone Bilbao, Patrizia Burra, Koert P de Jong, Christophe Duvoux, Norman M Kneteman, Rene Adam, Wolf O Bechstein, Thomas Becker, Susanne Beckebaum, Olivier Chazouillères, Umberto Cillo, Michele Colledan, Fred Fändrich, Jean Gugenheim, Johann P Hauss, Michael Heise, Ernest Hidalgo, Neville Jamieson, Alfred Königsrainer, Philipp E Lamby, Jan P Lerut, Heikki Mäkisalo, Raimund Margreiter, Vincenzo Mazzaferro, Ingrid Mutzbauer, Gerd Otto, Georges-Philippe Pageaux, Antonio D Pinna, Jacques Pirenne, Magnus Rizell, Giorgio Rossi, Lionel Rostaing, Andre Roy, Victor Sanchez Turrion, Jan Schmidt, Roberto I Troisi, Bart van Hoek, Umberto Valente, Philippe Wolf, Heiner Wolters, Darius F Mirza, Tim Scholz, Rudolf Steininger, Gunnar Soderdahl, Simone I Strasser, Karl-Walter Jauch, Peter Neuhaus, Hans J Schlitt, Edward K Geissler (2010)  A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.   BMC Cancer 10: 05  
Abstract: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC.
Notes:
Dirk Arnold, Hans-Joachim Schmoll, Hauke Lang, Wolfram Trudo Knoefel, Karsten Ridwelski, Tanja Trarbach, Ludger Staib, Thomas Kirchner, Michael Geissler, Thomas Seufferlein, Holger Amthauer, Hanno Riess, Hans J Schlitt, Pompiliu Piso (2010)  [Specific treatment situations in metastatic colorectal cancer].   Onkologie 33 Suppl 4: 8-18 04  
Abstract: As far as the management of primary resectable liver metastases is concerned, three approaches are currently competing with each other: surgery alone, surgery with pre- and postoperative chemotherapy, and surgery with postoperative chemotherapy alone. The core of the argument for pre- and postoperative chemotherapy in these patients is the European Organisation for Research and Treatment of Cancer (EORTC) 40983 study, which concluded that, in comparison with surgery alone, perioperative chemotherapy improved the 3-year progression-free survival (PFS) by 7 months. In contrast to this, there are two smaller studies--at a somewhat lower strength of evidence-- indicating that adjuvant chemotherapy extends PFS by 9.1 months compared with surgery alone. In Germany, the adjuvant approach continues to be favored in many places; this can also be seen in the formulation of the S3 guideline. In patients with unresectable liver metastases--with the associated difficulty of classification due to the lack of clear and definitive criteria--preoperative systemic therapy to induce 'conversion' is indicated, in order to allow secondary resection. In KRAS wild-type tumors, high response rates (in terms of a reduction in size of the metastases, such as according to RECIST (Response Evaluation Criteria in Solid Tumors)) and a high conversion rate are achieved using a cetuximab/chemotherapy combination. Triple chemotherapy combinations with 5-fluorouracil (5-FU), oxaliplatin and irinotecan also produce high response rates. Bevacizumab/chemotherapy combinations have led to a high number of complete and partial pathohistological remissions in phase II studies; these seem to correlate with long survival times. In the absence of long-term survival data, it therefore seems to remain unclear as to what is the best parameter to use in order to assess the success of preoperative treatment. Lung metastases, too, or local peritoneal carcinomatosis can nowadays be operated on in selected patients with a good prospect of long-term remission or even cure. The surgery should, however, generally only be carried out in experienced centers, especially in the case of peritoneal carcinomatosis. For synchronous metastasization, the appropriate management depends on the size and extent of liver metastases and of the primary tumor. Small, peripherally lying and safely resectable liver metastases can be removed before or at the same time as the primary tumor, especially if a hemicolectomy is being carried out. If the metastases are unresectable and there is no bleeding or stenosis, the primary tumor can also be left in situ and systemic chemotherapy can be carried out first. However, it should be borne in mind that, according to current data, palliative resection of the primary tumor combined with systemic therapy leads to longer overall survival than does chemotherapy alone. Whether resection or chemotherapy should be done first therefore depends on the patient's clinical situation.
Notes:
Bernd Krüger, Andreas Walberer, Jens Debler, Carsten A Böger, Stefan Farkas, Stephan W Reinhold, Aiman Obed, Hans Jürgen Schlitt, Michael Fischereder, Bernhard Banas, Bernhard K Krämer (2010)  Is inflammation prior to renal transplantation predictive for cardiovascular and renal outcomes?   Atherosclerosis 210: 2. 637-642 Jun  
Abstract: Markers of non-specific inflammation, such as C-reactive protein (CRP) or leukocyte count are increased in end-stage renal disease patients. Recent studies have shown positive associations between inflammatory markers and cardiovascular mortality in kidney transplant recipients, but these analyses had been limited by sample size. The aim of our study was to determine the association between pretransplant CRP levels and leukocyte counts with posttransplant outcome in a prospectively enrolled cohort of kidney transplant recipients.
Notes:
P Renner, F C Popp, E Eggenhofer, P Slowik, P Piso, E K Geissler, H J Schlitt, M H Dahlke (2010)  Antigen-specific recognition is critical for the function of regulatory CD8(+)CD28(-) T cells.   Transpl Immunol 22: 3-4. 144-149 Feb  
Abstract: The immunomodulatory properties of CD8 T cells with regulatory phenotype have become evident. It remains unclear whether the immunomodulatory function of CD8(+)CD28(-) T cells requires antigen-specific TCR interaction with major histocompatibility complex class I (MHC I). We have isolated naïve CD8(+)CD28(-) T suppressor cells (Tsup) from H2-Kk Des-TCR mice that express a transgenic, MHC class I-restricted, clonotypic TCR against an allogeneic MHC class I molecule (H2-Kb) plus self-peptide. These cells were compared to B10.BR wild type (w/t) CD8(+)CD28(-) T cells and to naïve CD4(+)CD25(+) regulatory T cells (Treg) of the same strains. Des CD8 effector T cells proliferated more readily when stimulated by H2-Kb splenocytes than w/t controls, whereas Des CD4 T cells showed the same alloresponse as w/t cells. Activation and proliferation of B10.BR CD4 T cells stimulated by H2-Kb APC were suppressed more effectively by Des CD8(+)CD28(-) T cells than by w/t CD8(+)CD28(-) T cells. On the contrary, Des CD4(+)CD25(+) T cells inhibited T cell proliferation less effectively than w/t CD4(+)CD25(+) T cells. In conclusion, we demonstrate that the function of naive Tsup is strongly enhanced by antigen recognition. Therefore we expect that Tsup are possible candidates for antigen-specific immunosuppressive therapy.
Notes:
Oliver Stoeltzing, Martin Loss, Elisabeth Huber, Volker Gross, Christoph Eilles, Jan Mueller-Brand, Hans J Schlitt (2010)  Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.   Langenbecks Arch Surg 395: 2. 185-192 Feb  
Abstract: Treatment with DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC), labeled with beta-emitting radioisotope yttrium-90 ((90)Y-DOTATOC), has successfully been used for the palliative treatment of patients with advanced somatostatin receptor-expressing neuroendocrine tumors (NETs). However, controversy persists as to whether patients with metastatic NETs of the pancreas should undergo radical (salvage) surgery or receive palliative therapy. We proposed that (90)Y-DOTATOC could be used in a neoadjuvant intention for improving therapy of hepatic NET metastases.
Notes:
Elke Eggenhofer, Axel Doenecke, Philipp Renner, Przemyslaw Slowik, Pompiliu Piso, Edward K Geissler, Hans J Schlitt, Marc H Dahlke, Felix C Popp (2010)  High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.   J Gastroenterol Hepatol 25: 5. 1002-1008 May  
Abstract: Despite pharmaceutical treatment with NTBC (2-2-nitro-4-fluoromethylbenzoyl-1,3-cyclohexanedione), a high incidence of liver malignancies occur in humans and mice suffering from hereditary tyrosinemia type 1 (HT1) caused by mutation of the fumarylacetoacetate hydrolase (fah) gene.
Notes:
A Stehr, I Töpel, S Müller, K Unverdorben, E K Geissler, P M Kasprzak, H J Schlitt, M Steinbauer (2010)  VEGF: a surrogate marker for peripheral vascular disease.   Eur J Vasc Endovasc Surg 39: 3. 330-332 Mar  
Abstract: This study aims to evaluate the value of VEGF as a surrogate marker for peripheral vascular disease (PVD). Prior to treatment, serum VEGF levels were evaluated by enzyme-linked immunosorbent assay (ELISA) in 293 PVD patients. Risk factors and clinical parameters of PVD were documented. Twenty-six age-matched healthy volunteers served as controls. Serum VEGF values strongly correlated with Fontaine stages (p<0.006, stage IV vs. controls). High VEGF values prior to treatment were associated with poor outcome. Serum VEGF appears to indicate the severity of PVD and might serve as a surrogate indicator of disease severity.
Notes:
Christina Hackl, Akira Mori, Christian Moser, Sven A Lang, Rania Dayoub, Thomas S Weiss, Hans J Schlitt, Edward K Geissler, Claus Hellerbrand, Oliver Stoeltzing (2010)  Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models.   Surgery 147: 5. 704-712 May  
Abstract: Targeting heat shock protein 90 (HSP90) has gained great interest for cancer therapy. However, in view of novel multimodality therapy approaches for treating hepatic metastases, concerns have raised regarding the impact of targeted therapies on liver regeneration and repair. In this study, we investigated the impact of HSP90 inhibition on liver regeneration in murine models.
Notes:
D Schacherer, D Decking, T Herold, A Obed, H - J Schlitt, S Gruene, J Schoelmerich, K Schlottmann (2010)  [Localisation of hepatic lesions to liver segments according to sonography (US), computed tomography (CT) and surgery (OP): a comparative study].   Z Gastroenterol 48: 2. 241-245 Feb  
Abstract: The localisation of focal liver lesions is usually performed according to the Couinaud classification system. The exact description of localisation and size of liver lesions is especially important for surgical procedures. The aim of this prospective study was the evaluation of differences and agreements in the localisation and size of hepatic lesions as found by ultrasound (US), computed tomography (CT) and according to the intraoperative status (OP).
Notes:
Sven A Lang, Christina Hackl, Christian Moser, Stefan Fichtner-Feigl, Gudrun E Koehl, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2010)  Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells.   Biochim Biophys Acta 1803: 4. 435-442 Apr  
Abstract: Inhibition of mTORC1 with the mTOR inhibitor rapamycin may lead to an induction of Akt phosphorylation in cancer cells via mTORC2 activation. Using gastric and pancreatic cancer cells, we further investigated this paradoxical signaling response and found that rapamycin additionally up-regulates both IGF-IR and Her2 expression. Using RNAi for down-regulating RICTOR, this induction of receptor kinase expression was identified to be mediated via an mTORC2-induced Akt activation. Moreover, mTORC2 inhibition reduced the phosphorylation of GSK-3 and NF-kappaB, and significantly impaired cancer cell motility. In conclusion, inhibition of mTORC2 may abrogate unfavorable signaling effects of mTOR inhibitors, hence providing a novel rationale for therapy.
Notes:
Igors Iesalnieks, Wolfgang B Gaertner, Heidi Glass, Ulrike Strauch, Matthias Hipp, Ayman Agha, Hans J Schlitt (2010)  Fistula-associated anal adenocarcinoma in Crohn's disease.   Inflamm Bowel Dis 16: 10. 1643-1648 Oct  
Abstract: Adenocarcinoma arising from perianal fistulae in patients with Crohn's disease (CD) is rare. The literature consists mainly of case reports and small series making characterization of this clinical entity difficult. We present 6 patients with CD and fistula-associated anal adenocarcinoma (FAAA) and a systematic review of published series.
Notes:
A Doenecke, T - Y Tsui, C Zuelke, M N Scherer, A A Schnitzbauer, H - J Schlitt, A Obed (2010)  Pre-existent portal vein thrombosis in liver transplantation: influence of pre-operative disease severity.   Clin Transplant 24: 1. 48-55 Jan/Feb  
Abstract: Portal vein thrombosis (PVT) is a surgical challenge in liver transplantation (LTx). In contrast to LTx in decompensated liver disease, which are associated with a higher morbidity and mortality, PVT influence on outcome is still under debate. To evaluate this influence at different stages of liver decompensation, we compared the outcome of patients suffering from PVT to patients with patent portal vein within different score ranges.
Notes:
J Hartl, R Buettner, F Rockmann, S Farkas, A Holstege, C Vogel, A Schnitzbauer, H J Schlitt, J Schoelmerich, G Kirchner (2010)  Giant cell hepatitis: an unusual cause of fulminant liver failure.   Z Gastroenterol 48: 11. 1293-1296 Nov  
Abstract: Giant cell hepatitis is a very rare disease of unknown origin. It has been hypothesized that drugs, viral infections, or autoimmune reactions may play a pathogenetic role. Here, we describe a 33 year old patient with bacterial bronchitis who was treated with doxycycline (100 mg/d) for one week. Furthermore the patient complained of malaise and a distinct jaundice. Liver parameters increased dramatically (AST 4670 U/l, ALT 5350 U/l, bilirubin 226 µmol/l) and liver function was impaired (INR = 1,45). The ultrasound scan showed a hepatomegaly with no signs of cirrhosis, normal spleen size and normal bile ducts; liver perfusion was normal. No evidence of Wilson's disease, hemochromatosis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis, hepatitis A, B, C and E, HIV, CMV, VZV, adenoviral infections, or paracetamol intoxication was found. Subsequently, the patient developed acute liver failure (AST 2134 U/l, ALT 2820 U/l, bilirubin 380 µmol/l, INR 3.0) and a beginning renal failure. Therefore, he was transferred to our transplant center. Due to increasing confusion and somnolence due to cerebral edema mechanical ventilation was needed. Because of an acute renal failure and severe hepatic encephalopathia MARS-hemodialysis was performed. Three weeks after the appearance of the jaundice he underwent liver transplantation (MELD 40). Surprisingly, in the explanted liver the diagnosis of giant cell hepatitis was made. Today--2 years after successful liver transplantation--the patient is in very good condition with normal liver function. In conclusion, giant cell hepatitis is a rare cause of acute liver failure that is often recognized only histologically.
Notes:
Thomas Bein, Eric Osborn, Hans Stefan Hofmann, Markus Zimmermann, Alois Philipp, Hans J Schlitt, Bernhard M Graf (2010)  Successful treatment of a severely injured soldier from Afghanistan with pumpless extracorporeal lung assist and neurally adjusted ventilatory support.   Int J Emerg Med 3: 3. 177-179 07  
Abstract: Life-threatening acute lung injury due to combat and/or terror attacks is associated with high mortality. The successful management includes the use of "rescue" extracorporeal lung assist and early transport by aeromedical evacuation teams.
Notes:
Edward K Geissler, Hans J Schlitt (2010)  The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation.   Kidney Int 78: 11. 1075-1079 Dec  
Abstract: Use of the mammalian target of rapamycin (mTOR) inhibitor rapamycin in organ transplantation has evolved through different phases over the past two decades. After its discovery in the mid 1970s, antifungal and cytotoxic effects were the first of its properties to be explored, but the most significant advancement was found in its use as an immunosuppressive agent to reduce transplant rejection. This was viewed as an important step forward for immunosuppression, as early studies suggested that rapamycin was less nephrotoxic than calcineurin inhibitors (CNIs). Later, detrimental effects of rapamycin on kidney function were found in some patients. Nonetheless, a fascination with the mTOR pathway and its central role in multiple cellular processes has ensued. Among the potential positive clinically relevant effects is rapamycin's capacity to interfere with fibrotic processes that often accompany transplant rejection, and to influence the preferential development of immunological tolerance. A feature of increasing importance is that the mTOR pathway is central for vital aspects of tumor development, including angiogenesis and cell growth; rapamycin, therefore, has anticancer activities, which may prove critical in the fight against high cancer rates in transplant recipients. The final chapters defining the value of rapamycin have not been written yet, and indeed remain a work in progress. Only further research will reveal the full potential of rapamycin in organ transplantation.
Notes:
A Agha, I Iesalnieks, G Glockzin, H J Schlitt (2010)  [Surgical therapy for adrenal tumours].   Zentralbl Chir 135: 3. 233-239 Jun  
Abstract: Four endoscopic and four open accesses are available for the surgery of adrenal tumours. The decision to use one of the available techniques depends on tumour size, body mass index, previous abdominal surgery and the experience of the surgeon. Currently, the lateral laparoscopic and the dorsal retroperitoneoscopic approaches are most frequently used. Conventional surgery should be used if malignancy is suspected, especially for tumours larger than 6 cm. In individual cases, even tumours up to 10 cm can be operated laparoscopically if there is no suspicion of invasive growth or lymphatic metastases. Each surgeon should choose the most familiar access. The retroperitoneoscopic and laparoscopic accesses for benign adrenal tumours up to 6 cm are considered to be equivalent. The surgeon should also be able to approach adrenal tumours conventionally.
Notes:
Christina Hackl, Sven A Lang, Christian Moser, Akira Mori, Stefan Fichtner-Feigl, Claus Hellerbrand, Wolfgang Dietmeier, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2010)  Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.   BMC Cancer 10: 12  
Abstract: Activating transcription factor-3 (ATF3) is involved in the complex process of cellular stress response. However, its exact role in cancer is discussed controversially because both tumor suppressive and oncogenic effects have been described. Here we followed-up on our previous observation that inhibition of Hsp90 may increase ATF3 expression and sought to determine the role of ATF3 in colon cancer.
Notes:
E M Jung, C J Ross, J Rennert, M N Scherer, S Farkas, P von Breitenbuch, A A Schnitzbauer, P Piso, P Lamby, C Menzel, A G Schreyer, S Feuerbach, H J Schlitt, M Loss (2010)  Characterization of microvascularization of liver tumor lesions with high resolution linear ultrasound and contrast enhanced ultrasound (CEUS) during surgery: First results.   Clin Hemorheol Microcirc 46: 2-3. 89-99  
Abstract: Evaluation of high resolution linear ultrasound and intra-operative linear contrast enhanced ultrasound (CEUS) and its benefit for the detection and characterization of tumor lesions.
Notes:
Ayman Agha, Matthias Hornung, Igors Iesalnieks, Gabriel Glockzin, Hans J Schlitt (2010)  Single-incision retroperitoneoscopic adrenalectomy and single-incision laparoscopic adrenalectomy.   J Endourol 24: 11. 1765-1770 Nov  
Abstract: Single-incision surgery is by now practicable in many fields of surgery, including surgery of the adrenal gland. We report on first experience with laparoscopic transperitoneal and retroperitoneoscopic single-incision adrenalectomy.
Notes:
Igors Iesalnieks, Alexandra Kilger, Heidi Glass, Florian Obermeier, Ayman Agha, Hans J Schlitt (2010)  Perforating Crohn's ileitis: delay of surgery is associated with inferior postoperative outcome.   Inflamm Bowel Dis 16: 12. 2125-2130 Dec  
Abstract: A perforating phenotype is associated with an increased postoperative morbidity in patients with Crohn's disease undergoing ileocolic resection. Sequential conservative treatment attempts applied to patients with unrecognized perforating complications may lead to a delay of surgery and a further increase in morbidity.
Notes:
Gabriele Kirchner, Georgi Kirovski, Alexandra Hebestreit, Jürgen Schölmerich, Hans Jürgen Schlitt, Oliver Stoeltzing, Claus Hellerbrand (2010)  Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany.   Int J Clin Exp Med 3: 2. 169-179 06  
Abstract: Hepatocellular carcinoma (HCC) belongs to the most frequent tumors worldwide with an incidence still rising. Patients with cirrhosis are at the highest risk for cancerogenesis and are candidates for surveillance, and here, as well as for the choice of potential forms of treatment, identification of suitable parameters for estimating the prognosis is of high clinical importance. The aim of this study was to describe the etiology of underlying liver disease and to identify predictors of survival in a large single center cohort of HCC patients in Southern Germany. Clinicopathologi-cal characteristics and survival rates of 458 patients (83.6% male; mean age: 62.5+/-11.2 years) consecutively admitted to a University Hospital between 1994 and 2008 were retrospectively analyzed. The results indicate that chronic alcohol abuse was the most common risk factor (57.2%), followed by infection with hepatitis B and C viruses (HBV: 10.9% and HCV: 20.5%). Overall median survival was 19.0 months, and higher OKUDA, CHILD and CLIP scores correlated negatively with prognosis. Of these, only the CLIP Score was an independent predictor in multivariate analysis. We conclude that chronic alcohol abuse is frequently associated with HCC in low hepatitis virus endemic areas, such as Germany. Our study suggests the CLIP score as a valuable prognostic marker for patients' survival, particularly of patients with alcohol related HCC.
Notes:
Martin J Hoogduijn, Felix C Popp, Anja Grohnert, Meindert J Crop, Marieke van Rhijn, Ajda T Rowshani, Elke Eggenhofer, Philipp Renner, Marlies E Reinders, Ton J Rabelink, Luc J W van der Laan, Frank J M F Dor, Jan N M Ijzermans, Paul G Genever, Claudia Lange, Antoine Durrbach, Jaco H Houtgraaf, Bruno Christ, Martina Seifert, Murat Shagidulin, Vincent Donckier, Robert Deans, Olle Ringden, Norberto Perico, Giuseppe Remuzzi, Amelia Bartholomew, Hans J Schlitt, Willem Weimar, Carla C Baan, Marc H Dahlke (2010)  Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT).   Transplantation 90: 2. 124-126 Jul  
Abstract: There is evolving interest in the use of mesenchymal stem cells (MSC) in solid organ transplantation. Pre-clinical transplantation models show efficacy of MSC in prolonging graft survival and a number of clinical studies are planned or underway. At a recent meeting of the MISOT consortium (MSC In Solid Organ Transplantation) the advances of these studies were evaluated and mechanisms underlying the potential effects of MSC discussed. Continued discussion is required for definition of safety and eventually efficacy endpoints for MSC therapy in solid organ transplantation.
Notes:
Axel Doenecke, Marcus N Scherer, Tung-Yu Tsui, Andreas A Schnitzbauer, Hans-Jürgen Schlitt, Aiman Obed (2010)  "Rescue allocation offers" in liver transplantation: is there any reason to reject "unwanted" organs?   Scand J Gastroenterol 45: 12. 1516-1517 Dec  
Abstract: To increase the number of transplanted organs, the Eurotransplant foundation uses a so-called "rescue-organ-allocation" procedure for organs that had been rejected by at least three consecutive transplant centers for medical reasons. The transplant center that finally accepts such an organ can then freely choose a patient from its own waiting list, without being bound to regular allocation criteria. Almost 30% of deceased donor livers are now allocated through this process in the Eurotransplant region. We report our results of 38 "rescue-allocation" livers (RA livers) transplanted at our institution (2003-2007), compared to a group of 115 regularly allocated organs within the same period. From our data, RA livers have the same results as regularly allocated livers. Type and frequency of postoperative morbidity did not differ between both groups, though the analysis of subgroups showed a tendency toward reduced survival of RA livers in patients with viral hepatitis. Interestingly, the Donor Risk Index (DRI) showed no difference between RA livers and regularly allocated livers. Although preliminary due to small numbers, we conclude that RA livers can be safely transplanted without increased mortality or morbidity. However, no donor specific criteria which would justify rejecting a RA liver were found. This highly challenges the applicability of the RA procedure in its current form.
Notes:
Axel Doenecke, Alexander Krömer, Marcus N Scherer, Hans-Jürgen Schlitt, Edward K Geissler (2010)  AAV plasmid DNA simplifies liver-directed in vivo gene therapy: comparison of expression levels after plasmid DNA-, adeno-associated virus- and adenovirus-mediated liver transfection.   J Gene Med 12: 10. 810-817 Oct  
Abstract: Successful liver gene therapy depends on efficient gene transfer techniques and long-lasting gene expression after successful transfer. Over the last decades, important progress has been made with the introduction of viral vectors using animal models, although their use is hampered by a complex and costly preparation compared to the simple and cost-effective preparation of plasmid DNA. These problems become even more critical when considering the application of viral vectors in human gene therapy and gene therapy trials. In a previous study, we were able to show that the hydrodynamics-based gene transfer of plasmid-DNA, containing the adeno-associated-virus specific inverted terminal repeats (AAV-ITR), prolongs gene expression in the liver, although it remained unclear whether plasmid gene transfer could achieve similar expression levels compared to viral-vector gene transfer.
Notes:
Peter Heiss, B Loewenhardt, C Manke, A Hellinger, K H Dietl, H J Schlitt, K Scheibl, S Feuerbach, C Paetzel (2010)  Primary percutaneous aspiration and thrombolysis for the treatment of acute embolic superior mesenteric artery occlusion.   Eur Radiol 20: 12. 2948-2958 Dec  
Abstract: To evaluate technical success rate and clinical outcome of patients with acute embolic superior mesenteric artery (SMA) occlusion who were treated with primary percutaneous revascularization.
Notes:
Andreas A Schnitzbauer, Marcus N Scherer, Justine Rochon, Johannes Sothmann, Stefan A Farkas, Martin Loss, Edward K Geissler, Aiman Obed, Hans J Schlitt (2010)  Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study.   BMC Nephrol 11: 09  
Abstract: Patients undergoing liver transplantation with preexisting renal dysfunction are prone to further renal impairment with the early postoperative use of Calcineurin-inhibitors. However, there is only little scientific evidence for the safety and efficacy of de novo CNI free "bottom-up" regimens in patients with impaired renal function undergoing liver transplantation. This is a single-center study pilot-study (PATRON07) investigating safety and efficacy of CNI-free, "bottom-up" immunosuppressive (IS) strategy in patients undergoing liver transplantation (LT) with renal impairment prior to LT.
Notes:
2009
Gabriel Glockzin, Hans J Schlitt, Pompiliu Piso (2009)  Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.   World J Surg Oncol 7: 01  
Abstract: Peritoneal tumor dissemination arising from colorectal cancer, appendiceal cancer, gastric cancer, gynecologic malignancies or peritoneal mesothelioma is a common sign of advanced tumor stage or disease recurrence and mostly associated with poor prognosis.
Notes:
T Bein, M Zimmermann, K Hergeth, M Ramming, L Rupprecht, H J Schlitt, A S Slutsky (2009)  Pumpless extracorporeal removal of carbon dioxide combined with ventilation using low tidal volume and high positive end-expiratory pressure in a patient with severe acute respiratory distress syndrome.   Anaesthesia 64: 2. 195-198 Feb  
Abstract: The effects of the combination of a 'lowest' lung ventilation with extracorporeal elimination of carbon dioxide by interventional lung assist are described in a patient presenting with severe acute respiratory distress syndrome due to fulminant pneumonia. Reducing tidal volume to 3 ml.kg(-1) together with interventional lung assist resulted in a decrease in severe hypercapnia without alveolar collapse or hypoxaemia but with a decrease in serum levels of interleukin-6. This approach was applied for 12 days with recovery of the patient, without complications. Extracorporeal removal of carbon dioxide by interventional lung assist may be a useful tool to enable 'ultraprotective' ventilation in severe acute respiratory distress syndrome.
Notes:
Peter Heiss, Stefan Feuerbach, Igors Iesalnieks, Felix Rockmann, Christian E Wrede, Niels Zorger, Hans J Schlitt, Jürgen Schölmerich, Okka W Hamer (2009)  Obscure gastrointestinal bleeding: preoperative CT-guided percutaneous needle localization of the bleeding small bowel segment.   J Vasc Interv Radiol 20: 4. 533-536 Apr  
Abstract: A 57-year-old woman presented with obscure gastrointestinal bleeding. Double balloon enteroscopy, angiography, and surgery including intraoperative enteroscopy failed to identify the bleeding site. Multidetector computed tomography (CT) depicted active bleeding of a small bowel segment. The bleeding segment was localized by CT-guided percutaneous needle insertion and subsequently removed surgically.
Notes:
Stefan A Farkas, Andreas A Schnitzbauer, Gabi Kirchner, Aiman Obed, Bernhard Banas, Hans J Schlitt (2009)  Calcineurin inhibitor minimization protocols in liver transplantation.   Transpl Int 22: 1. 49-60 Jan  
Abstract: Liver transplant recipients are at increasingly high risk for suffering from impaired renal function and probable need of renal replacement therapy. Extended criteria organs and transplantation of patients with higher model for end-stage liver disease scores further increase this problem. Acute and chronic nephrotoxicity are the trade-off in immunosuppression with potent calcineurin inhibitors (CNIs). As a good renal function is associated with better graft and patient survival, CNI minimization protocols have been developed. Current strategies to overcome CNI toxicity include reduction or withdrawal of CNIs concurrently with switching over to mammalian target of rapamycin inhibitor or mycophenolate mofetil (MMF)-based regimens. This strategy caused an improvement in renal function in a significant number of liver transplantation patients according to several studies. However, total CNI avoidance seems to result in higher rejection rates. To prevent chronic renal dysfunction in patients prone to or with acute renal failure, CNI delay - with induction therapy for bridging - followed by low-dose CNI in combination with MMF are proven strategies without risking higher rejection rates. An individualized, tailor-made immunosuppressive regime, with a special focus on renal function is recommended. This review gave an overview on CNI minimization protocols in liver transplantation also focusing on recently analyzed studies.
Notes:
V Benseler, A Obed, T Schubert, H - J Schlitt, U Bolder (2009)  [Case report--surgical therapy of a retroperitoneal liposarcoma weighing 45 kg].   Zentralbl Chir 134: 2. 174-177 Apr  
Abstract: Due to the late onset of symptoms, retroperitoneal liposarcoma are often diagnosed in advanced stages when adjacent organs have been infiltrated and the tumours have reached extensive sizes. Surgery remains the first choice of therapy. We report on the primary resection of a 45-kg liposarcoma that was removed en-bloc including the left kidney and descending colon with -tumour-free margins. Nine months later, the follow-up revealed a right-sided recurrence of the tumour, which was surgically removed including the right ureter. Since then, the patient has been without any signs of tumour recurrence or metastases. This report demonstrates that even extreme-ly large tumours can be removed safely and that the size is not a contraindication for primary surgical treatment. Local recurrence is common as seen in our case, and occurs even after R0 resection up to 10 years after the first operation. Recurrences should be surgically removed as this is the only treatment which has been shown to increase survival in even R1 and R2 situations.
Notes:
Markus Zimmermann, Thomas Bein, Matthias Arlt, Alois Philipp, Leopold Rupprecht, Thomas Mueller, Matthias Lubnow, Bernhard M Graf, Hans J Schlitt (2009)  Pumpless extracorporeal interventional lung assist in patients with acute respiratory distress syndrome: a prospective pilot study.   Crit Care 13: 1. 01  
Abstract: Pumpless interventional lung assist (iLA) is used in patients with acute respiratory distress syndrome (ARDS) aimed at improving extracorporeal gas exchange with a membrane integrated in a passive arteriovenous shunt. In previous studies, feasibility and safety of the iLA system was demonstrated, but no survival benefit was observed. In the present pilot study we tested the hypothesis that timely initiation of iLA using clear algorithms and an improved cannulation technique will positively influence complication rates and management of lung protective ventilation.
Notes:
Tung-Yu Tsui, Marcus N Scherer, Andreas A Schnitzbauer, Hans J Schlitt, Aiman Obed (2009)  Adult living donor liver transplantation: body mass index and MELD score of recipients are independent risk factors for hospital mortality.   Langenbecks Arch Surg 394: 2. 235-241 Mar  
Abstract: Adult living donor liver transplantation (LDLT) has been established as elective procedure or urgent procedure to save the life of patients with terminal liver diseases. The outcome of LDLT varies between transplant centers. Here, we aim to evaluate the outcome of LDLT in our center and to identify the risk factors that are associated with hospital mortality of recipients.
Notes:
Ingolf Töpel, Karin Pfister, Andrea Moser, Alexander Stehr, Markus Steinbauer, Lukas Prantl, Michael Nerlich, Hans-Jürgen Schlitt, Piotr M Kasprzak (2009)  Clinical outcome and quality of life after upper extremity arterial trauma.   Ann Vasc Surg 23: 3. 317-323 May/Jun  
Abstract: We assessed the long-term clinical outcome of 33 patients treated for arterial trauma of the upper extremity at the Regensburg University Medical Center between 1996 and 2004. Along with clinical parameters, the Disabilities of Arm, Shoulder, and Hand (DASH) score and the Short Form-36 Health Survey (SF-36) score of each patient were collected at the time of follow-up. Findings of the clinical assessment were compared to results obtained with the DASH score and the SF-36 questionnaire. The median follow-up time was 42 months. All arterial injuries had been reconstructed and were open at the time of follow-up. The prevalence of concomitant neural and/or orthopedic injuries was high (24/33, 72%). The influence of neural injury was by far greater than the impact of other factors on the long-term functional outcome. Furthermore, blunt trauma and the need for immediate fasciotomy were further markers for deficient functional recovery. Both the DASH and the SF-36 scores correlated with the clinical assessment of the severity of functional deficits. Upper extremity vascular trauma is almost always associated with severe concomitant orthopedic and/or neural injuries. The involvement of the brachial plexus and the peripheral nerves of the upper extremity is a predictor of worse long-term functional outcome.
Notes:
Pompiliu Piso, Przemyslaw Slowik, Felix Popp, Marc Hendrik Dahlke, Gabriel Glockzin, Hans Juergen Schlitt (2009)  Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.   Ann Surg Oncol 16: 8. 2188-2194 Aug  
Abstract: Cytoreductive surgery (CRS) including gastric resection combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the prognosis of selected patients with peritoneal surface malignancies. Perioperative morbidity of this aggressive treatment strategy is high; however, overall mortality can be low in specialized centers. The aim of this study was to assess the safety of gastric resections with anastomosis during CRS and HIPEC.
Notes:
P Vogel, U Bolder, M N Scherer, H - J Schlitt, K - W Jauch (2009)  Long-term outcome after multivisceral and tumor/vascular resection in patients with soft tissue sarcoma.   Langenbecks Arch Surg 394: 2. 331-337 Mar  
Abstract: Soft tissue sarcomas (STS) are rare tumors. General treatment is difficult while multimodality treatment strategies are more and more common. In these strategies, surgical resection of the primary tumor is essential to achieve local control of the tumor. In certain cases, complex resections (CR) including multivisceral and/or vascular resection are needed to achieve resection with tumor-free margins. In this study, we evaluated retrospectively the overall prognosis, morbidity, and mortality of patients treated for STS at our university hospital.
Notes:
J Ma, C K Lau, A Obed, A Dada, A Doenecke, S T Fan, H J Schlitt, T Y Tsui (2009)  A cell penetrating heme oxygenase protein protects heart graft against ischemia/reperfusion injury.   Gene Ther 16: 3. 320-328 Mar  
Abstract: Ischemia/reperfusion (I/R) injury is an unavoidable barrier that significantly affects outcome of solid organ transplantation. Here, we establish a protein transduction system to extend graft preservation time and to prevent I/R injury in heart transplantation. We generated a recombinant heme oxygenase-1 (HO-1) protein containing a modified protein transduction domain (PTD). PTD could cross cover cell membrane and carry target molecule to parenchymal cells of cold-preserved heart grafts. The newly generated PTD-HO-1 protein localized mainly in subcellular membrane organelle and nucleus after delivery that significantly prolonged cold preservation of heart grafts. This effect was associated with significantly less endothelial cell activation, less neutrophil and macrophage infiltration in PTD-HO-1-transduced heart grafts after reperfusion as compared with controls. In addition, transduction of PTD-HO-1 protein to heart graft significantly suppressed the I/R injury-associated myocardiocyte apoptosis. The infarct areas of heart graft after I/R injury were significantly reduced after PTD-HO-1 protein treatment. We show here for the first time that PTD can maintain its biological activities during cold preservation. Transduction of cell penetrating HO-1 protein significantly prolongs the cold preservation time and protects the graft from the I/R injury. This approach represents a novel method for the improvement of the overall outcome of organ transplantation.
Notes:
Sven A Lang, Christian Moser, Stefan Fichnter-Feigl, Philipp Schachtschneider, Claus Hellerbrand, Volker Schmitz, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2009)  Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice.   Hepatology 49: 2. 523-532 Feb  
Abstract: Hepatocellular carcinoma (HCC) remains associated with a poor prognosis, but novel targeted therapies in combination with anti-angiogenic substances may offer new perspectives. We hypothesized that simultaneous targeting of tumor cells, endothelial cells, and pericytes would reduce growth and angiogenesis of HCC, which represents a highly vascularized tumor entity. Recently, because of their anti-angiogenic properties, inhibitors of mammalian target of rapamycin (mTOR) have entered clinical trials for therapy of HCC. However, treatment with mTOR inhibitors may lead to paradoxical activation of Akt signaling in tumor cells via insulin-like growth factor-I receptor (IGF-IR)-dependent and IGF-IR-independent mechanisms. Because we have recently identified heat shock protein 90 (Hsp90) antagonists to impair both oncogenic and angiogenic signaling cascades in tumor cells, including Akt and IGF-IR, we sought to investigate whether Hsp90 blockade could improve growth-inhibitory and anti-angiogenic effects of the mTOR inhibitor rapamycin. Human HCC cells, a murine hepatoma cell line, endothelial cells (ECs), and vascular smooth muscle cells (VSMC) were employed in experiments. Results show that dual inhibition of mTOR and Hsp90 leads to effective disruption of oncogenic signaling cascades and substantially improves growth-inhibitory effects in vivo. Importantly, blocking Hsp90 abrogated the rapamycin-induced activation of Akt and of the downstream effector nuclear factor kappa-B (NF-kappaB) in HCC tumors. Furthermore, Hsp90 inhibition reduced the expression of platelet-derived growth factor-receptor-beta (PDGF-Rbeta) on VSMCs, and diminished vascular endothelial growth factor-receptor 2 (VEGFR-2) expression on ECs, which further improves the anti-angiogenic capacity of this regimen. CONCLUSION: Blocking Hsp90 disrupts rapamycin-induced activation of alternative signaling pathways in HCCs and substantially improves the growth-inhibitory effects of mTOR inhibition in vivo. Hence, the concept of targeting tumor cells, ECs, and VSMCs by blocking Hsp90/mTOR could prove valuable for treatment of HCC.
Notes:
E K Geissler, H J Schlitt (2009)  Immunosuppression for liver transplantation.   Gut 58: 3. 452-463 Mar  
Abstract: In the last few decades liver transplantation (LTx) has become a reliable life-saving procedure for patients with chronic end-stage liver diseases. LTx has an outstanding success rate in the first few years after allografting, especially considering that many patients are on the brink of survival at the time of transplantation. The success of LTx is owed to the pioneers who developed the surgical procedures and to researchers who discovered the medications to help prevent immunological rejection of allografts. However, several problems continue to impose serious limits on LTx today, including a shortage of donor livers, recurrence of disease (eg, hepatitis, hepatocellular cancer), preservation of long-term allograft function and the side effects of anti-rejection drugs. While the dilemma of organ shortage is not a focus of this review, we will address the latter issues as they relate to the "oldest" and "newest" approaches to immunosuppression, and discuss the prospect that recipients could potentially be made immunologically tolerant to liver transplants. Due to the critical shortage of organs, new strategies to preserve transplanted liver allografts for the longest possible time are of paramount importance.
Notes:
Andreas A Schnitzbauer, Tung-Yu Tsui, Gabriele Kirchner, Marcus N Scherer, Thomas Bein, Hans J Schlitt, Aiman Obed (2009)  Liver transplantation for sclerosing cholangitis in a polytraumatized patient.   Nat Clin Pract Gastroenterol Hepatol 6: 2. 121-126 Feb  
Abstract: Following a motorcycle accident, a 30-year-old male with multiple traumas-including liver rupture, traumatic fractures, cerebral hemorrhage, hepatic hematoma and respiratory failure-was referred to a university medical center. After initial stabilization, the patient developed pneumonia, acute kidney failure requiring intermittent hemodialysis, superinfection of the hepatic hematoma and systemic bacterial infection with multiple drug-resistant bacteria. The patient developed acute liver failure 8 weeks after the initial trauma.
Notes:
I Iesalnieks, H Glass, A Kilger, C Ott, F Klebl, A Agha, H J Schlitt, U Strauch (2009)  [Perianal fistulas in Crohn's disease: treatment results at an interdisciplinary unit].   Chirurg 80: 6. 549-558 Jun  
Abstract: Approximately one third of patients with Crohn's disease develop perianal fistulas. This study was conducted to determinate outcome predictors in patients treated at a specialized multidisciplinary unit.
Notes:
Vaclav Liska, Przemyslav Slowik, Elke Eggenhofer, Vladislav Treska, Phillip Renner, Felix C Popp, Hynek Mirka, Jiri Kobr, Roman Sykora, Hans-Juergen Schlitt, Lubos Holubec, Alena Chlumska, Tomas Skalicky, Martin Matejovic, Marc H Dahlke (2009)  Intraportal injection of porcine multipotent mesenchymal stromal cells augments liver regeneration after portal vein embolization.   In Vivo 23: 2. 229-235 Mar/Apr  
Abstract: Portal vein embolization (PVE) can be used prior to liver surgery to increase the volume of the remaining liver tissue after an extensive resection. However, the application of PVE is limited and new strategies to augment liver regeneration by cellular therapy are promising alternatives.
Notes:
Pompiliu Piso, Gabriel Glockzin, Phillipp von Breitenbuch, Felix Cristoph Popp, Marc Hendrik Dahlke, Hans J Schlitt, Aviram Nissan (2009)  Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.   J Surg Oncol 100: 4. 317-320 Sep  
Abstract: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with high morbidity. The Quality of Life (QoL) assessment in this patient group with a limited life expectancy and high recurrence rate is important. Published data show an impairment of postoperative Quality of Life at 3 months postoperatively with an improvement over 6-12 months at levels higher than the baseline. Standardized instruments QoL have to be included in clinical trials assessing the efficacy of CRS and HIPEC.
Notes:
Gabriel Glockzin, Nabil Ghali, Sven A Lang, Hans J Schlitt, Pompiliu Piso (2009)  Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer.   J Surg Oncol 100: 4. 306-310 Sep  
Abstract: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide a promising additional treatment option for selected patients with peritoneal carcinomatosis arising from colorectal cancer. Due to the aggressive surgery the concept is associated with a significant morbidity rate. Thus, the operative risk has to be evaluated against the background of the expected improvement of the oncological outcome.
Notes:
P Renner, E Eggenhofer, A Rosenauer, F C Popp, J F Steinmann, P Slowik, E K Geissler, P Piso, H J Schlitt, M H Dahlke (2009)  Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function.   Transplant Proc 41: 6. 2607-2611 Jul/Aug  
Abstract: Mesenchymal stem cells (MSC) have emerged to be one of the most promising candidates for cellular immunotherapy in solid organ transplantation because the reduction of conventional immunosuppression is highly desirable. However, little is known about the details of MSC-mediated immunomodulation and their clinical relevance. To address conflicting studies about the ability of MSC to suppress or augment T-cell proliferation, we introduce a transplantation-related rat model that allows studying the influence of MSC on alloproliferation. Hearts transplanted in a fully allogeneic transplantation model (LEW to ACI) were rejected earlier when recipients were pretreated with donor MSC, indicating activation of T cells in vivo. In additional co-culture experiments, T cells were differently affected by allogeneic MSC depending on the extent of previous activation: When conditions were rendered proinflammatory by adding high concanavalin A (ConA) concentrations or proinflammatory cytokines (interferon-gamma, interleukin-2, or tumor necrosis factor-alpha), MSC inhibited proliferation. Application of low doses of ConA or anti-inflammatory cytokines like IL-10 abrogated the suppressive effect of MSC. For application of MSC in solid organ transplantation, it will be important to further describe this switch effect of MSC function.
Notes:
Marc H Dahlke, Martin Hoogduijn, Elke Eggenhofer, Felix C Popp, Philipp Renner, Przemyslaw Slowik, Agnes Rosenauer, Pompiliu Piso, Edward K Geissler, Claudia Lange, Dominique Chabannes, Benedetta Mazzanti, Sinda Bigenzahn, Patrick Bertolino, Uta Kunter, Martino Introna, Alessandro Rambaldi, Chiara Capelli, Norberto Perico, Federica Casiraghi, Marina Noris, Eliana Gotti, Martina Seifert, Riccardo Saccardi, Hein W Verspaget, Bart van Hoek, Amelia Bartholomew, Thomas Wekerle, Hans D Volk, Giuseppe Remuzzi, Robert Deans, Hillard Lazarus, Hans J Schlitt, Carla C Baan (2009)  Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.   Transplantation 88: 5. 614-619 Sep  
Abstract: The following position paper summarizes the recommendations for early clinical trials and ongoing basic research in the field of mesenchymal stem cell-induced solid organ graft acceptance--agreed upon on the first meeting of the Mesenchymal Stem Cells In Solid Organ Transplantation (MISOT) study group in late 2008.
Notes:
Felix C Popp, Philipp Renner, Elke Eggenhofer, Przemyslaw Slowik, Edward K Geissler, Pompiliu Piso, Hans J Schlitt, Marc H Dahlke (2009)  Mesenchymal stem cells as immunomodulators after liver transplantation.   Liver Transpl 15: 10. 1192-1198 Oct  
Abstract: Mesenchymal stem cells (MSCs) are promising candidate cells for immunomodulation therapy that are currently being tested in the preclinical and clinical setting. MSCs suppress the immune response in a variety of in vitro and disease models and may thus be of benefit for patients suffering from autoimmune disorders or transplant rejection. The mechanism by which MSCs modulate the immune response is still under thorough investigation, but it most likely involves expression of local factors such as indoleamine 2,3-dioxygenase, inducible nitric oxide synthase, and others as well as interactions with dendritic or antigen-presenting cells. Although MSCs have been evaluated in clinical phase I and II studies for graft-versus-host disease and heart, kidney, and bone disease, their introduction into solid organ transplantation is still eagerly awaited. In this short review, we summarize the current understanding of immunomodulation achieved by MSC therapies and introduce a possible outline for a clinical study that will use MSCs in the context of a calcineurin inhibitor-free induction protocol after liver transplantation.
Notes:
M Loss, N Zorger, G I Kirchner, H J Schlitt (2009)  [Hepatic trauma. Interventional and conservative therapy].   Chirurg 80: 10. 908-914 Oct  
Abstract: The non-operative management of hemodynamically stable patients with liver trauma has become the standard of care. Non-operative treatment has a success rate of >80%. In the majority of cases of hemodynamic instability or high grade liver injuries, however, a surgical approach is necessary. As for conservative treatment of liver trauma the surveillance of patients in the ICU is of utmost importance. Repeat CT scans are only necessary in patients with high grade injuries or in case of complications. Interventional procedures, such as the endoscopic retrograde cholangiopancreatography in cases of biliary complications or angiography for vascular complications, are increasingly being used in order to avoid surgery. The success rates of non-operative strategies have been improving continuously over the last decades.
Notes:
Akira Mori, Christian Moser, Sven A Lang, Christina Hackl, Eva Gottfried, Marina Kreutz, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2009)  Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha.   Mol Cancer Res 7: 8. 1390-1398 Aug  
Abstract: Krüppel-like factor 5 (KLF5) is a transcription factor involved in cell transformation, proliferation, and carcinogenesis that can be up-regulated by RAS mutations. However, controversy persists as to whether it functions as a tumor suppressor or as an oncogene. Because KRAS is frequently mutated in pancreatic cancer, we investigated the regulation of KLF5 in this cancer entity. Our results show that KLF5 is overexpressed in pancreatic cancer cells and exceeds KLF5 expression of KRAS-mutated colon cancer cells. Surprisingly, inhibition of B-Raf/C-Raf or MAPK/Erk did not reduce KLF5 levels, suggesting that KLF5 expression is not promoted by KRAS-Raf-MEK-Erk signaling in pancreatic cancer. This finding is in striking contrast to reports on MEK-Erk-mediated KLF5 induction in colon cancer cells. Moreover, KLF5 expression levels neither correlated with the mutational status of KRAS nor with MEK phosphorylation in pancreatic cancer cells. Importantly, KLF5 was significantly up-regulated by interleukin (IL)-1beta or hypoxia. The IL-1 beta-mediated induction of KLF5 was diminished by blocking the p38 pathway. In addition, blocking IL-1R reduced the constitutive KLF5 expression, suggesting an autocrine activation loop. Moreover, KLF5 coimmunoprecipitated with hypoxia-inducible factor-1alpha (HIF-1alpha) and HIF-1alpha(siRNA) reduced constitutive KLF5. Similarly, KLF5(siRNA) reduced the expression of the HIF-1alpha target gene GLUT-1. Furthermore, KLF5 expression was significantly elevated by high cell density, by anchorage-independent cell growth, and in tumor spheroids. Down-regulation of KLF5 by RNAi reduced the expression of the target genes, survivin, and platelet-derived growth factor-A. In conclusion, overexpression of KLF5 in human pancreatic cancer cells is not mediated by KRAS/Raf/MAPK/Erk signaling, but involves the IL-1beta/IL-1R system, p38, and the transcription factor HIF-1alpha.
Notes:
B Krüger, A Walberer, S Farkas, F Tokmak, A Obed, P Schenker, B Henning, H J Schlitt, B K Krämer, B Banas (2009)  The impact of "high-producer" interleukin-6 haplotypes on cardiovascular morbidity and mortality in a kidney transplant population.   Transplant Proc 41: 6. 2539-2543 Jul/Aug  
Abstract: At present, inflammation is considered to be one of the key players in the development and maintenance of atherosclerosis, with ample impact on renal transplant outcomes. Interleukin-6 (IL-6) levels and the underlying genetically determined "high-producer" status impact cardiovascular morbidity and mortality. In end-stage renal disease (ESRD) patients, the role of genetically determined IL-6 differences in cardiovascular and renal outcomes of kidney transplantation is controversial. In this study, we sought to clarify the influence of IL-6 haplotypes on cardiovascular and renal outcomes among kidney transplant recipients.
Notes:
Pompiliu Piso, Gabriel Glockzin, Phillip von Breitenbuch, Talal Sulaiman, Felix Popp, Marc Dahlke, Jesus Esquivel, Hans Juergen Schlitt (2009)  Patient selection for a curative approach to carcinomatosis.   Cancer J 15: 3. 236-242 May/Jun  
Abstract: There is an increasing evidence showing that in selected patients with peritoneal carcinomatosis cytoreductive surgery and hyperthermic intraperitoneal chemotherapy may improve survival. Adequate patient selection is crucial to obtain a complete macroscopic cytoreduction, a leading predictor of patient outcome. However, selection is a very difficult process and is associated with a significant learning curve. Many selection criteria have to be assessed in each patient: performance status, comorbiditites, response to previous chemotherapies, histology grading, and presence of extra-abdominal or liver metastases, small bowel involvement, and tumor volume assessed by the peritoneal cancer index. All these factors have to be discussed interdisciplinary and with the patient to create an individualized treatment strategy. It is difficult to decide the relative importance of each selection criteria. However, completeness of cytoreduction, tumor volume, and histology grading are most important in many multivariate analysis independent prognostic factors. For appropriate selected patients with peritoneal carcinomatosis arising from appendiceal and colon cancer, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be considered standard of care.
Notes:
B F Henning, S Kuchlbauer, C A Böger, A Obed, S Farkas, C Zülke, M N Scherer, M Scherer, A Walberer, M Banas, B Krüger, H J Schlitt, B Banas, B K Krämer (2009)  Percutaneous transluminal angioplasty as first-line treatment of transplant renal artery stenosis.   Clin Nephrol 71: 5. 543-549 May  
Abstract: Transplant renal artery stenosis (TRAS) is a frequent complication after renal transplantation, however long-term follow-up data after interventional treatment are rare.
Notes:
S A Lang, G Glockzin, M H Dahlke, F C Popp, A Agha, H J Schlitt, P Piso (2009)  [The techniques of peritonectomy and hyperthermic intraperitoneal chemotherapy].   Zentralbl Chir 134: 5. 443-449 Sep  
Abstract: The treatment of peritoneal carcinomatosis represents a challenge in the therapy for gastrointestinal cancer. A multimodal approach with complete surgical cytoreduction and hyperthermic intraperitoneal chemotherapy can improve the prognosis in selected patients. Complete surgical cytoreduction, consisting of parietal and visceral peritonectomy, is a sophisticated procedure, frequently requiring multivisceral resections and should only be performed by experienced visceral surgeons. In addition, hyperthermic intraperitoneal chemotherapy is of some complexity. Furthermore, regarding the learning curve for this procedure, combined treatment should only be performed in specialised centres. Under optimal conditions, the therapy can be carried out with reasonable morbidity and mortality rates. Patients with peritoneal carcinomatosis should be evaluated by an interdisciplinary team concerning this multimodal therapy option and, if applicable, they should be referred to therapy within the framework of clinical studies.
Notes:
Dirk Arnold, Ernst J Rummeny, Thomas Kirchner, Karsten Ridwelski, Helmut Oettle, Jörg Thomas Hartmann, Markus Moehler, Arnulf Hölscher, Hauke Lang, Hans J Schlitt, Peter Neuhaus (2009)  [Diagnosis and treatment of liver metastases from primary colorectal tumour].   Onkologie 32 Suppl 2: 7-12 06  
Abstract: Contrast-enhanced multislice computer tomography (MSCT) has established itself as the standard tomographic imaging method both for diagnosis and for treatment monitoring of hepatic lesions. To clarify local conditions before partial liver resection, diffusion-weighted magnetic resonance tomography (DWI-MRT) can also provide important additional information. In order to meet the criteria for a R0 resection, a margin of 0.5 mm seems to be sufficient. Neoadjuvant chemotherapy aiming to reduce tumour size can be given in parallel with portal artery embolisation without adversely affecting perioperative morbidity and mortality. As far as the management of primary resectable liver metastases is concerned, there is an urgent need for more studies. Despite the relatively limited evidence, adjuvant chemotherapy is currently more widely favoured in Germany than perioperative chemotherapy. There is also considerable need for studies concerning preoperative therapy in patients with liver metastases that are not (yet) resectable. In KRAS wild-type tumours, high response rates (in terms of a reduction in the size of metastases) are achieved with a cetuximab/chemotherapy combination. Bevacizumab/chemotherapy combinations lead to high rates of pathohistological complete and partial remissions. What the best parameter for judging the success of preoperative therapy is remains unknown, and so comparison studies using survival as a 'hard' endpoint must be carried out.
Notes:
Felix C Popp, Elke Eggenhofer, Philipp Renner, Edward K Geissler, Pompiliu Piso, Hans J Schlitt, Marc H Dahlke (2009)  Mesenchymal stem cells can affect solid organ allograft survival.   Transplantation 87: 9 Suppl. S57-S62 May  
Abstract: It has recently been recognized that mesenchymal stem cells (MSCs) isolated from adult bone marrow are able to modify the alloimmune response in vitro and in vivo. MSCs can be expanded into large quantities in culture, thereby facilitating potential future applications in solid organ transplantation. To develop novel MSC-based antirejection treatments, the mechanism behind the immunomodulatory ability of MSCs has to be elucidated further. At present, a variety of possible in vitro effects of MSCs on immune system effector cells have been reported, but little is known about their in vivo properties. Here, we discuss recent findings regarding the influence of MSCs on different effector cell populations in vitro and summarize the available data describing their in vivo properties.
Notes:
Claus Rödel, Wolfram Trudo Knoefel, Hans J Schlitt, Ludger Staib, Thomas Höhler (2009)  [Neoadjuvant and surgical treatment for rectal cancer].   Onkologie 32 Suppl 2: 17-20 06  
Abstract: According to the 2008 guidelines on colorectal cancer, whether preoperative therapy is indicated for rectal cancer should be judged based on the T and N categories. A few centres limit the indication for preoperative radio(chemo)therapy to patients with tumours that, according to magnetic resonance tomography (MRT), extend to the fascia mesorectalis or are 1 mm or less away from it - so-called circumferential resection margin-positive or CRM-positive tumours. Omitting preoperative therapy for MRT CRM-negative tumours is, however, a matter that still requires further study in clinical trials. The high rate of distant metastases continues to be a problem. Assuming that pathohistological complete remission (pCR) is a predictive marker of long-term disease-free survival after neoadjuvant radiochemotherapy, attempts are now being undertaken to intensify the neoadjuvant therapy. Phase II trials show improved pCR rates by combining the preoperative radiation with the double combinations oxaliplatin or irinotecan plus infusional or oral 5-FU (capecitabine). In the case of limited T1 rectal cancer without further risk factors, transanal local excision can be used.
Notes:
2008
A Doenecke, E Frank, M N Scherer, H - J Schlitt, E K Geissler (2008)  Prolongation of heart allograft survival after long-term expression of soluble MHC class I antigens and vIL-10 in the liver by AAV-plasmid-mediated gene transfer.   Langenbecks Arch Surg 393: 3. 343-348 May  
Abstract: INTRODUCTION: The essential prerequisite for successful gene therapy in vivo is an effective and long-lasting transfer of the desired gene into the respective cell type or tissue. Over the last decades, many different methods have been developed for this purpose. The use of plasmid DNA seems to be a good alternative to the commonly used viral vectors because its large-scale production is simple, and side effects are low. Unfortunately, most reports describe only short-term expression in vivo, probably due to the lack of genomic integration in the target cell. This problem can possibly be addressed by the use of adeno-associated virus plasmids (AAV plasmids), where the coding sequences are cloned between the AAV-specific inverted terminal repeats. Here, we report our results after allogeneic heart transplantation, which followed AAV-plasmid-mediated gene transfer of the rat soluble major histocompatibility complex class I antigen RT1.A(a) and viral interleukin (vIL)-10 in the "high"-responder Dark Agouti to Lewis rat strain combination. RESULTS: A high and stable long-term expression was achieved by in vivo transfection of the liver using AAV plasmids. Serum levels over 1,000 ng/ml of soluble RT1.A(a) and over 300 pg of vIL-10, respectively, were achieved. Expression levels remained high for up to several months. A mean prolongation of heart allograft survival of 1 to 2 days was demonstrated after transfection of either RT1.A(a) or vIL-10.
Notes:
Sven Arke Lang, Isabel Brecht, Christian Moser, Aiman Obed, David Batt, Hans Juergen Schlitt, Edward Kenneth Geissler, Oliver Stoeltzing (2008)  Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model.   Langenbecks Arch Surg 393: 3. 333-341 May  
Abstract: Activation of the mitogen-activated protein kinase-extracellular-signal-regulated kinase (ERK) pathways plays an important role in the progression of hepatocellular carcinoma (HCC). Importantly, Raf kinases are principal effectors within this oncogenic signaling cascade. We hypothesized that concomitant inhibition of Raf and vascular endothelial growth factor receptor 2 (VEGFR2) will affect tumor growth and angiogenesis of HCC.
Notes:
T S Weiss, M Lichtenauer, S Kirchner, P Stock, H Aurich, B Christ, G Brockhoff, L A Kunz-Schughart, K - W Jauch, H - J Schlitt, W E Thasler (2008)  Hepatic progenitor cells from adult human livers for cell transplantation.   Gut 57: 8. 1129-1138 Aug  
Abstract: Liver regeneration is mainly based on cellular self-renewal including progenitor cells. Efforts have been made to harness this potential for cell transplantation, but shortage of hepatocytes and premature differentiated progenitor cells from extra-hepatic organs are limiting factors. Histological studies implied that resident cells in adult liver can proliferate, have bipotential character and may be a suitable source for cell transplantation.
Notes:
Ayman Agha, Gabriel Glockzin, Nabil Ghali, Igors Iesalnieks, Hans J Schlitt (2008)  Surgical treatment of substernal goiter: an analysis of 59 patients.   Surg Today 38: 6. 505-511 05  
Abstract: Substernal goiter is defined as a thyroid mass of which more than 50% is located below the thoracic inlet. In this article we report the diagnosis, symptoms, thyroid function, treatment, and postoperative complications of 59 patients with substernal goiter.
Notes:
Stefan Fichtner-Feigl, Masaki Terabe, Atsushi Kitani, Cheryl A Young, Ivan Fuss, Edward K Geissler, Hans-Jürgen Schlitt, Jay A Berzofsky, Warren Strober (2008)  Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.   Cancer Res 68: 9. 3467-3475 May  
Abstract: In previous studies, we described a "counter-immunosurveillance" mechanism initiated by tumor-activated, interleukin-13 (IL-13)-producing natural killer T cells that signal Gr-1(+) cells to produce transforming growth factor-beta(1) (TGF-beta(1)), a cytokine that suppresses the activity of tumor-inhibiting cytolytic CD8(+) T cells. Here, we show that in two tumor models (the CT-26 metastatic colon cancer and the 15-12RM fibrosarcoma regressor models), this counter-surveillance mechanism requires the expression of a novel IL-13 receptor, IL-13R alpha(2), on Gr-1(intermediate) cells, because down-regulation of IL-13R alpha(2) expression or the activator protein-1 signal generated by the receptor via in vivo administration of specific small interfering RNA or decoy oligonucleotides leads to loss of TGF-beta(1) production. Furthermore, acting on prior studies showing that IL-13R alpha(2) expression is induced (in part) by tumor necrosis factor-alpha (TNF-alpha), we show that receptor expression and TGF-beta(1) production is inhibited by administration of a TNF-alpha-neutralizing substance, TNF-alpha R-Fc (etanercept). Taking advantage of this latter fact, we then show in the CT-26 model that counter-immunosurveillance can be inhibited, anti-CT-26-specific CD8(+) cytolytic activity can be restored, and CT-26 metastatic tumor nodules can be greatly decreased by administration of TNF-alpha R-Fc. Corroborative data were obtained using the 15-12RM fibrosarcoma model. These studies point to the prevention of metastatic cancer with an available agent with already known clinically acceptable adverse effects and toxicity.
Notes:
Christian Moser, Philipp Schachtschneider, Sven A Lang, Andreas Gaumann, Akira Mori, Johann Zimmermann, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2008)  Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.   Eur J Cancer 44: 11. 1577-1586 Jul  
Abstract: The insulin-like growth factor-I receptor (IGF-IR) is frequently overexpressed and constitutively activated in pancreatic cancer, thus representing a promising target for therapy. We investigated the impact of a novel inhibitor of IGF-IR (NVP-AEW541) on signalling and growth of pancreatic cancer. Human pancreatic cancer cells and endothelial cells were employed, and effects of NVP-AEW541 on signalling pathways investigated by Western blotting. NVP-AEW541 diminished the activation of IGF-IR, IRS-1, Erk, Akt and STAT3. Furthermore, NVP-AEW541 reduced cancer cell proliferation and abrogated migratory effects of IGF-I. NVP-AEW541 elicited a direct effect on endothelial cells in terms of reducing endothelial cell migration. In vivo, treatment of mice with NVP-AEW541 significantly reduced orthotopic pancreatic tumour growth, vascularisation, and VEGF expression. Interestingly, NVP-AEW541 lowered serum levels of IGF-binding-protein-3 (IGFBP-3). In conclusion, the IGF-IR inhibitor NVP-AEW541 effectively disrupts IGF-I signalling and reduces pancreatic tumour growth. Hence, blocking IGF-IR could prove valuable for targeted therapy of pancreatic cancer.
Notes:
Hartmut H-J Schmidt, Uwe J F Tietge, Janine Buettner, Hannelore Barg-Hock, Gisela Offner, Susanne Schweitzer, Giorgos V Dedoussis, Burkhard Rodeck, Hans C Kallfelz, Hans-Jürgen Schlitt, Karl Oldhafer, Jürgen Klempnauer (2008)  Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p.W577R LDL-receptor gene mutation.   Clin Transplant 22: 2. 180-184 Mar/Apr  
Abstract: Mutations within the low density lipoprotein (LDL)-receptor gene result in familial hypercholesterolemia, an autosomal dominant inherited disease. Clinical homozygous affected subjects die of premature coronary artery disease as early as in early childhood. We identified a girl at the age of five yr with clinical homozygous familial hypercholesterolemia presenting with achilles tendon xanthomas and arcus lipoides. Her total cholesterol reached up to 1050 mg/dL. Molecular characterization of the LDL-receptor gene revealed a homozygous p.W577R mutation. Despite intensive treatment interventions with the combination of diet, statins, colestipol, and LDL-apheresis, the patient developed symptomatic coronary artery disease at the age of 16 yr. Subsequently, orthotopic liver transplantation was performed to cure the defective LDL-receptor gene. Clinical follow-up for almost nine yr post-transplantation revealed excellent liver function, normal liver enzymes, normal LDL-cholesterol, and regression of both tendon xanthomas and symptomatic coronary artery disease. In conclusion, liver transplantation can effectively reduce LDL-cholesterol in a familial hypercholesterolemia recipient with subsequent regression of xanthomas and atherosclerosis. Timing is extremely important in these exceptional cases to exclude the demand for heart transplantation due to severe coronary artery disease. In addition, the identification of the LDL-receptor as etiology of clinical homozygous hypercholesterolemia is a prerequisite once liver transplantation is considered as therapeutic option.
Notes:
A Agha, A Fürst, I Iesalnieks, S Fichtner-Feigl, N Ghali, D Krenz, M Anthuber, K W Jauch, P Piso, H J Schlitt (2008)  Conversion rate in 300 laparoscopic rectal resections and its influence on morbidity and oncological outcome.   Int J Colorectal Dis 23: 4. 409-417 Apr  
Abstract: The negative influence of conversion from laparoscopic to open colorectal resection on early postoperative morbidity and outcome has been demonstrated several times. In this study, we analyzed the conversion rate and its influence on early postoperative morbidity and short-term oncological outcome following laparoscopic rectal resections.
Notes:
Andreas Gaumann, Hans J Schlitt, Edward K Geissler (2008)  Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.   Transpl Int 21: 3. 207-217 Mar  
Abstract: Cancer morbidity and mortality are increasingly apparent risks in transplant recipients, thus reducing life quality and overall survival. These risks have largely been attributed to long-term immunosuppressive drug therapy, which remains necessary to prevent organ allograft rejection. Interestingly, however, recent studies challenge the premise that all immunosuppressive drugs necessarily promote cancer. A particular class of immunosuppressants, referred to as mammalian target of rapamycin (mTOR) inhibitors, has been shown to have potent anti-cancer effects that are presently being tested in clinical studies. The focus of this review is to present current evidence that allows us to understand better the dual immunosuppressive and anti-cancer functions of this class of drugs used to prevent allograft rejection. We will concentrate on the different functions of mTOR that allow it to simultaneously control the immune system and tumor development. We will also discuss results from current clinical studies that either support or refute this potential dualistic role.
Notes:
Aiman Obed, Tung-Yu Tsui, Andreas A Schnitzbauer, Manal Obed, Hans J Schlitt, Heinz Becker, Thomas Lorf (2008)  Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified?   Langenbecks Arch Surg 393: 2. 141-147 Mar  
Abstract: Liver transplantation is considered as one of therapeutic approaches to hepatocellular carcinoma (HCC). The present study aims to evaluate the efficacy of various therapeutic options for HCC.
Notes:
Marc G Jeschke, Dagmar Klein, Wolfgang E Thasler, Ulrich Bolder, Hans-Jürgen Schlitt, Karl-Walter Jauch, Thomas S Weiss (2008)  Insulin decreases inflammatory signal transcription factor expression in primary human liver cells after LPS challenge.   Mol Med 14: 1-2. 11-19 Jan/Feb  
Abstract: Hepatic homeostasis is essential for survival in critically ill and burned patients. Insulin administration improves survival and decreases infections in these patients. To determine the molecular mechanisms, the aim of the present study was to establish a stress model using primary human hepatocytes (PHHs) and to study the effects of insulin on the hepatic inflammatory signaling cascade. Liver tissue was obtained from general surgical patients, and PHHs were isolated and maintained in culture. Primary hepatocyte cultures were challenged with various doses of lipopolysaccharide (LPS), and the inflammatory signal transcription cascade was determined by real-time PCR. In subsequent experiments, primary hepatocyte cultures were challenged with LPS and insulin was added in various doses. Glucose was determined by colorimetric assays. PHHs treated with 100 microg/mL LPS showed a profound inflammatory reaction with increased expression of interleukin (IL)-6, IL-10, IL-1beta, tumor necrosis factor (TNF), and signal transducer and activator of transcription 5 (STAT-5). Insulin at 10 IU/mL significantly decreased IL-6, TNF, and IL-1beta at pretranslational levels, an effect associated with decreased STAT-5 mRNA expression (P < 0.05). Glucose concentration and cellular metabolic activity were not different between controls and insulin-treated cells. Based on our results, we suggest that primary hepatocyte cultures can be used to study the effect of LPS on the inflammatory cascade. Insulin decreases hepatic cytokine expression, which is associated with decreased STAT-5 expression.
Notes:
Ayman Agha, Christian Moser, Igors Iesalnieks, Pompiliou Piso, Hans-J Schlitt (2008)  Combination of hand-assisted and laparoscopic proctocolectomy (HALP): Technical aspects, learning curve and early postoperative results.   Surg Endosc 22: 6. 1547-1552 Jun  
Abstract: Various techniques for laparoscopic proctocolectomy have been reported worldwide. We evaluated the technical aspects and early postoperative results of hand-assisted laparoscopic proctocolectomy (HALP) with construction of an ileal pouch-anal anastomosis through a Pfannenstiel incision.
Notes:
Peter Heiss, Maike Bachthaler, Okka Wilkea Hamer, Pompiliu Piso, Thomas Herold, Hans Juergen Schlitt, Stefan Feuerbach, Niels Zorger (2008)  Delayed visceral arterial hemorrhage following Whipple's procedure: minimally invasive treatment with covered stents.   Ann Surg Oncol 15: 3. 824-832 Mar  
Abstract: Delayed visceral arterial hemorrhage caused by inflammatory vessel erosion represents a rare but life-threatening complication after pancreatic head resection. Therapeutic options include reoperation or endovascular minimally invasive techniques such as embolization or stent graft placement. The present article describes our experiences with implantation of newly developed low-profile stent grafts.
Notes:
Ayman Agha, Philipp von Breitenbuch, Nabil Gahli, Pompiliu Piso, Hans J Schlitt (2008)  Retroperitoneoscopic adrenalectomy: lateral versus dorsal approach.   J Surg Oncol 97: 1. 90-93 Jan  
Abstract: For tumours of the adrenal gland different surgical retroperitoneal approaches have been established, including the lateral and the dorsal approach. It is still unclear if the lateral or the dorsal approach should be preferred.
Notes:
M Loss, A Obed, H J Schlitt (2008)  [Split-liver transplantation].   Chirurg 79: 2. 144-148 Feb  
Abstract: Split-liver transplantation is now established as a safe and successful technique that extends the donor pool for patients of all ages and thus reduces waiting-list mortality, although it can not solve the problem of organ shortage alone. Split-liver transplantation additionally represents an alternative to living liver transplantation without a potential risk of harm to the donor. Careful selection of donor and recipient, high technical and surgical skill, and experience are necessary to achieve results comparable to those of whole organ transplantation.
Notes:
Aiman Obed, Andreas A Schnitzbauer, Tung-Yu Tsui, Hani Abu Gosh, Anwar Jarrad, Abdulla Bashir, Hans J Schlitt (2008)  Living donor liver resection: a low-tech but highly efficient technique. The Regensburg experience.   Langenbecks Arch Surg 393: 3. 413-421 May  
Abstract: To evaluate a low-tech blunt liver dissecting technique for living-liver-donor procedures. Thirty three adult-to-adult living-donor operations were performed at Regensburg University and Jordan Hospital, Amman.
Notes:
Beate G Brem-Exner, Christine Sattler, James A Hutchinson, Gudrun E Koehl, Katharina Kronenberg, Stefan Farkas, Seiichiro Inoue, Christian Blank, Stuart J Knechtle, Hans J Schlitt, Fred Fändrich, Edward K Geissler (2008)  Macrophages driven to a novel state of activation have anti-inflammatory properties in mice.   J Immunol 180: 1. 335-349 Jan  
Abstract: Recurrent episodes of inflammation underlie numerous pathologies, notably those of inflammatory bowel diseases. In this study, we describe a population of macrophages in a novel state of activation that mitigates colitis in mice. The cells responsible for this effect, called IFN-gamma-stimulated monocyte-derived cells (IFNgamma-MdC), derive from mouse spleen, blood, and bone marrow monocytes and are distinguished from known macrophage populations by mode of generation, cell surface phenotype, and function. IFNgamma-MdC only arise when macrophages are cultivated in the presence of CD40L-expressing CD4+ T cells, M-CSF, and IFN-gamma. IFNgamma-MdC express markers including F4/80, CD11b/c, CD86, and CD274; they are negative for CD4, CD8, Gr1, CD19, CD80, and CD207. Functionally, IFNgamma-MdC are defined by their capacity to enrich cocultured T cell populations for CD4+CD25+Foxp3+ regulatory cells; this enrichment, constituting up to 60% or more of residual lymphocytes, is attributed to an expansion, but also to a cell contact and caspase-dependent depletion of activated T cells. In mice, IFNgamma-MdC delivered i.v. traffic to gut-associated peripheral lymphoid tissues, including the mesenteric lymph nodes, Peyer's patches, and colonic mucosa, and promote the clinical and histological resolution of chronic colitis. We conclude that IFNgamma-MdC represent macrophages in a novel state of activation, possessing multiple T cell-suppressive effects with therapeutic potential for the treatment of autoimmune inflammation.
Notes:
Matthias Hornung, Peter Vogel, Thomas Schubert, Hans-Jürgen Schlitt, Ulrich Bolder (2008)  A case of virilization induced by a Krukenberg tumor from gastric cancer.   World J Surg Oncol 6: 02  
Abstract: The Krukenberg tumor represents ovarian metastases associated with gastric cancer or other gastrointestinal malignancies. Histology shows typical mucus-production and numerous signet-ring cells. Occasionally Krukenberg tumors have endocrine function and, as a consequence, some patients demonstrate hirsutism and virilization.
Notes:
M H Dahlke, L Asshoff, F C Popp, S Feuerbach, S A Lang, P Renner, P Slowik, O Stoeltzing, H J Schlitt, P Piso (2008)  Mesenteric ischemia--outcome after surgical therapy in 83 patients.   Dig Surg 25: 3. 213-219 06  
Abstract: Intestinal ischemia is the prime vascular emergency for the visceral surgeon. However, the diagnosis of mesenteric ischemia is difficult, the surgical options are often limited and the overall outcome is generally poor.
Notes:
Stefan Fichtner-Feigl, Cheryl A Young, Atsushi Kitani, Edward K Geissler, Hans-Jürgen Schlitt, Warren Strober (2008)  IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis.   Gastroenterology 135: 6. 2003-13, 2013.e1-7 Dec  
Abstract: Previous studies have shown that fibrosis developing in chronic experimental colitis is driven by interleukin (IL)-13 signaling via IL-13R alpha(2) and the production of transforming growth factor (TGF)-beta1. In the present study, we sought to determine the fibrogenic downstream events set in motion by such signaling.
Notes:
Tao Xu, Cristina Haering, Chi-Keung Lau, Aiman Obed, Jian Ma, Axel Doenecke, Marcus N Scherer, Andreas A Schnitzbauer, Sheung-Tat Fan, Hans J Schlitt, Tung-Yu Tsui (2008)  Targeting of interleukin-10 is superior to cytotoxic T-lymphocyte associated antigen 4 with human immunoglobulin G(1) for the prevention of chronic allograft deterioration in organ transplantation.   J Gene Med 10: 12. 1315-1323 Dec  
Abstract: Genetic manipulation of the allograft is an attractive approach to prevent the graft against chronic deterioration through stable expression of immunomodulatory or protective genes. However, the best strategy for prevention of chronic allograft deterioration remains unclear.
Notes:
Edward K Geissler, Hans J Schlitt, George Thomas (2008)  mTOR, cancer and transplantation.   Am J Transplant 8: 11. 2212-2218 Nov  
Abstract: One of the most clinically important molecular signalling networks to emerge over the past decade is the mammalian target of rapamycin (mTOR) pathway. mTOR, the protein kinase at the core of this intricate and continually evolving pathway, controls cellular growth and behavior, impacting vital processes from immune reactivity to cancer progression. As researchers, surgeons and physicians in the field of organ transplantation, we have acquired a keen interest in regulating mTOR activity, because this molecule is not only able to block IL-2 signalling in T cells, and thus alloimmune reactivity, it is a critical part of the cellular circuitry which is often constitutively activated in neoplastic cells, leading to the all-too-often occurrence of cancer. Since allograft rejection and the development of cancer lead most lists for causing excess morbidity and mortality in our organ transplant population, a thorough and current understanding of the mTOR pathway becomes essential. In this review, we endeavor to unravel the latest molecular developments in mTOR signalling and use this basic knowledge to generate perspectives on how pharmacologic mTOR intervention may form a balance to impact long-term antidonor immune responses and the development of malignancy in transplant recipients.
Notes:
V Guralnik, A Schäffler, J Schölmerich, H J Schlitt, R Müller-Wille, S Feuerbach, F Obermeier (2008)  [Partial splenic artery embolization for the treatment of a patient with hypersplenism due to liver cirrhosis].   Dtsch Med Wochenschr 133: 38. 1893-1896 Sep  
Abstract: A 52-year-old man with liver cirrhosis and ascites, hepatorenal syndrome and severe pancytopenia was admitted to hospital for treatment and consideration for future liver transplantation.
Notes:
Hans Jürgen Schlitt, Dirk Arnold, Wolfram T Knoefel, Karsten Ridwelski, Markus Moehler, Andrea Tannapfel, Anke Reinacher-Schick (2008)  [Surgical and perioperative therapy of liver metastases].   Onkologie 31 Suppl 5: 9-13 11  
Abstract: Multimodal management approaches and innovative surgical techniques have completely transformed treatment and prognosis for patients with liver metastases, bringing considerable improvements. Whether patients with resectable liver metastases should be given neoadjuvant and/or adjuvant chemotherapy is still a matter of controversy. If a R0 resection is possible (either first-line or after pretreatment), then from a surgical point of view this should be carried out without delay. A limited resection (subsegment/segment/non-anatomical resection) is sufficient if the metastases can be removed completely - and has the advantage of retaining more functional liver tissue, thus allowing a 2nd or 3rd resection to be carried out in the event of tumor recurrence. A small disease-free margin (< 1 cm) is enough, and does not worsen the prognosis. Perioperative chemotherapy with FOLFOX4 was shown to reduce the risk of recurrence by approximately 25% (7.3% in absolute terms) in patients with metastases that are resectable (EORTC 40983) - and this in a group of patients who, in terms of their metastasis patterns, with a median of only 1 solitary metastasis, were "ideal" candidates for primary resection. The difference was not significant in intention to treat (ITT) analysis, but was significant in the 'eligible' patients. It is notable, however, that the whole of the overall difference arose as a result of events in the first 10 weeks - thereafter the curves run in parallel. The EORTC and the majority of the experts now, on the basis of the clinically relevant improvement in disease-free survival, recommend adopting pre- and postoperative chemotherapy with FOLFOX4 (3 months before and after surgery) as the new standard. This recommendation is, however, controversial. The question of whether cetuximab or bevacizumab should be given in addition is still open, but clinical trials have started. The evidence concerning adjuvant chemotherapy alone after R0 metastasis resection is less clear. Despite this, and especially among specialist surgeons, adjuvant chemotherapy is however more widely supported than is perioperative chemotherapy - because the risk of presurgical toxicity and thus potential inoperability or tumor progression during chemotherapy is avoided. The new S3 guidelines from 2008 also favor adjuvant treatment - even if data are only available for adjuvant treatment with bolus 5-FU. If adjuvant treatment is given, then combination chemotherapy should be used. Surgeons, for the most part, continue to regard primary resection as the standard.
Notes:
M Loss, C Zülke, A Obed, O Stöltzing, H J Schlitt (2008)  [Surgical therapy of benign liver tumors].   Chirurg 79: 8. 722-728 Aug  
Abstract: Benign liver tumors are being detected more frequently due to the widespread use of ultrasound and complementary methods and due to improvements in diagnostic accuracy. In the case of a reliable diagnosis of asymptomatic hemangioma or focal nodular hyperplasia surgery is not indicated. Hepatic adenoma of considerable size should be resected primarily based on the risk of rupture. Improvements in diagnostic imaging as well as the optimization of surgical procedures with extremely low complication rates permit an individualized management strategy founded on evidence-based algorithms. In the case of an equivocal diagnosis, we advocate low-risk tumor resection instead of tumor biopsy due to the inherent complication rates of hemorrhage or tumor-cell dissemination and possible misleading histology.
Notes:
S Fichtner-Feigl, W Strober, E K Geissler, H - J Schlitt (2008)  Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis.   Mucosal Immunol 1 Suppl 1: S24-S27 Nov  
Abstract: To investigate the immunopathogenesis of inflammation-associated fibrosis we analyzed the chronic colitis and late-developing fibrosis occurring in BALB/c mice administered weekly doses of intrarectal trinitrobenzene sulfonic acid (TNBS). We showed first in this model that an initial T helper type 1 response involving interleukin (IL)-12p70 and interferon-gamma subsides after 3 weeks to be supplanted by an IL-23/IL-25 response beginning after 4-5 weeks. This evolution is followed by gradually increasing production of IL-17 and cytokines ordinarily seen in a T helper type 2 response, particularly IL-13, which reaches a plateau at 8-9 weeks. We then show that IL-13 production results in the induction of an IL-13 receptor formerly thought to function only as a decoy receptor, IL-13Ralpha(2), and this receptor is critical to the production of tumor growth factor (TGF)-beta(1) and the onset of fibrosis. Thus, if IL-13 signaling through this receptor is blocked by administration of soluble IL-13Ralpha(2)-Fc, or by administration of IL-13Ralpha(2)-specific siRNA, TGF-beta(1) is not produced and fibrosis does not occur. These studies show that in chronic TNBS colitis, fibrosis is dependent on the development of an IL-13 response that acts through a novel cell-surface-expressed IL-13 receptor to induce TGF-beta(1).
Notes:
Markus Moehler, Karsten Ridwelski, Meinolf Karthaus, Ludger Staib, Wolfram T Knoefel, Michael Kneba, Hans-Jürgen Schlitt, Dirk Arnold, Andrea Tannapfel, Anke Reinacher-Schick, Pompiliu Piso (2008)  [Treatment of nonresectable liver metastases].   Onkologie 31 Suppl 5: 14-18 11  
Abstract: A standardized procedure for dealing with nonresectable liver metastases does not currently exist. It is important that an interdisciplinary approach to treatment be taken, in order to look for the optimum solution for each individual patient. High response rates appear to be important, in order to make more patients with nonresectable liver metastases 'resectable' and thus provide a chance of cure. A series of randomized phase II-III trials found a clear increase in response rates and an improvement in the R0 resection rate as a result of more intensive therapy (triple chemotherapy or combination chemotherapy plus cetuximab or bevacizumab). In the NO16966 trial, too, under blinded conditions, more liver metastasis resections were carried out among patients who had received bevacizumab than among patients in the control arm without bevacizumab, although the response rates in the two arms were the same. A gap of 6-8 weeks between the last dose of bevacizumab and surgery is clinically optimal from the point of view of perioperative safety. If neoadjuvant treatment is given, then resection should be carried out as soon as the metastases are resectable. If the patient's response is not adequate, then consideration should be given to an adaptation or change of the treatment regimen. Regular evaluation for secondary resectability is important. Surgically, in addition to 2- or multi-stage surgery, other possible techniques include portal embolization and intraoperative ablation. The goal remains R0 resection. In order to minimize complications, clinicians must select patients carefully, take account of comorbidities, and know the critical resection volume.
Notes:
F C Popp, E Eggenhofer, P Renner, P Slowik, S A Lang, H Kaspar, E K Geissler, P Piso, H J Schlitt, M H Dahlke (2008)  Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate.   Transpl Immunol 20: 1-2. 55-60 Nov  
Abstract: The induction of tolerance towards allogeneic solid organ grafts is one of the major goals in transplantation medicine. Mesenchymal stem cells (MSC) inhibit the immune response in vitro, and thus are promising candidate cells to promote acceptance of transplanted organs in vivo. Such novel approaches of tolerance induction are needed since, to date, graft acceptance can only be maintained through life-long treatment with unspecific immunosuppressants that are associated with toxic injury, opportunistic infections and malignancies. We demonstrate that donor-derived MSC induce long-term allograft acceptance in a rat heart transplantation model, when concurrently applied with a short course of low-dose mycophenolate. This tolerogenic effect of MSC is at least partially mediated by the expression of indoleamine 2,3-dioxygenase (IDO), demonstrated by the fact that blocking of IDO with 1-methyl tryptophan (1-MT) abrogates graft acceptance. Moreover we hypothesize that MSC interact with dendritic cells (DC) in vivo, because allogeneic MSC are rejected in the long-term but DC acquire a tolerogenic phenotype after applying MSC. In summary, we demonstrate that MSC constitute a promising tool for induction of non-responsiveness in solid organ transplantation that warrants further investigation in clinical trials.
Notes:
Sven A Lang, Philipp Schachtschneider, Christian Moser, Akira Mori, Christina Hackl, Andreas Gaumann, David Batt, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2008)  Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.   Mol Cancer Ther 7: 11. 3509-3518 Nov  
Abstract: The Ras/Raf/MEK pathway represents an important oncogenic signaling pathway in gastrointestinal malignancies, including pancreatic cancer. Although activating B-Raf mutations are infrequent in pancreatic cancer, we hypothesized that targeting Raf could be valuable for therapy of this cancer entity. Moreover, as vascular endothelial growth factor receptor 2 (VEGFR2) is involved in tumor angiogenesis, we sought to investigate the effects of dual inhibition of Raf and VEGFR2 on pancreatic tumor growth, vascularization, and metastasis. Effects of a Raf/VEGFR2 inhibitor (NVP-AAL881) on pancreatic cancer cells, endothelial cells, and vascular smooth muscle cells were determined by Western blotting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis, and migration assays, respectively. Changes in the expression of VEGF-A or survivin were investigated by ELISA and/or real-time PCR. The growth-inhibitory effects of Raf/VEGFR2 inhibition were additionally evaluated in orthotopic tumor models. Results showed that various Raf isoforms were activated in pancreatic cancer cells and NVP-AAL881 diminished the activation of MEK, Akt, Erk, and also STAT3. Moreover, dual inhibition of Raf/VEGFR2 significantly reduced VEGF expression and impaired cancer cell migration. Importantly, besides blocking VEGF-induced Erk and SAPK phosphorylation in endothelial cells, the Raf inhibitor diminished STAT3 phosphorylation, independent of a VEGFR2 blockade, and reduced the expression of survivin. In addition, cell proliferation and migration of both endothelial cells and vascular smooth muscle cells were significantly reduced. In vivo, blocking Raf/VEGFR2 significantly inhibited orthotopic tumor growth and vascularization and reduced cancer metastasis. In conclusion, blocking Raf exerts growth-inhibitory effects on pancreatic tumor cells, endothelial cells, and pericytes and elicits antiangiogenic properties. Dual targeting of Raf and VEGFR2 appears to be a valid strategy for therapy of pancreatic cancer.
Notes:
Ayman Agha, Alois Fürst, Johanna Hierl, Igors Iesalnieks, Gabriel Glockzin, Matthias Anthuber, Karl-Walter Jauch, Hans J Schlitt (2008)  Laparoscopic surgery for rectal cancer: oncological results and clinical outcome of 225 patients.   Surg Endosc 22: 10. 2229-2237 Oct  
Abstract: The efficacy and feasibility of laparoscopic resection for rectal cancer has been proved, but the results of prospective, randomized studies are not yet available. Here we present a prospective observational study evaluating oncological and clinical outcome after laparoscopic surgery in patients with rectal cancer.
Notes:
T Lorf, A A Schnitzbauer, S K H Schaefers, M N Scherer, H J Schlitt, M Oellerich, H Becker, A Obed (2008)  Prognostic value of the monoethylglycinexylidide (MEGX)-test prior to liver resection.   Hepatogastroenterology 55: 82-83. 539-543 Mar/Apr  
Abstract: The critical issue before major hepatic resection is to evaluate and detect patients with a potentially increased risk of hepatic failure. In this study the prognostic value of the monoethylglycinexylidide (MEGX)- liver function test was evaluated with regards to clinical course and survival after partial liver resection.
Notes:
R T Grundmann, P Hermanek, S Merkel, C - T Germer, J Hauss, D Henne-Bruns, K Herfarth, U T Hopt, T Junginger, E Klar, J Klempnauer, W H Knapp, M Kraus, H Lang, K - H Link, F Löhe, K J Oldhafer, H - R Raab, H - G Rau, A Reinacher-Schick, J Ricke, J Roder, A - O Schäfer, H J Schlitt, M R Schön, D Stippel, A Tannapfel, K Tatsch, T J Vogl (2008)  [Diagnosis and treatment of colorectal liver metastases - workflow].   Zentralbl Chir 133: 3. 267-284 Jun  
Abstract: In this review, standards of diagnosis and treatment of colorectal liver metastases are described on the basis of a workshop discussion. Algorithms of care for patients with synchronous / metachronous colorectal liver metastases or locoregional recurrent tumour are presented. Surgical resection is the procedure of choice in the curative treatment of liver metastases. The decision about the resection of liver metastases should consider the following parameters: 1. General operability of the patient (comorbidity); 2. Achievability of an R 0 situation: i. if necessary, in combination with ablative methods, ii. if necessary, neoadjuvant chemotherapy, iii. the ability to eradicate extrahepatic tumour manifestations; 3. Sufficient volume of the liver remaining after resection ("future liver remnant = FLR): i. if necessary, in combination with portal vein embolisation or two-stage hepatectomy; 4. The feasibility to preserve two contiguous hepatic segments with adequate vascular inflow and outflow as well as biliary drainage; 5. Tumour biological aspects ("prognostic variables"); 6. Experience of the surgeon and centre! Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases provided a complete resection of both intra- and extrahepatic disease is feasible. Even in bilobar colorectal metastases and 5 or more tumours in the liver, a complete tumour resection has been described. The type of resection (hepatic wedge resection or anatomic resection) does not influence the recurrence rate. Preoperative volumetry is indicated when major hepatic resection is planned. The FLR should be 25 % in patients with normal liver, 40 % in patients who have received intensive chemotherapy or in cases of fatty liver, liver fibrosis or diabetes, and 50-60 % in patients with cirrhosis. In patients with initially unresectable colorectal liver metastases, preoperative chemotherapy enables complete resection in 15-30 % of the cases, whereas the value of neoadjuvant chemotherapy in patients with resectable liver metastases has not been sufficiently supported. In situ ablative procedures (radiofrequency ablation = RFA and laser-induced interstitial thermotherapy = LITT) are local therapy options in selected patients who are not candidates for resection (central recurrent liver metastases, bilobar multiple metastases and high-risk resection or restricted patient operability). Patients with tumours larger than 3 cm have a high local recurrence rate after percutaneous RFA and are not optimal candidates for this procedure. The physician's experience influences the results significantly, both after hepatectomy and after in situ ablation. Therefore, patients with colorectal liver metastases should be treated in centres with experience in liver surgery.
Notes:
Igors Iesalnieks, Hauke Winter, Evelyne Bareck, Georgios C Sotiropoulos, Peter E Goretzki, Monika Klinkhammer-Schalke, Stefan Bröckner, Arnold Trupka, Matthias Anthuber, Holger Rupprecht, Maximilian Raab, Willibald Meyer, Florian Reichmann, Manfred Kästel, Max Mayr, Wolfgang Braun, Hans J Schlitt, Ayman Agha (2008)  Thyroid metastases of renal cell carcinoma: clinical course in 45 patients undergoing surgery. Assessment of factors affecting patients' survival.   Thyroid 18: 6. 615-624 Jun  
Abstract: Metastases of renal cell carcinoma (RCC) to the thyroid gland are uncommon. There is no clear consensus regarding the role of surgery in metastatic disease to the thyroid since most clinical studies include small numbers of patients. Also, risk factors associated with disease progression following thyroidectomy are not yet defined. We examined the determinants of the outcome in patients undergoing surgery for thyroid metastases of RCC.
Notes:
Christian Moser, Sven A Lang, Akira Mori, Claus Hellerbrand, Hans J Schlitt, Edward K Geissler, William E Fogler, Oliver Stoeltzing (2008)  ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.   BMC Cancer 8: 07  
Abstract: Hepatocellular carcinoma (HCC) represents a highly vascularized tumor entity and the process of angiogenesis is essential for the growth of HCC. Importantly, the pro-angiogenic transcription factors HIF-1alpha and STAT3 have been implicated in HCC progression, thus representing interesting targets for molecular targeted therapy. We hypothesized that therapeutic inhibition of HIF-1alpha could be achieved by using a novel tubulin-binding agent (ENMD-1198). ENMD-1198 is an analog of 2-methoxyestradiol (2ME2) with antiproliferative and antiangiogenic activity.
Notes:
Elke Eggenhofer, Felix C Popp, Philipp Renner, Pczemyslaw Slowik, Annette Neuwinger, Pompiliu Piso, Edward K Geissler, Hans J Schlitt, Marc H Dahlke (2008)  Allogeneic bone marrow transplantation restores liver function in Fah-knockout mice.   Exp Hematol 36: 11. 1507-1513 Nov  
Abstract: In murine models, transplantation of wild-type bone marrow cells (BMC) can counterbalance genetic liver defects by fusion between transplanted marrow cells and resident hepatocytes. This phenomenon, however, is of no immediate clinical use because all syngeneic BMC harbor the same underlying genetic defect.
Notes:
Igors Iesalnieks, Alexandra Kilger, Heidi Glass, Rene Müller-Wille, Frank Klebl, Claudia Ott, Ulrike Strauch, Pompiliu Piso, Hans J Schlitt, Ayman Agha (2008)  Intraabdominal septic complications following bowel resection for Crohn's disease: detrimental influence on long-term outcome.   Int J Colorectal Dis 23: 12. 1167-1174 Dec  
Abstract: A number of studies deal with factors affecting postoperative recurrence; however, they do not analyze the influence of postoperative morbidity on the long-term outcome. This was the aim of the present study.
Notes:
2007
Gudrun E Koehl, Ferdinand Wagner, Oliver Stoeltzing, Sven A Lang, Markus Steinbauer, Hans J Schlitt, Edward K Geissler (2007)  Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability.   Transplantation 83: 5. 607-614 Mar  
Abstract: Identifying immunosuppressive agents with antitumor effects could help address the problem of posttransplant malignancy. Here we tested for potential inhibitory effects of mycophenolate mofetil (MMF) on tumors in vitro and in vivo.
Notes:
B Krüger, M Fischereder, K - W Jauch, C Graeb, U Hoffmann, C A Böger, B Banas, A Obed, H J Schlitt, B K Krämer (2007)  Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.   Transplant Proc 39: 2. 518-521 Mar  
Abstract: Chronic allograft nephropathy (CAN) is, among others, caused by nephrotoxic side effects of calcineurin inhibitors (CNI), which are to date still the mainstay of immunosuppressive therapy. Sirolimus (SIR), an immunosuppressive compound without effects on glomerular perfusion, has been used in CNI-sparing immunosuppressive protocols. We report the 5-year follow-up of a prospective, controlled conversion study from CNI to SIR in patients with moderately to severely impaired renal function.
Notes:
Sven A Lang, Dagmar Klein, Christian Moser, Andreas Gaumann, Gabriel Glockzin, Marc H Dahlke, Wolfgang Dietmaier, Ulrich Bolder, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2007)  Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.   Mol Cancer Ther 6: 3. 1123-1132 Mar  
Abstract: Oncogenic signaling through activation of epidermal growth factor receptor (EGFR), HER-2, and hypoxia inducible-factor-1alpha (HIF-1alpha) has been implicated in gastric cancer growth and angiogenesis through up-regulation of vascular endothelial growth factor (VEGF). Recently, heat shock protein 90 (Hsp90) has been identified as a critical regulator of oncogenic protein stability, including EGFR, HER-2, and HIF-1alpha. We hypothesized that inhibition of Hsp90 impairs EGF- and hypoxia-mediated angiogenic signaling in gastric cancer cells and consequently inhibits angiogenesis and tumor growth. In vitro, the geldanamycin derivate 17-allylamino-17-demethoxygeldanamycin (17-AAG) led to marked reduction in constitutive and inducible activation of extracellular signal-regulated kinase 1/2, Akt, and signal transducer and activator of transcription 3 and decreased nuclear HIF-1alpha protein. In addition, EGFR and HER-2 were down-regulated after Hsp90 inhibition. With respect to regulation of angiogenic molecules, 17-AAG significantly reduced EGF-mediated VEGF secretion. Phosphorylation of focal adhesion kinase and paxillin were both abrogated by 17-AAG, which resulted in significant impairment of cancer cell motility. Interestingly, cytotoxic effects of 17-AAG in vitro were higher on cancer cells and gastric fibroblasts than on pericytes. In vivo, the water-soluble compound 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG; 25 mg/kg, thrice per week) significantly reduced s.c. xenografted tumor growth. By immunohistochemistry, 17-DMAG significantly reduced vessel area and numbers of proliferating tumor cells in sections. Furthermore, similar significant growth-inhibitory effects of 17-DMAG were achieved when administered as low-dose therapy (5 mg/kg, thrice per week). In conclusion, blocking Hsp90 disrupts multiple proangiogenic signaling pathways in gastric cancer cells and inhibits xenografted tumor growth in vivo. Hence, gastric cancer harbors attractive molecular targets for therapy with Hsp90 inhibitors, which could lead to improved efficacy of antineoplastic therapy regimens.
Notes:
Andreas A Schnitzbauer, Matthias Hornung, Ulrike Seidel, Bernd Krüger, Bernhard K Krämer, Hans J Schlitt, Aiman Obed (2007)  Does mini-incision donor nephrectomy improve quality of life in living kidney donors?   Clin Transplant 21: 2. 235-240 Mar/Apr  
Abstract: Living kidney donation helps to avoid or reduce the time period of dialysis and on waiting lists in patients requiring a new organ. Mini-incision donor nephrectomy (MIDN) shows to result in better clinical outcome in comparison with traditional open donor nephrectomy (ODN). This study was performed to evaluate the impact of different surgical procedures on the quality of life (QoL) in patients that underwent donor nephrectomy.
Notes:
Jay A Fishman, Vincent Emery, Richard Freeman, Manuel Pascual, Lionel Rostaing, Hans J Schlitt, Dino Sgarabotto, Julian Torre-Cisneros, Marc E Uknis (2007)  Cytomegalovirus in transplantation - challenging the status quo.   Clin Transplant 21: 2. 149-158 Mar/Apr  
Abstract: Cytomegalovirus (CMV) infection of solid organ transplant (SOT) recipients causes both ''direct'' and ''indirect'' effects including allograft rejection, decreased graft and patient survival, and predisposition to opportunistic infections and malignancies. Options for CMV prevention include pre-emptive therapy, whereby anti-CMV agents are administered based on sensitive viral assays, or universal prophylaxis of all at-risk patients. Each approach has advantages and disadvantages in terms of efficacy, costs, and side effects. Standards of care for prophylaxis have not been established.
Notes:
Tung-Yu Tsui, Aiman Obed, Yeung-Tung Siu, Shaw-Fang Yet, Lukas Prantl, Hans J Schlitt, Sheung-Tat Fan (2007)  Carbon monoxide inhalation rescues mice from fulminant hepatitis through improving hepatic energy metabolism.   Shock 27: 2. 165-171 Feb  
Abstract: Heme oxygenase 1 (HO-1) enhances cellular antioxidative capability by increasing the cleavage of the endogenous and exogenous heme. Besides the biochemical activities of HO, the products of heme degradation significantly contribute to the cytoprotective effects of HO. Here, we show that HO-1 deficiency significantly increases the susceptibility of mice to apoptotic insults, whereas expression of HO-1 significantly increased the resistance of primary hepatocyte to apoptosis. This phenomenon was correlated with the production of one of its catalytic products-carbon monoxide (CO). Surprisingly, exposing the primary mouse hepatocyte to CO could improve the cellular energy metabolism in a soluble guanylyl cyclase-dependent manner. One-hour inhalation of low-dose CO enhanced the hepatic soluble guanylyl cyclase activities in mice. In parallel, the levels of hepatic adenosine triphosphate increased significantly and were associated with a marked reduction of TNF-alpha-induced apoptosis in the liver of D-galactosamine-sensitized mice. In addition, CO inhalation for 1 h significantly improved the survival of mice after initiation of fulminant hepatitis. Up to 90% of mice given CO survived for more than 7 days, whereas control mice died within 12 h. The data provide novel insight of CO-mediated cytoprotection.
Notes:
Mark D Jäger, Jian Y Liu, Kai F Timrott, Felix C Popp, Oliver Stoeltzing, Sven A Lang, Pompiliu Piso, Edward K Geissler, Hans J Schlitt, Marc H Dahlke (2007)  Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.   Exp Hematol 35: 1. 164-170 Jan  
Abstract: Mixed chimerism after allogeneic bone marrow transplantation (BMT) promotes immunologic tolerance. Graft-vs-host disease (GvHD) can occur when immunosuppressive control of the graft fails. Here we evaluate the influence of concurrent immunosuppression after irradiation-based induction therapy on development of tolerance and GvHD.
Notes:
Stefan Fichtner-Feigl, Ivan J Fuss, Cheryl A Young, Tomohiro Watanabe, Edward K Geissler, Hans-Jürgen Schlitt, Atsushi Kitani, Warren Strober (2007)  Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis.   J Immunol 178: 9. 5859-5870 May  
Abstract: To investigate the immunopathogenesis of inflammation-associated fibrosis, we analyzed the chronic colitis and late-developing fibrosis occurring in BALB/c mice administered weekly doses of intrarectal 2,4,6-trinitrobenzene sulfonic acid. We showed first in this model that an initial Th1 response involving IL-12p70 and IFN-gamma subsides after 3 wk to be supplanted by an IL-23/IL-25 response beginning after 4-5 wk. This evolution is followed by gradually increasing production of IL-17 and cytokines ordinarily seen in a Th2 response, particularly IL-13, which reaches a plateau at 8-9 wk. In vitro stimulation studies suggest that this IL-13 production is dependent on IL-23 and IL-25, but not on IL-12p70. We then show that IL-13 production results in the induction of an IL-13R formerly thought to function only as a decoy receptor, IL-13Ralpha(2), and this receptor is critical to the production of TGF-beta(1) and the onset of fibrosis. Thus, if IL-13 signaling through this receptor is blocked by administration of soluble IL-13Ralpha(2)-Fc, or by administration of IL-13Ralpha(2)-specific small interfering RNA, TGF-beta(1) is not produced and fibrosis does not occur. These studies show that in chronic 2,4,6-trinitrobenzene sulfonic acid colitis, fibrosis is dependent on the development of an IL-13 response that acts through a novel cell surface-expressed IL-13R to induce TGF-beta(1). A similar mechanism may obtain in certain forms of human inflammatory bowel disease.
Notes:
Markus Neumeier, Alexander Sigruener, Elke Eggenhofer, Johanna Weigert, Thomas S Weiss, Andreas Schaeffler, Hans J Schlitt, Charalampos Aslanidis, Pompiliu Piso, Thomas Langmann, Gerd Schmitz, Jürgen Schölmerich, Christa Buechler (2007)  High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes.   Biochem Biophys Res Commun 352: 2. 543-548 Jan  
Abstract: Low circulating levels of high molecular weight adiponectin (HMW-Apm) have been linked to dyslipidaemia and systemic HMW-Apm negatively correlates with very low density lipoprotein (VLDL), apolipoprotein B (ApoB), and ApoE and is positively associated with ApoA-I. Therefore, it was investigated whether HMW-Apm alters the hepatic synthesis of ApoB, ApoE, and ApoA-I or the activity of the hepatic ATP-binding cassette transporter A1 (ABCA1), as the main determinant of plasma HDL. HMW-Apm reduces hepatic ApoB and ApoE release whereas ABCA1 protein, activity and ApoA-I were not altered. Global gene expression analysis revealed that hepatic nuclear factor 4-alpha (HNF4-alpha) and HNF4-alpha regulated genes like ApoB are downregulated by HMW-Apm and this was confirmed at the mRNA and protein level. Therefore it is concluded that HMW-adiponectin may ameliorate dyslipidaemia by reducing the hepatic release of ApoB and ApoE, whereas ABCA1 function and ApoA-I secretion are not influenced.
Notes:
Ayman Agha, Gabriel Glockzin, Matthias Woenckhaus, Wolfgang Dietmaier, Igors Iesalnieks, Hans J Schlitt (2007)  Insular carcinomas of the thyroid exhibit poor prognosis and long-term survival in comparison to follicular and papillary T4 carcinomas.   Langenbecks Arch Surg 392: 6. 671-677 Nov  
Abstract: Insular thyroid carcinoma was described as a tumor with aggressive behavior, and patients usually present themselves with an advanced tumor stage. Whether the insular component is an independent factor for poor prognosis remains unclear. Therefore, in the present study, we compared the survival of patients with advanced insular, follicular, and papillary thyroid cancer.
Notes:
Felix C Popp, Przemyslaw Slowik, Elke Eggenhofer, Phillip Renner, Sven A Lang, Oliver Stoeltzing, Edward K Geissler, Pompiliu Piso, Hans J Schlitt, Marc H Dahlke (2007)  No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury.   Stem Cells 25: 3. 639-645 Mar  
Abstract: Multipotent mesenchymal stromal (MS) cells from adult bone marrow are a cell population that can be expanded to large numbers in culture. MS cells might be differentiated toward hepatocytes in vitro and thus are promising candidates for therapeutic applications in vivo. The efficacy of bone marrow-derived MS cells versus hepatocytes to contribute to liver regeneration was compared in a rat model of prolonged toxic hepatic injury. Liver damage was induced by injection of carbon tetrachloride (CCl(4)) or allyl alcohol (AA) with and without retrorsine (R) pretreatment. MS cells or hepatocytes of wild-type F344 rats were injected into dipeptidyl peptidase IV (DPPIV)-deficient syngeneic rats. Hepatocyte chimerism was higher after intraportal hepatocyte transplantation in the R/AA group (mean maximal cluster size [MCS] = 21 cells) compared with the R/CCl(4) treatment group (MCS = 18). No hepatocyte engraftment was outlined following post-transplant CCl(4) injection only, whereas mere AA injection resulted in small clusters of donor-derived hepatocytes (MCS = 2). Intraparenchymal injection of hepatocytes was associated with a MCS = 11 after R/AA treatment and a MCS = 6 after AA administration alone. Redistribution of MS cells to the liver was shown after intraportal and intraparenchymal injection. In contrast to hepatocyte transplantation, however, donor-derived DPPIV-positive cells could not be demonstrated in any recipient after MS cell transplantation. Data from the present study indicate that a well-defined population of MS cells obtained according to established standard protocols does not differentiate into hepatocytes in vivo when transplanted under regenerative conditions, in which the application of hepatocytes results in stable hepatic engraftment.
Notes:
Igors Iesalnieks, Arnold Trupka, Maximilian Raab, Gabriel Glockzin, Matthias Woenckhaus, Hans Jürgen Schlitt, Ayman Agha (2007)  Renal cell carcinoma metastases to the thyroid gland-8 cases reported.   Thyroid 17: 1. 49-52 Jan  
Abstract: Clinically important, isolated metastases to the thyroid gland is a rare occurrence. Renal cell carcinoma (RCC) is the most common primary tumor site. We report on 8 cases of late onset metachronous thyroid metastases of RCC.
Notes:
Sven A Lang, Andreas Gaumann, Gudrun E Koehl, Ulrike Seidel, Frauke Bataille, Dagmar Klein, Lee M Ellis, Ulrich Bolder, Ferdinand Hofstaedter, Hans-Jürgen Schlitt, Edward K Geissler, Oliver Stoeltzing (2007)  Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.   Int J Cancer 120: 8. 1803-1810 Apr  
Abstract: The mammalian target of rapamycin (mTOR) has become an interesting target for cancer therapy through its influence on oncogenic signals, which involve phosphatidylinositol-3-kinase and hypoxia-inducible factor-1alpha (HIF-1alpha). Since mTOR is an upstream regulator of HIF-1alpha, a key mediator of gastric cancer growth and angiogenesis, we investigated mTOR activation in human gastric adenocarcinoma specimens and determined whether rapamycin could inhibit gastric cancer growth in mice. Expression of phospho-mTOR was assessed by immunohistochemical analyses of human tissues. For in vitro studies, human gastric cancer cell lines were used to determine S6K1, 4E-BP-1 and HIF-1alpha activation and cancer cell motility upon rapamycin treatment. Effects of rapamycin on tumor growth and angiogenesis in vivo were assessed in both a subcutaneous tumor model and in an experimental model with orthotopically grown tumors. Mice received either rapamycin (0.5 mg/kg/day or 1.5 mg/kg/day) or diluent per intra-peritoneal injections. In addition, antiangiogenic effects were monitored in vivo using a dorsal-skin-fold chamber model. Immunohistochemical analyses showed strong expression of phospho-mTOR in 60% of intestinal- and 64% of diffuse-type human gastric adenocarcinomas. In vitro, rapamycin-treatment effectively blocked S6K1, 4E-BP-1 and HIF-1alpha activation, and significantly impaired tumor cell migration. In vivo, rapamycin-treatment led to significant inhibition of subcutaneous tumor growth, decreased CD31-positive vessel area and reduced tumor cell proliferation. Similar significant results were obtained in an orthotopic model of gastric cancer. In the dorsal-skin-fold chamber model, rapamycin-treatment significantly inhibited tumor vascularization in vivo. In conclusion, mTOR is frequently activated in human gastric cancer and represents a promising new molecular target for therapy.
Notes:
Aiman Obed, Alexander Beham, Kerstin Püllmann, Heinz Becker, Hans J Schlitt, Thomas Lorf (2007)  Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation.   World J Gastroenterol 13: 5. 761-767 Feb  
Abstract: To assess the outcome of patients, who underwent transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) and subsequently liver transplantation (OLT) irrespective of tumor size when no tumor progression was observed.
Notes:
Ayman Agha, Marcus Nils Scherer, Kiriaki Mantouvalou, Matthias Woenckhaus, Dieter Froehlich, Stefan Barlage, Ashraf Dada, Hans Jürgen Schlitt (2007)  Effectiveness of parathyroid-hormone measurement in detecting patients with multiple gland disease causing primary hyperparathyroidism.   Langenbecks Arch Surg 392: 6. 703-708 Nov  
Abstract: Intraoperative parathyroid hormone measurement (iPTH) has strengthened the successful use of minimal-invasive approaches in surgery of primary hyperparathyroidism (pHPT). The aim of the study was to evaluate the efficacy of iPTH monitoring in treating pHPT resulting from multiple gland disease.
Notes:
Sven A Lang, Christian Moser, Andreas Gaumann, Dagmar Klein, Gabriel Glockzin, Felix C Popp, Marc H Dahlke, Pompiliu Piso, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2007)  Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.   Clin Cancer Res 13: 21. 6459-6468 Nov  
Abstract: Inhibitors of heat-shock protein 90 (Hsp90) may interfere with oncogenic signaling pathways, including Erk, Akt, and hypoxia-inducible factor-1alpha (HIF-1alpha). Because insulin-like growth factor-I receptor (IGF-IR) and signal transducer and activator of transcription 3 (STAT3) signaling pathways are implicated in the progression of pancreatic cancer, we hypothesized that blocking Hsp90 with geldanamycin derivates [17-allylamino-geldanamycin (17-AAG), 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG)] would impair IGF-I- and interleukin-6-mediated signaling and thus reduce pancreatic tumor growth and angiogenesis in vivo.
Notes:
Doris Schacherer, Martina Zeitoun, Roland Buttner, Cornelia Gelbmann, Aiman Obed, Hans-Jurgen Schlitt, Jurgen Scholmerich, Gabi-I Kirchner (2007)  Sirolimus-induced drug fever and ciclosporin-induced leukencephalopathia with seizures in one liver transplant recipient.   World J Gastroenterol 13: 45. 6090-6093 Dec  
Abstract: We describe the first case of sirolimus-induced drug fever in a female liver transplant recipient, with a history of hepatitis C-induced end-stage liver cirrhosis in 1999. In 2005, six years after transplantation, she developed calcineurin inhibitor-induced renal function impairment. Immunosuppression was switched from tacrolimus to sirolimus. Two days after the intake of sirolimus, she developed daily fever spikes, but no infectious focus was found. Antibiotic therapy had no influence on the fever. After fourteen days, sirolimus was switched back to tacrolimus and the fever disappeared. In history, the patient developed ciclosporin-induced generalized seizures eleven days after liver transplantation, followed by the development of a motoric speech disorder. Magnetic resonance imaging (MRI) findings were consistent with leucoencephalopathy, therefore immunosuppressive therapy was changed from ciclosporin to tacrolimus and the neurologic symptoms improved significantly. Our case is the first reported case of sirolimus-induced drug fever. In addition, the patient showed the rare occurrence of ciclosporin-induced leukencephalopathy with seizures.
Notes:
Christian Moser, Sven A Lang, Silvia Kainz, Andreas Gaumann, Stefan Fichtner-Feigl, Gudrun E Koehl, Hans J Schlitt, Edward K Geissler, Oliver Stoeltzing (2007)  Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.   Mol Cancer Ther 6: 11. 2868-2878 Nov  
Abstract: We recently showed that inhibition of heat shock protein 90 (Hsp90) decreases tumor growth and angiogenesis in gastric cancer through interference with oncogenic signaling pathways. However, controversy still exists about the antimetastatic potential of Hsp90 inhibitors. Moreover, in vitro studies suggested that blocking Hsp90 could overcome p53-mediated resistance of cancer cells to oxaliplatin. We therefore hypothesized that blocking oncogenic signaling with a Hsp90 inhibitor would impair metastatic behavior of colon cancer cells and also improve the efficacy of oxaliplatin in vivo. Human colon cancer cells (HCT116, HT29, and SW620) and the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) were used for experiments. In vitro, 17-DMAG substantially inhibited phosphorylation of epidermal growth factor receptor, c-Met, and focal adhesion kinase, overall resulting in a significant decrease in cancer cell invasiveness. Importantly, 17-DMAG led to an up-regulation of the transcription factor activating transcription factor-3, a tumor suppressor and antimetastatic factor, on mRNA and protein levels. In a cell death ELISA, 17-DMAG markedly induced apoptosis in both p53-wt and p53-deficient cells. In vivo, 17-DMAG significantly reduced tumor growth and vascularization. Furthermore, blocking Hsp90 reduced hepatic tumor burden and metastatic nodules in an experimental model of hepatic colon cancer growth. Importantly, combining oxaliplatin with 17-DMAG in vivo significantly improved growth inhibitory and proapoptotic effects on p53-deficient cells, compared with either substance alone. In conclusion, inhibition of Hsp90 abrogates the invasive properties of colon cancer cells and modulates the expression of the antimetastatic factor activating transcription factor-3. Hence, targeting Hsp90 could prove valuable for treatment of advanced colorectal cancer by effectively inhibiting colon cancer growth and hepatic metastasis and improving the efficacy of oxaliplatin.
Notes:
P von Breitenbuch, I Iesalnieks, P Piso, P Pompiliu, H - J Schlitt, A Agha (2007)  [Primary hyperparathyroidism: clinical symptoms, diagnostic significance and localisation--a retrospective analysis].   Zentralbl Chir 132: 6. 497-503 Dec  
Abstract: The primary hyperparathyroidism (pHPT) is one of the most frequent metabolic diseases. Due to improvement in diagnostics it is a point of interest whether patients with pHPT still suffer from the typical symptoms. Moreover, the question of the best localisation-diagnostics and the most frequent localisation of the adenoma is not yet clarified. New operation strategies and more cost-efficient strategies for diagnostic and therapy could be developed due to the clinically established electrochemiluminescence immunoassay for intraoperative monitoring of intact parathyroid hormone (iPTH).
Notes:
Marcus N Scherer, Bernhard Banas, Kiriaki Mantouvalou, Andreas Schnitzbauer, Aiman Obed, Bernhard K Krämer, Hans J Schlitt (2007)  Current concepts and perspectives of immunosuppression in organ transplantation.   Langenbecks Arch Surg 392: 5. 511-523 Sep  
Abstract: BACKGROUND: While early surgical success made organ transplantation possible in the 1950s and 1960s, the breakthrough in clinical organ transplantation was achieved through the discovery and invention of modern immunosuppressive agents in the early/mid-1980s. Especially during the 1990 s, a large array of immunosuppressants has expanded the armamentarium used to prevent and treat allograft rejection, resulting in an excellent short-term and an acceptable long-term outcome. However, these drugs have potent but still non-specific immunosuppressive properties and frequently show severe acute and chronic side effects, sometimes questioning the overall success. CONCEPTS/TRENDS: As the "Holy-Grail" of the transplant community, the induction of "true donor-specific tolerance" has not been achieved yet; current immunosuppressive strategies, in particular in Europe, include "individually tailored immunosuppressive" protocols, mostly based on specific immunologic and non-immunologic risk factors. These protocols allow for optimal immunosuppressive protocols for each patient group according to their needs by choosing the most suitable, well-tolerated combination of agents and the most effective doses to avoid acute rejection episodes (incidence and severity) and minimise drug-related toxicity to reduce long-term drug-related morbidity and mortality. Nevertheless, transplant recipient are still being forced to take a life-long course of chemical immunosuppressive agents to keep their graft, knowing about the possible life-threatening side effects. SUMMARY: We review current trends of immunosuppressive protocols in liver and kidney transplantation, focusing on calcineurin-inhibitor-sparing protocols, mammalian-target-of-rapamycin (mTOR) inhibitor based-protocols and corticosteroid-avoidance protocols, being aware of the fact, that most of these strategies could be applicable for other transplanted organs, too. Finally, we describe future trends and new developments that are rising on the horizon.
Notes:
Ingolf Topel, Alexander Stehr, Markus G Steinbauer, Pompilio Piso, Hans J Schlitt, Piotr M Kasprzak (2007)  Surgical strategy in aortoesophageal fistulae: endovascular stentgrafts and in situ repair of the aorta with cryopreserved homografts.   Ann Surg 246: 5. 853-859 Nov  
Abstract: The surgical treatment of aortoesophageal fistulae (AEF) has a high morbidity and mortality rate. We report our experience with the sequential use of endovascular thoracic stentgrafts and cryopreserved aortic homografts for in situ repair of the descending thoracic aorta.
Notes:
G Glockzin, N Ghali, S A Lang, A Agha, H J Schlitt, P Piso (2007)  [Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy].   Chirurg 78: 12. 1100, 1102-6, 1108-10 Dec  
Abstract: Colorectal cancer is a common malignant disease with increasing incidence and a significant cause of death in cancer patients. More than 10% of patients with colorectal cancer show peritoneal carcinomatosis at initial diagnosis. Moreover, peritoneal metastasis is a common sign of recurrence. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a new treatment strategy for highly selected patients with peritoneal carcinomatosis. Numerous studies show prolonged survival after CRS and HIPEC with acceptable morbidity and mortality rates. Accurate preoperative diagnostics and patient selection play a pivotal role in postoperative patient outcome. This promising treatment strategy is discussed regarding surgical technique, intraperitoneal chemotherapy, and patient outcome.
Notes:
P Piso, M H Dahlke, N Ghali, I Iesalnieks, M Loss, F Popp, P von Breitenbuch, A Agha, S A Lang, F Kullmann, H J Schlitt (2007)  Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies.   Int J Colorectal Dis 22: 11. 1295-1300 Nov  
Abstract: The presence of peritoneal carcinomatosis arising from colorectal cancer is associated with a poor prognosis. It was the purpose of this study to analyze morbidity, mortality, and survival after major cytoreductive surgery and intraperitoneal chemotherapy.
Notes:
Volker Benseler, Geoffrey W McCaughan, Hans J Schlitt, G Alex Bishop, David G Bowen, Patrick Bertolino (2007)  The liver: a special case in transplantation tolerance.   Semin Liver Dis 27: 2. 194-213 May  
Abstract: Liver transplants are not often rejected in patients weaned from immunosuppression and are spontaneously accepted in some animal models. We review past and recent findings of liver transplantation and propose a unified model in which several mechanisms act in concert to induce and maintain tolerance in both naïve and effector T cell compartments. First, passenger leukocytes migrate to lymphoid tissues and induce apoptosis of alloreactive naïve T cells. Second, antigen-specific activation and subsequent deletion of naïve and effector cells within the liver itself purge the repertoire of alloreactive T cells. Other mechanisms such as microchimerism and migration of donor dendritic cells to the thymus may play a predominant role in maintaining tolerance, and soluble major histocompatibility complex molecules, donor peptides, and regulatory T cells may participate in the induction and maintenance phases. Thus, the major challenge in liver transplantation will be to favor these tolerogenic processes while developing strategies that specifically inhibit alloreactive memory T cells.
Notes:
Gudrun E Koehl, Edward K Geissler, Massimo Iacobelli, Caroline Frei, Verena Burger, Silvia Haffner, Ernst Holler, Reinhard Andreesen, Hans J Schlitt, Günther Eissner (2007)  Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo.   Cancer Biol Ther 6: 5. 686-690 May  
Abstract: Defibrotide (DF) is a polydisperse mixture of 90% single-stranded oligonucleotides with anti-thrombotic and anti-apoptotic functions. DF is used in the treatment of endothelial complications in the course of allogeneic stem cell transplantation. Recent preclinical evidence suggests that DF might also have anti-neoplastic properties. In the present study we hypothesized that DF might inhibit tumors via an anti-angiogenic effect. The anti-angiogenic potential of DF was tested in vitro using human microvascular endothelial cells forming vessel structures across a layer of dermal fibroblasts. Our results show that pharmacologic DF concentrations (100 mug/ml) significantly reduced vessel formation in this assay. Similarly, DF blocked sprouting from cultured rat aortic rings. In vivo, angiogenesis in a human gastric tumor (TMK1) implanted in dorsal skin-fold chambers (in nude mice) was inhibited by i.v. application of 450 mg/kg DF. Notably, due to its short half-life, DF was most effective when given on a daily basis. Although the precise mechanism of DF remains to be elucidated, initial Western blots show that DF reduces phosphorylation-activation of p70S6 kinase, which is a key target in the PI3K/Akt/mTOR signaling pathway linked to endothelial cell and pericyte proliferation and activation. However, in vitro data suggest that DF acts independently of vascular endothelial growth factor. Taken together, our data suggest that while DF is known for its endothelium-protecting function in SCT, it also inhibits formation of new blood vessels, and thus should be considered for further testing as an adjuvant anti-cancer agent, either alone, or in combination with other drugs.
Notes:
Carl Zülke, H J Schlitt (2007)  [Incidentalomas of the liver and gallbladder. Evaluation and therapeutic procedure].   Chirurg 78: 8. 698-712 Aug  
Abstract: The expanding use of ultrasound in general practice is leading to an ever increasing rate of detection of true hepatic incidentaloma. The correct diagnosis of hepatic incidentaloma may be made in over 90% with non-invasive means. The questionable diagnosis of "symptomatic" incidentaloma should undergo close scrutiny prior to a decision in favour of surgery. With regard to more recent literature, the former "absolute" requirement for surgical resection in all cases of liver cell adenoma may have to be reappraised. Final inability to rule out malignancy represents an unquestionable indication for surgery in the light of low rates of morbidity and lack of mortality in this otherwise healthy patient group. Percutaneous biopsies should not be performed due to oncological hazards, indeterminate results and potential for acute complications.The stage-oriented radical re-resection following diagnosis of an incidentally detected gallbladder cancer may lead to significantly improved long-term survival, especially in the early tumour stages T1b and T2, which represents the most common stage of gallbladder cancer in incidentaloma. Patients at elevated risk for incidental gallbladder cancer should undergo thorough instruction with regard to the potential hazards of laparoscopic cholecystectomy. Multimodal therapeutic strategies directed at advanced stages of incidentally detected gallbladder cancer should be evaluated in prospective multicentre studies.
Notes:
2006
Tung-Yu Tsui, Chi-Keung Lau, Jian Ma, Gabriel Glockzin, Aiman Obed, Hans-J Schlitt, Sheung-Tat Fan (2006)  Adeno-associated virus-mediated heme oxygenase-1 gene transfer suppresses the progression of micronodular cirrhosis in rats.   World J Gastroenterol 12: 13. 2016-2023 Apr  
Abstract: To test the hypothesis that enhancement of the activity of heme oxygenase can interfere with processes of fibrogenesis associated with recurrent liver injury, we investigated the therapeutic potential of over-expression of heme oxygense-1 in a CCl(4)-induced micronodular cirrhosis model.
Notes:
Michael Bucher, Frieder K Kees, Barbara Messmann, Dirk Lunz, Stephan Rath, Marek Zelenka, Hans J Schlitt, Jonny Hobbhahn (2006)  Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1.   Eur J Pharmacol 536: 3. 296-300 May  
Abstract: Our study aimed to determine the role of cyclooxygenase-2 in the release of prostaglandin-(PG)-I2 following mesenteric traction during abdominal surgery. In a prospective double-blind, randomized, placebo-controlled study, 40 patients electively scheduled for non-laparoscopic abdominal surgery, were pretreated with the cyclooxygenase-2 inhibitor parecoxib (n=20) or placebo (n=20). Heart rate, arterial blood pressure, oxygenation ratio and plasma concentrations of the stable PGI2-metabolite 6-keto-PGF1alpha were compared between groups before injection of parecoxib (-40 min), immediately before mesenteric traction (0 min), and 5, 10, and 30 min thereafter. In addition, plasma concentrations of valdecoxib, the active metabolite of the prodrug parecoxib, were determined. Plasma concentrations of 6-keto-PGF1alpha and heart rate increased in both groups after mesenteric traction. There were no significant differences between groups at individual times in heart rate, arterial blood pressure and plasma concentrations of 6-keto-PGF1alpha. Oxygenation ratio decreased after 10 and 30 min following mesenteric traction in the parecoxib group with a significant difference between treatment groups at 10 and 30 min. Plasma concentrations of valdecoxib revealed therapeutic values. Our data indicate that PGI2 release following mesenteric traction is mediated by cyclooxygenase-1.
Notes:
Matthias Hornung, Stefan A Farkas, Christine Sattler, Hans J Schlitt, Edward K Geissler (2006)  DX5+ NKT cells induce the death of colitis-associated cells: involvement of programmed death ligand-1.   Eur J Immunol 36: 5. 1210-1221 May  
Abstract: NKT cells are activated by CD1d and show an immune regulating function. Here, we investigated whether DX5+ NKT cells could be used to reduce colitis in a chronic colitis mouse model and studied the potential immunological mechanisms involved. Chronic colitis was induced either by transfer of enriched CD62L+ CD4+ T cells to severe-combined-immunodeficient mice or by feeding dextran sodium sulfate to immune competent mice. DX5+ NKT cells were transferred to mice with chronic colitis. Co-transfer of DX5+ NKT cells, but not CD8+ control cells, prevented the onset of colitis, and the immune regulatory effect of DX5+ NKT cells was completely abrogated by injecting CD1d blocking antibody. Moreover, DX5+ NKT cells reduced established colitis in both chronic colitis models. In vitro, DX5+ NKT cells induced cell death of colon-infiltrating lymphocytes isolated from diseased mice. This effect was inhibited in the presence of either anti-CD1d or anti-programmed death ligand-1 (PD-L1) blocking antibodies. The specific potency of DX5+ NKT cells in regulating chronic colitis in two mouse models is demonstrated. In vitro testing suggests that DX5+ NKT cells activated by CD1d induce cell death of colitis-inducing lymphocytes, which is mediated through PD-L1. Therefore, DX5+ NKT cells could be important in the regulation of immune responses associated with chronic colitis.
Notes:
Ulrich Bolder, Marc Gerhard Jeschke, Lukas Landmann, Francine Wolf, Corina de Sousa, Hans-Jürgen Schlitt, René Przkora (2006)  Heat stress enhances recovery of hepatocyte bile acid and organic anion transporters in endotoxemic rats by multiple mechanisms.   Cell Stress Chaperones 11: 1. 89-100  
Abstract: Heat stress (HS) reduces the many sequelae of lipopolysaccharide (LPS)-induced endotoxemia. Without HS, endotoxins have been shown to induce a transcriptional down-regulation of hepatocyte transport proteins for bile acids and organic anions. We performed experiments in isolated perfused rat livers at various times after LPS administration with and without HS pretreatment to determine whether HS would correct deficient transport of bromosulfophthalein (BSP). Possible mechanisms involved were investigated in livers from intact animals. In isolated perfused livers, LPS injection reduced BSP excretion to 48% compared with saline-injected controls (P < 0.01). When HS was applied 2 hours prior to LPS, BSP excretion increased to 74% of controls (P < 0.05 vs LPS and controls). Expression of the basolateral (Oatp1a1) and canalicular (Mrp2) organic anion transporter involved in the transport of BSP recovered more rapidly when HS preceded LPS application. Recovery of mRNA levels of these transporters occurred also earlier. Coimmunoprecipitation experiments and immunoelectron microscopy using a double immunogold labeling of heat shock protein 70 (HSP70) and various hepatocyte transporters suggested colocalization with HSP70 for the canalicular bile acid transporter (Bsep) in the subcanalicular space. In contrast, no colocalization was shown for Ntcp and anion transporters. In conclusion, we could show that HS enhances recovery of organic anion transporters and bile acid transporters following endotoxemia. Faster recovery of mRNA seems to be a key mechanism for anion transporters, whereas physical interaction with HSP70 plays a role in preservation of bile acid transporters. This interaction of HSP70 and canalicular transporters occurs only in pericanalicular vesicles but not when the protein is integrated into the plasma membrane.
Notes:
I Iesalnieks, M Woenckhaus, G Glockzin, H J Schlitt, A Agha (2006)  [Renal cell carcinoma metastases to the thyroid gland -- report of 3 cases and review of the literature].   Zentralbl Chir 131: 3. 235-239 Jun  
Abstract: Clinically significant, solitary metastasis to the thyroid gland is a rare occurrence. The clear cell carcinoma of the kidney (RCC) is the most common primary tumor site. Late recurrence is a notable feature of renal carcinoma. Solitary metastases in the thyroid gland occur as late as 100-120 months from the date of nephrectomy. There is a clear survival benefit in selected cases if surgical approach to the thyroid metastases is chosen. In those patients who have undergone complete resection, 5-year-survival-rates of 50 % have been reported. We describe 3 cases of surgically treated thyroid metastases of RCC, and review the literature.
Notes:
B Krüger, A A Schnitzbauer, C A Böger, U Hoffmann, B Banas, S Farkas, H J Schlitt, A Obed, B K Krämer (2006)  Pretransplant calcium levels have no predictive value for delayed graft function, long-term graft function, cardiovascular events, or graft and patient survival in renal transplantation.   Transplant Proc 38: 3. 697-700 Apr  
Abstract: Disorders of calcium homeostasis are one of the most common problems in patients with end-stage renal disease (ESRD). Elevated calcium levels increase the incidence of cardiovascular mortality in ESRD patients, and appear to be a risk factor for the occurrence of delayed graft function (DGF) after kidney transplantation. Therefore, we investigated the impact of pretransplant serum calcium levels on outcomes after kidney transplantation: DGF, acute rejection, graft function, and survival, as well as the incidence of cardiovascular events.
Notes:
Wolfgang E Thasler, Rania Dayoub, Marcus Mühlbauer, Claus Hellerbrand, Thomas Singer, Anja Gräbe, Karl-Walter Jauch, Hans-Jürgen Schlitt, Thomas S Weiss (2006)  Repression of cytochrome P450 activity in human hepatocytes in vitro by a novel hepatotrophic factor, augmenter of liver regeneration.   J Pharmacol Exp Ther 316: 2. 822-829 Feb  
Abstract: Pathological disorders of the liver were shown to be associated with an impairment of hepatic drug metabolism mediated in part by growth factors. Augmenter of liver regeneration (ALR) is a novel liver-specific hepatotrophic growth factor, whereas its action on cytochrome P450 (P450) metabolism is completely unknown. Application of ALR to primary human hepatocytes in vitro reduced P450 isoenzyme activities (1A2 and 2A6) in a dose-dependent manner. Time-course analysis revealed that the maximal inhibitory effect was reached after 24 to 72 h of exposure with 50 nM ALR. The reduction of basal activities upon ALR treatment was 35% for CYP1A2, 56% for CYP2A6, 18% for CYP2B6, and 45% for CYP2E1. Additionally, after induction of P450 with specific inducers, ALR revealed an inhibitory effect on the isoenzyme activities (CYP1A2, 41%; CYP2B6, 35%). Investigations of protein and mRNA expression of basal and induced CYP1A2 and CYP3A4 after ALR treatment by Western blotting and real-time reverse transcriptase-polymerase chain reaction, respectively, suggest a regulation on the transcriptional level. Furthermore, ALR treatment increased nuclear factor kB activity and reduced constitutive androstane receptor but not pregnane X receptor or aryl hydrocarbon receptor expression. In contrast, ALR revealed no effects on phase II reactions (glutathione/oxidized glutathione, UDP-glucuronyltransferase conjugation). Our results indicate that ALR, as a member of hepatotrophic factors, down-regulates basal and induced P450 in human liver and therefore cross-links growth signals to regulation of hepatic metabolism. These findings further imply a possible role of ALR in drug interactions during impaired hepatic function, whereas liver regeneration is triggered.
Notes:
Stefan Farkas, Matthias Hornung, Christine Sattler, Karoline Edtinger, Markus Steinbauer, Matthias Anthuber, Hans J Schlitt, Hans Herfarth, Edward K Geissler (2006)  Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis.   Int J Colorectal Dis 21: 1. 71-78 Jan  
Abstract: Leukocyte recruitment to sites of intestinal inflammation is a crucial multi-step process, leading ultimately to the accumulation of cells in the inflamed tissue. These interactions in the gut are critically dependent on the mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is expressed on endothelial cells within the mesenteric lymph nodes and the lamina propria of the intestine. Here, we investigate the pathophysiologic role of MAdCAM-1 in the intestinal microcirculation in vivo.
Notes:
Marc H Dahlke, Roberto Loi, Alessandra Warren, Lauren Holz, Felix C Popp, Daniel J Weiss, Pompiliu Piso, David G Bowen, Geoffrey W McCaughan, Hans J Schlitt, Patrick Bertolino (2006)  Immune-mediated hepatitis drives low-level fusion between hepatocytes and adult bone marrow cells.   J Hepatol 44: 2. 334-341 Feb  
Abstract: The role of adult bone marrow-derived cells (BMC) in hepatic regeneration is controversial. Both transdifferentiation of BMC as well as fusion with hepatocytes have been suggested in toxin-based and genetic selection models.
Notes:
Stefan Farkas, Matthias Hornung, Christine Sattler, Markus Guba, Markus Steinbauer, Matthias Anthuber, Hans Herfarth, Hans J Schlitt, Edward K Geissler (2006)  Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis.   Int J Colorectal Dis 21: 8. 747-753 Dec  
Abstract: Immunosuppressive calcineurin inhibitors, like cyclosporine (CsA), can be used for the clinical management of severe ulcerative colitis. However, patients treated with CsA are at a risk for developing kidney failure and may be more susceptible to colon cancer. Furthermore, severe neurotoxicity and hypertension are common problems. To avoid the side effects of CsA, new immunosuppressive drugs to treat colitis are needed. The aim of the present study was to test the immunosuppressive mammalian target of rapamycin inhibitor rapamycin in an experimental model of chronic colitis and to compare its effectiveness with CsA.
Notes:
Aiman Obed, Andreas A Schnitzbauer, Thomas Bein, Norbert Lehn, Hans-Jörg Linde, Hans J Schlitt (2006)  Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation.   Transplantation 81: 1. 121-124 Jan  
Abstract: Severe infections are the most dangerous complications in liver transplantation and their prevention is one of the major goals. A 60-year-old Saudi-Arabian female with decompensated hepatitis C liver cirrhosis received a right-lobe liver graft from her healthy daughter. After 9 days, the patient developed a rapidly progressive necrotizing pneumonia that was fatal in spite of extracorporal lung assist. The pneumonia was due to a Panton-Valentine Leucocidine-positive (PVL) methicillin-resistant Staphylococcus aureus (MRSA), or "community-acquired" MRSA, that had not been detectable in the patient preoperatively. The same strain of PVL-MRSA could be demonstrated in the nares of the asymptomatic donor, but not of other relatives, patients, or medical staff. These findings strongly suggest transmission of PVL-MRSA from the donor to the recipient. This case demonstrates a previously unknown, and potentially fatal, risk in living-donor liver transplantation: transmission of a severe infection from a healthy donor to the recipient.
Notes:
Thomas Bein, Frank Weber, Alois Philipp, Christopher Prasser, Michael Pfeifer, Franz-Xaver Schmid, Bernhard Butz, Dietrich Birnbaum, Kai Taeger, Hans J Schlitt (2006)  A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia.   Crit Care Med 34: 5. 1372-1377 May  
Abstract: Pump-driven extracorporeal gas exchange systems have been advocated in patients suffering from severe acute respiratory distress syndrome who are at risk for life-threatening hypoxemia and/or hypercapnia. This requires extended technical and staff support.
Notes:
Rania Dayoub, Wolfgang E Thasler, Anja K Bosserhoff, Thomas Singer, Karl-Walter Jauch, Hans J Schlitt, Thomas S Weiss (2006)  Regulation of polyamine synthesis in human hepatocytes by hepatotrophic factor augmenter of liver regeneration.   Biochem Biophys Res Commun 345: 1. 181-187 Jun  
Abstract: Different stages of liver regeneration are regulated by a variety of factors such as the liver growth associated protein ALR, augmenter of liver regeneration. Furthermore, small molecules like polyamines were proven to be essential for hepatic growth and regeneration. Therefore, using primary human hepatocytes in vitro we investigated the effect of ALR on the biosynthesis of polyamines. We demonstrated by HPLC analysis that recombinant ALR enhanced intracellular hepatic putrescine, spermidine, and spermine levels within 9-12h. The activation of polyamine biosynthesis was dose dependent with putrescine showing the strongest increase. Additionally, ALR treatment induced mRNA expression of ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase, both key enzymes of polyamine biosynthesis. Further, ALR induced c-myc mRNA expression, a regulator of ODC expression, and therefore we assume that ALR exerts its liver regeneration augmenting effects through stimulation of its signalling pathway leading in part to enhanced polyamine synthesis.
Notes:
Th Bein, A Obed, H J Schlitt (2006)  [Prevention of organ failure in an organ donor. Early identification and maximum protective therapy after multiple trauma].   Dtsch Med Wochenschr 131: 44. 2465-2468 Nov  
Abstract: ANAMNESIS: A 18-year-old woman suffered from severe multi-trauma in combination with acute brain injury (Glasgow Coma Scale Score = 4) after road accident. After prolonged rescue measures and emergency stabilisation the patient was transferred by helicopter to the emergency department of our clinic.
Notes:
Gudrun E Koehl, Andreas Gaumann, Carl Zuelke, Anna Hoehn, Ferdinand Hofstaedter, Hans J Schlitt, Edward K Geissler (2006)  Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used.   Transplantation 82: 6. 741-748 Sep  
Abstract: Development of cancer in transplant recipients may be influenced by different immunosuppressive agents. Recent publications suggest that rapamycin (RAPA), or possibly mycophenolate mofetil (MMF), may reduce established tumor growth; however, experimental data is lacking for de novo cancer prevention.
Notes:
A Beham, M Rentsch, K Püllmann, L Mantouvalou, H Spatz, H J Schlitt, A Obed (2006)  Survival benefit in patients after palliative resection vs non-resection colon cancer surgery.   World J Gastroenterol 12: 41. 6634-6638 Nov  
Abstract: To evaluate survival in patients undergoing palliative resection versus non-resection surgery for primary colorectal cancer in a retrospective analysis.
Notes:
Kerstin Puellmann, Alexander Beham, Klaus Kienle, Mandy Vogel, Hans Juergen Schlitt, Karl Walter Jauch, Markus Rentsch (2006)  Inhibition of apoptosis reduces immunogeneic potential of adenoviral-treated syngeneic liver grafts.   Transplantation 82: 10. 1377-1382 Nov  
Abstract: Effects of adenoviral therapy and reduced apoptosis on immune response were investigated in a rat liver transplantation model after prolonged ischemia-reperfusion. Liver donors were treated i.v. either with an adenoviral construct, expressing bcl-2, green-fluorescent-protein, or doxycyclin. Intrahepatic apoptosis was assessed by terminal transferase dUTP nick end labeling assay. The intrahepatic presence of CD4, CD8a, CD163, immunoglobulin (Ig)beta, tumor necrosis factor (TNF)-alpha and myeloperoxidase (MPO) was quantified by realtime polymerase chain reaction at 24 hours and seven days after transplantation. Bcl-2 expression abrogated the TNF-alpha elevation and reduced apoptosis of hepatocytes and sinusoidal endothelial cells as compared to advCMV green fluorescent protein. No effects on CD4, CD8a, CD163 and MPO expression were noticed in bcl-2 pretreated livers, whereas Igbeta was slightly enhanced compared to controls. Adenoviral infected liver grafts trigger an immune response but reduced apoptosis resulted in down-regulation of TNF-alpha. Thus, bcl-2 transfer might simultaneously reduce graft ischemia reperfusion injury and immunogenicity.
Notes:
Felix C Popp, Pompiliu Piso, Hans J Schlitt, Marc H Dahlke (2006)  Therapeutic potential of bone marrow stem cells for liver diseases.   Curr Stem Cell Res Ther 1: 3. 411-418 Sep  
Abstract: Stem cells of the bone marrow, including hematopoietic stem cells (HSC), mesenchymal stem cells (MSC) and hepatic progenitors were reported to give rise to hepatocytes by both transdifferentiation and cellular fusion. Transdifferentiation was observed without liver damage although significant numbers of stem cell derived hepatocytes were not described. Cellular fusion was demonstrated in the presence of a proliferation stimulus in conjunction with impaired intrinsic liver regeneration capacity. Here, we review potential therapeutic applications of stem cell derived hepatocytes depending on how they emerge. Stem cells turning into hepatocytes by transdifferentiation introduce new functioning liver cells into a diseased organ, which can support intrinsic liver regeneration or bridge the time gap until a definitive treatment is available. When cellular fusion is the mechanism behind stem cell plasticity, however, no new cells emerge in the first place, whereas new genetic material is introduced. The fusion cell thereby acquires a selective advantage over resident hepatocytes allowing for extensive proliferation and liver repopulation. Therefore genetic deficiencies might be the predominant target for cell fusion therapies. We conclude that transdifferentiation and cellular fusion might be powerful tools for the therapy of liver diseases in the future and we propose the introduction of artificial cell fusion as well as stem cell differentiation as therapeutic options.
Notes:
I Iesalnieks, F Kullmann, M Dahlke, N Ghali, A Agha, P von Breitenbuch, J Schoelmerich, H J Schlitt, P Piso (2006)  [Surgical management of patients with peritoneal carcinomatosis of gastrointestinal origin].   Z Gastroenterol 44: 12. 1237-1245 Dec  
Abstract: Peritoneal carcinomatosis is found in approximately 15 % of patients with colorectal cancer during the course of their disease, and is associated with a poor prognosis. Even more patients with gastric cancer develop peritoneal seeding. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) have been introduced in the past decade and have led to 5-year survival rates of 30 to 40 % for selected patients with colorectal cancer and peritoneal carcinomatosis. These numbers have been demonstrated by many retrospective analyses and by prospective Phase II studies. The clinical assessment to select patients who will benefit from the combined therapy and achievement of complete macroscopic cytoreduction both play a crucial role. Less favourabale results have been achieved for patients suffering from stage IV gastric cancer with peritoneal seeding. Promising results were demonstrated for postoperative intraperitoneal chemotherapy following curative gastrectomy. Patients with hepatic, biliary and pancreatic cancers and peritoneal carcinomatosis do not benefit from cytoreductive surgery. There is a need for further multicentre, prospective trials analysing the use of hyperthermic intraperitoneal chemotherapy. They should be conducted in the specialised centres by interdisciplinary teams.
Notes:
M Rentsch, A Beham, H J Schlitt, K W Jauch (2006)  Crohn's disease activity index and Vienna classification--is it worthwhile to calculate before surgery?   Dig Surg 23: 4. 241-249 08  
Abstract: Crohn's disease (CD) patients with increased disease activity may reveal an increased risk for perioperative complications. The "Crohn's disease activity index" (CDAI) and the "Vienna classification" (VC) were developed for standardized disease activity estimations. The significance of these scores to predict extent, type and early outcome of surgery in CD patients was analyzed.
Notes:
A A Schnitzbauer, M Loss, M Hornung, S Farkas, B Krämer, W Wieland, H J Schlitt, A Obed (2006)  [Pararectal mini-incision for strictly retroperitoneal nephrectomy in living kidney donation].   Urologe A 45: 9. 1170-1175 Sep  
Abstract: In this study we present the technique of a strictly retroperitoneal donor nephrectomy via a pararectal mini-incision.
Notes:
Aimann Obed, Matthias Hornung, Klaus Schlottmann, Hans-Jürgen Schlitt, Ulrich Bolder (2006)  Unnecessary delay of diagnosis of buried bumper syndrome resulting in surgery.   Eur J Gastroenterol Hepatol 18: 7. 789-792 Jul  
Abstract: Percutaneous endoscopic catheter gastrostomy (PEG) is a convenient way to supply enteral nutrition for patients with swallowing disorders. One rare complication of PEG is the buried bumper syndrome where gastric mucosa overgrows the internal bumper and prevents free flow of the feeding solution. As a consequence, the application of enteral feeding has to be stopped until a free outflow is re-established. We report a case of buried bumper where symptoms were misinterpreted for several months as PEG stoma infection by the homecare service. This led to a vastly delayed diagnosis and treatment. As endoscopic intervention was unsuccessful, surgical PEG removal was required. In consequence, we recommend early endoscopic exploration in cases with prolonged inflammatory signs at the PEG stoma site in order to avoid misdiagnosis of buried bumper syndrome and to allow timely endoscopic intervention.
Notes:
Seiichiro Inoue, Felix C Popp, Gudrun E Koehl, Pompiliu Piso, Hans J Schlitt, Edward K Geissler, Marc H Dahlke (2006)  Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model.   Transplantation 81: 11. 1589-1595 Jun  
Abstract: Recent reports suggest that mesenchymal stem cells (MSCs) have immunomodulatory properties. Mesenchymal stem cells can suppress the immune response toward alloantigen in vitro by inhibiting T cell proliferation in mixed-lymphocyte reactions (MLRs). However, relatively little has been reported regarding the immunomodulative potential of MSCs in vivo. Herein the authors confirm the immunomodulatory effects of rat MSCs in vitro and tested for tolerogenic features in a model of allogeneic heart transplantation.
Notes:
F C Popp, N Eggert, L Hoy, S A Lang, A Obed, P Piso, H J Schlitt, M H Dahlke (2006)  Who is willing to take the risk? Assessing the readiness for living liver donation in the general German population.   J Med Ethics 32: 7. 389-894 Jul  
Abstract: Shortage of donor organs is one of the major problems for liver transplant programmes. Living liver donation is a possible alternative, which could increase the amount of donor organs available in the short term.
Notes:
A A Schnitzbauer, M Loss, M Hornung, G Glockzin, L Mantouvalou, B Krüger, B K Krämer, H J Schlitt, A Obed (2006)  Mini-incision for strictly retroperitoneal nephrectomy in living kidney donation vs flank incision.   Nephrol Dial Transplant 21: 10. 2948-2952 Oct  
Abstract: Mini-incision donor nephrectomies (MIDNs) were established during the last decade, as an alternative to traditional open donor nephrectomy (ODN) via flank incision. In this study, we investigated intra-operative and post-operative data on outcome following MIDN in comparison with ODN data.
Notes:
2005
S Farkas, U Bolder, T Schlittenbauer, A Obed, C Zuelke, M Anthuber, E K Geissler, H J Schlitt (2005)  Conditioning of liver grafts with prostaglandins improves bile acid transport.   Transplant Proc 37: 1. 435-438 Jan/Feb  
Abstract: Conditioning of liver grafts by bolus pretreatment with prostaglandins has been previously demonstrated to improve hepatic bile flow. However, the underlying mechanisms have not been investigated. To elucidate whether improved bile flow after prolonged ischemia is due to maintained bile acid secretion or due to increased paracellular permeability, we performed a study using increasing doses of the marker acid taurocholate in the isolated perfused rat liver system.
Notes:
Ursula Schmidt, Denis Simunec, Pompiliu Piso, Jürgen Klempnauer, Hans J Schlitt (2005)  Quality of life and functional long-term outcome after partial pancreatoduodenectomy: pancreatogastrostomy versus pancreatojejunostomy.   Ann Surg Oncol 12: 6. 467-472 Jun  
Abstract: To determine the effects of pancreatogastrostomy (PG) versus pancreatojejunostomy (PJ) as types of reconstruction after partial pancreatoduodenectomy on postoperative quality of life and long-term gastrointestinal morbidity, the outcomes of 104 patients (PG, n = 63; PJ, n = 41) were evaluated.
Notes:
Marc H Dahlke, Felix C Popp, Nadine Eggert, Ludwig Hoy, Hideaki Tanaka, Katsunori Sasaki, Pompiliu Piso, Hans J Schlitt (2005)  Differences in attitude toward living and postmortal liver donation in the United States, Germany, and Japan.   Psychosomatics 46: 1. 58-64 Jan/Feb  
Abstract: Living liver donation is a possible immediate option for decreasing the shortage of liver allografts worldwide. Risks related to the donation make this procedure ethically controversial. Study groups of medical students (N= 330) from three different nations were analyzed with a complex questionnaire, and data were subjected to multiparameter analysis. The readiness for living liver donation was dependent upon the cultural background of the study groups. It was higher in the U.S. than in Germany and Japan, with a higher donation readiness for children as recipients than adults. Major differences among distinct sociodemographic groups need to be carefully addressed when setting up consensus guidelines for the clinical practice of living donation.
Notes:
U Schmidt, M H Dahlke, J Klempnauer, H J Schlitt, P Piso (2005)  Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.   Eur J Surg Oncol 31: 1. 53-58 Feb  
Abstract: Improved prognosis can be achieved in selected patients with peritoneal carcinomatosis (PC) by major surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Notes:
Z Güner, U Schmidt, M H Dahlke, H J Schlitt, J Klempnauer, P Piso (2005)  Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.   Int J Colorectal Dis 20: 2. 155-160 Mar  
Abstract: Surgical improvement can be achieved in selected patients with pseudomyxoma peritonei (PMP) by major cytoreductive surgery and intraperitoneal chemotherapy (IPEC). The purpose of this retrospective study was to analyze morbidity, mortality, and survival following therapy.
Notes:
S A Farkas, M Hornung, Christine Sattler, M Steinbauer, M Anthuber, F Obermeier, H Herfarth, H J Schlitt, E K Geissler (2005)  Preferential migration of CD62L cells into the appendix in mice with experimental chronic colitis.   Eur Surg Res 37: 2. 115-122 Mar/Apr  
Abstract: Clinical and experimental studies suggest that appendectomy can protect against development of ulcerative colitis and Crohn's disease. However, how T cells in the appendix affect the development of colitis has not been clarified.
Notes:
Markus Guba, Gudrun E Koehl, Evelyn Neppl, Axel Doenecke, Markus Steinbauer, Hans J Schlitt, Karl-Walter Jauch, Edward K Geissler (2005)  Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer.   Transpl Int 18: 1. 89-94 Jan  
Abstract: Rapamycin has antiangiogenic activity against tumors. This has been discussed while addressing the problem of cancer in organ transplantation. Here we investigated effective dosing schedules against tumors and angiogenesis. Growth of established CT-26 colon adenocarcinoma tumors was measured in Balb/c mice treated with total equivalent rapamycin doses (1.5 mg/kg/day) given once a day, once every 3 days, or by continuous infusion. Tumors were most inhibited with continuous rapamycin infusion, and less by bolus dosing. Interestingly, however, continuous dosing produced the lowest rapamycin blood levels (15 ng/ml). As rapamycin-sensitive p70S6-kinase intracellular signaling is critical for angiogenesis, p70S6-kinase activation was measured in endothelial cells by Western blotting. Maximal p70S6-kinase inhibition occurred from 1-5 ng/ml rapamycin. These same rapamycin concentrations optimally blocked vessel-sprouting from cultured aortic rings. Therefore, low-level rapamycin dosing most effectively controls tumors in mice. Importantly, antiangiogenic rapamycin levels are compatible with immunosuppressive doses, supporting its potential use in transplant patients with cancer.
Notes:
W E Thasler, T Schlott, P Thelen, C Hellerbrand, F Bataille, M Lichtenauer, H - J Schlitt, K - W Jauch, T S Weiss (2005)  Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma.   Histopathology 47: 1. 57-66 Jul  
Abstract: To determine the expression of a protein termed augmenter of liver regeneration (ALR), recently found to have a specific and beneficial effect on the process of liver regeneration in normal and diseased human liver.
Notes:
Igors Iesalnieks, Petra Rümmele, Wolfgang Dietmaier, Thomas Jantsch, Carl Zülke, Hans J Schlitt, Ferdinand Hofstädter, Matthias Anthuber (2005)  Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era.   Am J Clin Pathol 124: 5. 740-748 Nov  
Abstract: The aim of this study was to determine the predictors of survival in 38 patients with curatively resected gastrointestinal stromal tumors (GISTs). The tumor was located in the stomach in 23 cases, the small bowel in 13, and the colon in 2. In 23 patients (61%), a mutation in exon 11 of the kit gene was detected. In 7 cases, all small gastric tumors, a mutation in the platelet-derived growth factor receptor a (PDGFRA) gene was detected. The overall 5-year survival rate was 70%. In 9 patients, GISTs relapsed, leading to an actuarial 5-year disease-free survival of 78%. By multivariate analysis, the presence of distant metastases, the proliferative (MIB-1) index, and deletional mutation in codons 557 and/or 558 of kit exon 11 correlated significantly with poor outcome. None of the PDGFRA mutant GISTs relapsed. These findings suggest a strong relationship between various tyrosine kinase receptor mutations and survival outcome in patients with GISTs.
Notes:
Jian Wu, Jian Ma, Sheung-Tat Fan, Hans J Schlitt, Tung-Yu Tsui (2005)  Bilirubin derived from heme degradation suppresses MHC class II expression in endothelial cells.   Biochem Biophys Res Commun 338: 2. 890-896 Dec  
Abstract: The enzymatic action of heme oxygenase (HO) is mediated by the cleavage of heme into carbon monoxide, ferrous iron, and biliverdin/bilirubin. Here, we show that induction of HO-1 expression, an inducible form of HO, down-regulates IFN-gamma-induced MHC class II expression in endothelial cells. Among three catalytic products of HO, bilirubin, but not carbon monoxide or ferrous iron, mediated the suppressive effects of HO through the reduction of mRNA levels of Stat-1-dependent class II transactivator. Expression of HO-1 could suppress the levels of IFN-gamma-induced Stat-1 phosphorylation. This effect could be mimicked by exposing the cells to one of its catalytic products, bilirubin. In addition, HO-1 or bilirubin could modulate the transcript activities of Stat-1-driven gene expression in luciferase reporter assays. These findings suggest an important role of HO-1 in the modulation of immune responses through suppression of MHC-II expression in antigen presenting cells. Our data provide a new line of evidence supporting HO-1-targeted therapy for immune modulation.
Notes:
B K Krämer, B Krüger, M Mack, A Obed, B Banas, L Paczek, H J Schlitt (2005)  Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.   Transplant Proc 37: 4. 1789-1791 May  
Abstract: Steroid-induced adverse effects after transplantation include cosmetic, metabolic, and cardiovascular complications. Steroid withdrawal or avoidance with cyclosporine-based regimens have been hampered by an unacceptably high rate of acute rejections and increased rates of graft loss. Recently the results of several large, randomized trials of steroid withdrawal/avoidance with tacrolimus-based immunosuppression in renal transplant recipients became available. A review of these trials appeared to be of clinical interest. Data from the THOMAS trial clearly indicate that steroid withdrawal from a regimen of tacrolimus, mycophenolate mofetil (MMF), steroids after 3 months after transplantation is safe with regard to acute rejection rate and graft survival. If an induction therapy with daclizumab is used in combination with tacrolimus and MMF (CARMEN trial), even steroid avoidance is safe with regard to acute rejection rate and graft survival. Finally, in the ATLAS trial, steroid avoidance with basiliximab in combination with tacrolimus (resulting in tacrolimus monotherapy) or alternatively with tacrolimus and MMF both resulted in similar graft survival, but higher rates of acute rejection. In conclusion, steroid withdrawal is safe from a triple-drug regimen of tacrolimus, MMF, and steroids after 3 months after transplantation, and steroid use may completely be avoided with tacrolimus, and MMF combined with daclizumab induction. Tacrolimus monotherapy may be achieved using basiliximab induction at the price of higher rates of acute rejection, but with unaffected graft survival. Thus tacrolimus-based immunosuppression with or without interleukin-2 receptor antagonist induction has made steroid withdrawal or avoidance a realistic option in renal transplantation.
Notes:
Florian P Limbourg, Stefanie Ringes-Lichtenberg, Arnd Schaefer, Christoph Jacoby, Yasmin Mehraein, Mark D Jäger, Anne Limbourg, Martin Fuchs, Gunnar Klein, Matthias Ballmaier, Hans-J Schlitt, Juergen Schrader, Denise Hilfiker-Kleiner, Helmut Drexler (2005)  Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment.   Eur J Heart Fail 7: 5. 722-729 Aug  
Abstract: Transplantation of bone marrow derived adult stem cells (BMC) improves cardiac function after acute myocardial infarction (MI). However, the cell population mediating myocardial recovery and the fate of the transplanted cells are still controversial.
Notes:
S Farkas, M Hornung, C Sattler, M Anthuber, U Gunthert, H Herfarth, H J Schlitt, E K Geissler, B M Wittig (2005)  Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice.   Clin Exp Immunol 142: 2. 260-267 Nov  
Abstract: Increased expression of CD44 variant isoforms have been shown on the inflammatory infiltrates in human and mouse colitis and blockade or deletion of CD44 isoforms inhibit experimental colitis. The objective of this study was to find out if short-term treatment of CD44 antibodies specific to CD44v7, but not to other variant isoforms, suppresses leucocyte-endothelial interaction in chronic dextran sodium sulphate (DSS)-induced colitis in mice. Chronic colitis was induced by oral administration of four cycles of 5% DSS in BALB/c mice. Expression of CD44 was investigated on isolated mononuclear cells of the gut immune system. In established colitis, mice were treated with antibodies against CD44v7 or CD44v4 three times in 7 days. Intravital microscopy was used to study leucocyte-endothelial interactions and leucocyte extravasation. As a marker of inflammatory infiltrates myeloperoxidase was quantified in gut tissue. CD44-induced apoptosis was determined by fluorescence staining of hypodiploidic cell nuclei. In chronic DSS-induced colitis both CD44 variant isoforms, v4 and v7 were significantly up-regulated on mononuclear cells. However, whereas anti-CD44v7 antibody treatment induced a marked restoration of the gut mucosa and significantly reduced endothelial sticking and extravasation of circulating leucocyte in vivo (P < 0.01), application of anti-CD44v4 or an isotype control antibody had no anti-inflammatory effect. A significant reduction of myeloperoxidase activity was detected after blockade of CD44v7, but not v4. Short-term treatment with anti-CD44v7 antibody blocks T cell extravasation and recruitment to the intestinal mucosa and cures established experimental colitis.
Notes:
Markus Rentsch, Klaus Kienle, Thomas Mueller, Mandy Vogel, Karl Walter Jauch, Kerstin Püllmann, Aiman Obed, Hans J Schlitt, Alexander Beham (2005)  Adenoviral bcl-2 transfer improves survival and early graft function after ischemia and reperfusion in rat liver transplantation.   Transplantation 80: 10. 1461-1467 Nov  
Abstract: Primary graft dysfunction due to ischemia and reperfusion injury represents a major problem in liver transplantation. The related cell stress may induce apoptosis, which can be suppressed by bcl-2. The purpose of the study was to investigate the effect of adenoviral bcl-2 gene transfer on early graft function and survival in rat liver transplantation.
Notes:
Tung-Yu Tsui, Yeung-Tung Siu, Hans J Schlitt, Sheung-Tat Fan (2005)  Heme oxygenase-1-derived carbon monoxide stimulates adenosine triphosphate generation in human hepatocyte.   Biochem Biophys Res Commun 336: 3. 898-902 Oct  
Abstract: Heme oxygenases cleave the pro-oxidant heme molecule into carbon monoxide, ferrous iron, and biliverdin, which is subsequently converted to bilirubin. Increasing the enzymatic activities of heme oxygenase by expression of its inducible isoform, heme oxygenase-1, protects hepatocyte from apoptosis. In the present study, we investigated the mechanisms involving in heme oxygenase-1-mediated cytoprotection. Heme oxygenase-1 could induce the expression of anti-apoptotic protein-Bcl-xL in human hepatocyte. This effect is associated with the activation of p38 MAPK signaling pathway. Carbon monoxide derived from heme oxygenase activities significantly increased adenosine triphosphate levels in hepatocyte that was essential for potentiation of the activation of p38 MAPK signaling. Our demonstration of the importance of the energy status to maximize an anti-apoptotic response provides a new insight into HO-mediated cytoprotection.
Notes:
Tung-Yu Tsui, Chi-Keung Lau, Jian Ma, Xiaobing Wu, Yan-Qing Wang, Stefan Farkas, Ruian Xu, Hans J Schlitt, Sheung-Tat Fan (2005)  rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats.   Hepatology 42: 2. 335-342 Aug  
Abstract: Liver fibrosis is the consequence of activation of hepatic stellate cells mediated by persistent or recurrent liver injury, where oxidative stress or inflammatory response resulting from immune cells and cytokines are involved. Targeting of hepatic stellate cells could be an important strategy for the therapy of liver fibrosis. In this study, we showed a tropism of recombinant adeno-associated virus (rAAV, serotype 2) with high efficiency in transduction of a homeostatic gene, heme oxygenase-1 (HO-1), to activated stellate cells. The binding of rAAVs to stellate cells increased significantly after serum-stimulated activation compared with quiescent status. Portal injection of rAAVs to normal or carbon tetrachloride (CCl(4))-induced liver fibrosis showed a distinct distribution of rAAV binding. The majority of injected rAAVs bound to the cells in fibrotic areas that were associated with higher expression levels of fibroblast growth factor receptor-1alpha at 2 hours after administration. Isolation of different types of cells from CCl(4)-induced fibrotic livers showed predominant expression of transgene in stellate cells after rAAV/HO-1 administration on day 3 and remained stable for 12 weeks. In addition, HO-1-transduced stellate cells showed reduced transcript levels of type 1 collagen and impaired proliferative ability compared with controls. With this approach, the severity of established micronodular cirrhosis was markedly reduced. In conclusion, these findings suggest a new approach for the treatment of liver fibrosis using adeno-associated virus-mediated gene transfer.
Notes:
2004
Marc H Dahlke, Stephen R Larsen, John E J Rasko, Hans J Schlitt (2004)  The biology of CD45 and its use as a therapeutic target.   Leuk Lymphoma 45: 2. 229-236 Feb  
Abstract: All mature hemopoietic lineage cells, with exclusion of platelets and mature erythrocytes, share the surface expression of a transmembrane phosphatase, the CD45 molecule. It is also present on hemopoietic stem cells and most leukemic clones and therefore presents as an appropriate target for immunotherapy with anti-CD45 antibodies. This short review details the biology of CD45 and its recent targeting for both treatment of malignant disorders and tolerance induction. In particular, the question of potential stem cell depletion for induction of central tolerance or depletion of malignant hemopoietic cells is addressed. Mechanisms underlying the effects downstream of CD45 binding to the cell surface are discussed.
Notes:
Marc H Dahlke, Heiko Aselmann, Dilek Ceylan, Tobias Bellin, Peer Flemming, Peter N Meier, Karl Oldhafer, Juergen Klempnauer, Hans J Schlitt, Pompiliu Piso (2004)  Effectiveness of peripheral hepatogastrostomy versus hepatojejunostomy in the treatment of obstructive cholestasis: results of an experimental model.   Surg Today 34: 4. 349-353  
Abstract: Tumors of the liver hilum frequently cause obstructive cholestasis. When a curative resection of the tumor is impossible, palliative bile drainage is indicated. A hepatojejunostomy is performed if conservative treatment fails or if irresectability is proven during an initial laparotomy. In patients with peritoneal carcinosis and mesentery retraction, a hepatogastrostomy may represent a helpful alternative. An experimental study was designed to compare the bile drainage effectiveness of a hepatogastrostomy versus a hepatojejunostomy.
Notes:
V Lufft, B Dannenberg, H J Schlitt, R Pichlmayr, R Brunkhorst (2004)  Cardiovascular morbidity and mortality in patients with diabetes mellitus type I after kidney transplantation: a case-control study.   Clin Nephrol 61: 4. 238-245 Apr  
Abstract: The proportion of diabetics among patients requiring renal replacement therapy continues to increase in most western countries. The acceptance rate for renal transplantation varies among transplant centers and is influenced by the current opinion on the outcome of transplantation in diabetics. Controlled data on patient and graft survival in type I diabetics, however, are scarce.
Notes:
Marc H Dahlke, Felix C Popp, Stephen Larsen, Hans J Schlitt, John E J Rasko (2004)  Stem cell therapy of the liver--fusion or fiction?   Liver Transpl 10: 4. 471-479 Apr  
Abstract: Various stem cell populations have been described in distinct models of liver regeneration. This review provides an overview of these different stem cell populations aimed at unifying diverse views of liver stem cell biology. Embryonic stem cells, hemopoietic stem cells, mesenchymal stem cells, liver-derived hepatic stem cells, bone marrow-derived hepatic stem cells, and mature hepatocytes (as cells with stemlike properties) are considered separately. In so doing, we seek to clarify the nomenclature of putative liver stem cell types. Experiments that address the question of cellular fusion versus transdifferentiation as explanations for observed liver regeneration are highlighted. This review concludes with a series of open questions that should be addressed in the context of clinical liver disease before attempts at human therapeutic interventions.
Notes:
Pompiliu Piso, Marc-Hendrik Dahlke, Martin Loss, Hans Juergen Schlitt (2004)  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer.   World J Surg Oncol 2: 06  
Abstract: In selected patients with peritoneal carcinomatosis from ovarian cancer prognosis can be improved by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Notes:
T Bein, K Sabel, A Scherer, C Papp-Jambor, M Hekler, R Dubb, H J Schlitt, K Taeger (2004)  [Comparison of incomplete (135 degrees ) and complete prone position (180 degrees ) in patients with acute respiratory distress syndrome. Results of a prospective, randomised trial].   Anaesthesist 53: 11. 1054-1060 Nov  
Abstract: Ventilation in the prone position is carried out for improvement of pulmonary gas exchange in patients with acute respiratory distress syndrome (ARDS). We compared the effects of an incomplete prone position (IPP, 135( degrees )) with a complete prone position (CPP, 180( degrees )) in patients with ARDS.
Notes:
Gudrun E Koehl, Joachim Andrassy, Markus Guba, Sebastian Richter, Alexander Kroemer, Marcus N Scherer, Markus Steinbauer, Christian Graeb, Hans J Schlitt, Karl-Walter Jauch, Edward K Geissler (2004)  Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.   Transplantation 77: 9. 1319-1326 May  
Abstract: Cancer is an increasingly recognized problem associated with immunosuppression. Recent reports, however, suggest that the immunosuppressive agent rapamycin has anti-cancer properties that could address this problem. Thus far, rapamycin's effects on immunity and cancer have been studied separately. Here we tested the effects of rapamycin, versus cyclosporine A (CsA), on established tumors in mice simultaneously bearing a heart allograft. In one tumor-transplant model, BALB/c mice received subcutaneous syngenic CT26 colon adenocarcinoma cells 7 days before C3H ear-heart transplantation. Rapamycin or CsA treatment was initiated with transplantation. In a second model system, a B16 melanoma was established in C57BL/6 mice that received a primary vascularized C3H heart allograft. In vitro angiogenic effects of rapamycin and CsA were tested in an aortic ring assay. Results show that CT26 tumors grew for 2 weeks before tumor complications occurred. However, rapamycin protected allografts, inhibited tumor growth, and permitted animal survival. In contrast, CsA-treated mice succumbed to advancing tumors, albeit with a functioning allograft. Rapamycin's antitumor effect also functioned in severe combined immunodeficient BALB/c mice. Similar effects of the drugs occurred with B16 melanomas and primary vascularized C3H allografts in C57BL/6 mice. Furthermore, in this model, rapamycin inhibited the tumor growth-enhancing effects of CsA. Moreover, in vitro experiments showed that CsA promotes angiogenesis by a transforming growth factor-beta-related mechanism, and that this effect is abrogated by rapamycin. This study demonstrates that rapamycin simultaneously protects allografts from rejection and attacks tumors in a complex transplant-tumor situation. Notably, CsA protects allografts from rejection, but cancer progression is promoted in transplant recipients.
Notes:
T Bein, C Prasser, A Philipp, T Müller, F Weber, H J Schlitt, F - X Schmid, K Taeger, D Birnbaum (2004)  [Pumpless extracorporeal lung assist using arterio-venous shunt in severe ARDS. Experience with 30 cases].   Anaesthesist 53: 9. 813-819 Sep  
Abstract: Extracorporeal lung assist has been proposed as an invasive measure in patients with acute respiratory distress syndrome (ARDS) when oxygenation is critically impaired. However, this technique generally requires high personnel and technical resources. We report on a new system, which is characterised by a short circuit arterio-venous shunt using arterio-venous pressure gradient as driving force (pumpless extracorporeal lung assist [pECLA]).
Notes:
Pompiliu Piso, Marc-Hendrik Dahlke, Petrit Mirena, Ursula Schmidt, Heiko Aselmann, Hans Juergen Schlitt, Rudolf Raab, Juergen Klempnauer (2004)  Total mesorectal excision for middle and lower rectal cancer: a single institution experience with 337 consecutive patients.   J Surg Oncol 86: 3. 115-121 Jun  
Abstract: There have been reports on improved prognosis after TME for middle and lower rectal cancer. No prospective randomized studies have yet been performed. This is a large single institution series evaluating its own results of TME.
Notes:
2003
Marc H Dahlke, Felix C Popp, Ferdinand H Bahlmann, Heiko Aselmann, Mark D Jäger, Michael Neipp, Pompiliu Piso, Jürgen Klempnauer, Hans J Schlitt (2003)  Liver regeneration in a retrorsine/CCl4-induced acute liver failure model: do bone marrow-derived cells contribute?   J Hepatol 39: 3. 365-373 Sep  
Abstract: Adult bone marrow contains progenitors capable of generating hepatocytes. Here a new liver failure model is introduced to assess whether bone marrow-derived progeny contribute to liver regeneration after acute hepatotoxic liver failure.
Notes:
P Piso, H Aselmann, R von Wasielewski, M H Dahlke, J Klempnauer, H J Schlitt (2003)  Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model.   Eur Surg Res 35: 6. 470-476 Nov/Dec  
Abstract: We analyzed the effect of intraperitoneal immunotherapy in an animal model mimicking locoregional dissemination of tumor cells during resection of advanced tumors.
Notes:
2002
Saiho Ko, Mark D Jaeger, Marc H Dahlke, Yoshiyuki Nakajima, Hans J Schlitt (2002)  Manipulation of CD45 antigen in transplantation tolerance.   Curr Mol Med 2: 3. 249-255 May  
Abstract: CD45 is known to have tyrosine phosphatase activity for signal transduction of T cells. Immunomodulation of CD45 has been tried to prevent T cell-mediated graft rejection in organ transplantation. In vitro study showed that blockade of CD45RB, an alternative splicing isoform of CD45, inhibited proliferative response of T cells after allogeneic stimulation. Treatment with a monoclonal antibody (mAb) against CD45RB induced long-term allograft acceptance in some mouse organ transplantation models. In a rat heart allograft model, a single injection of anti-rat CD45 (RT7) mAb which bound to allomorphic region of RT7 also induced allograft acceptance. CD45/RT7 is also a useful tool of targeting hematopoietic cells, because of the selective expression on all hematopoietic cells. There are two allomorphic forms of CD45 (RT7a and RT7b) in the rat. Using RT7 system, a rat heart allograft model from RT7a donors to RT7b recipients was designed to test functional relevance of graft-associated hematopoietic cells (microchimerism) to allograft acceptance. Then donor-derived hematopoietic cells were selectively depleted using anti-RT7a mAb in vivo. Depletion on day 0 prevented allograft acceptance and was associated with severe acute or chronic graft rejection, while depletion on day 18 after transplantation showed no effect. This experimental study showed a crucial role of microchimerism in induction phase of allograft acceptance. In conclusion, the CD45/RT7 system is not only a target molecule for tolerance induction, but also an useful tool for experimental models in transplantation immunology. In this review, we introduce basic properties of CD45 and recent results with manipulation of CD45.
Notes:
Tung-Yu Tsui, Mark D Jäger, Andrea Deiwick, Heiko Aselmann, Michael Neipp, Sheung-Tat Fan, Hans J Schlitt (2002)  Delayed low-level calcineurin inhibition promotes allospecific tolerance induction by posttransplantation donor leukocyte infusion.   Transplantation 73: 8. 1325-1332 Apr  
Abstract: Donor lymphocytes infused after organ transplantation can have strong immunoregulatory effects. Application of such protocols for transplant tolerance induction in a clinical setting will, however, require combination of specific immunomodulatory strategies with nonspecific immunosuppressive medication for safety reasons. The aim of this study was to analyze the effects of immunosuppressive treatment on tolerance induction protocols by posttransplantation donor lymphocyte infusion.
Notes:
Michael Neipp, Gisela Offner, Rainer Lück, Kay Latta, Jürgen Strehlau, Hans J Schlitt, Jochen H H Ehrich, Jürgen Klempnauer, Bjö rn Nashan (2002)  Kidney transplant in children weighing less than 15 kg: donor selection and technical considerations.   Transplantation 73: 3. 409-416 Feb  
Abstract: Small children represent a challenging patient group in kidney transplantation (KTx). The aim of this study was to analyze patient and donor data influencing outcome in children that weighed <15 kg.
Notes:
P Piso, H Bektas, U Werner, T Becker, H Aselmann, H J Schlitt, J Klempnauer (2002)  [Comparison between treatment results for gastric cancer in younger and elderly patients].   Zentralbl Chir 127: 4. 270-274 Apr  
Abstract: While gastric cancer shows an increased incidence in elderly patients, the rate of younger patients affected by this disease represents up to 15 %. Younger patients are frequently diagnosed with advanced tumor stages with a poor prognosis although literature data on this issue are controversial.
Notes:
Marc H Dahlke, Oliver S Lauth, Mark D Jäger, Till Roeseler, Kai Timrott, Stefan Jackobs, Michael Neipp, Kurt Wonigeit, Hans J Schlitt (2002)  In vivo depletion of hematopoietic stem cells in the rat by an anti-CD45 (RT7) antibody.   Blood 99: 10. 3566-3572 May  
Abstract: Anti-CD45 monoclonal antibodies (mAbs) are potentially powerful tools for the depletion of mature leukocytes. As their application for immunotherapy also depends on their effects on bone marrow (BM) progeny, the in vivo effects of an anti-CD45 mAb (anti-RT7(a) mAb) on BM precursor cells were analyzed in a rat model. Anti-RT7(a) mAb treatment was performed in LEW.1W (RT1(u) RT7(a)) rats with the use of different dosages. In addition, major histocompatibility complex (MHC)-congenic BM transplantation making use of a diallelic polymorphism (RT7(a)/RT7(b)) of rat CD45 was applied. Following injection of anti-RT7(a) mAb into normal LEW.1W rats, T cells were profoundly depleted in blood, lymph nodes, and spleen, whereas B cells were coated only by the antibody. Single injection of anti-RT7(a) mAb in a high dose induced a lethal aplastic syndrome with severe thrombocytopenia. Rescue of antibody-treated animals with BM from congenic LEW.1W-7B rats (RT1(u) RT7(b)) and transplantation of BM from LEW.1W rats pretreated with anti-RT7(a) mAb into sublethally irradiated LEW.1W-7B recipients revealed a profound effect of the mAb on progeny of myeloid and T-cell lineage. Following repeated antibody treatment of stable mixed chimeras (RT7(b)/RT7(a)), very few RT7(a)-positive B cells were still detectable after 6 months and their number declined during the subsequent year. These observations show that this anti-RT7(a) mAb effectively depletes mature T cells as well as BM precursor cells of myeloid, T-cell, and thrombocytic lineage after in vivo application. In contrast, mature B cells are not depleted, but precursors also appear to be eliminated. Overall, the findings suggest that the anti-RT7(a) mAb efficiently depletes early rat hematopoietic stem cells.
Notes:
Julie von Woellwarth, Andreas Meyer zu Vilsendorf, Hans J Schlitt (2002)  Complete small bowel recovery after prolonged total venous occlusion.   Ann R Coll Surg Engl 84: 3. 175-176 May  
Abstract: Acute small bowel ischaemia is a mostly irreversible condition associated with high mortality. Here we report the case of a patient after severe abdominal trauma in whom the superior mesenteric vein (SMV) was completely occluded for more than 15 h in the absence of any collateral venous drainage. Following surgical reconstruction of the SMV and with scheduled relaparotomies for 5 days, the bowel showed slow recovery. Now the patient is well and on complete oral nutrition.
Notes:
P Piso, T Bellin, H Aselmann, H Bektas, H J Schlitt, J Klempnauer (2002)  Results of combined gastrectomy and pancreatic resection in patients with advanced primary gastric carcinoma.   Dig Surg 19: 4. 281-285  
Abstract: Although the incidence of primary gastric carcinoma is decreasing, the majority of patients in Western countries are still diagnosed with advanced tumor stages. In many cases surgical therapy can be performed only by multivisceral resections including the pancreas.
Notes:
2001
H J Schlitt, M W Hoffmann (2001)  Reconstruction of necrotic kidney graft pelvis with a vascularized small bowel patch.   Transpl Int 14: 2. 95-98  
Abstract: Complete necrosis of the pelvis in a transplanted kidney is a rare but particularly severe complication that generally requires removal of the graft. Here, the case of a patient is reported in whom complete necrosis of the ureter and the pelvis occurred a few days after transplantation, while kidney function was excellent. After resection of all necrotic tissue, reconstruction of the pelvis was performed with a vascularized small bowel patch fixed to the renal parenchyma at the border of the intrarenal pelvis. The native ureter was then anastomosed to this reconstructed pelvis. Although the patient suffered from recurrent urinary tract infections in the early postoperative phase, he is now well, with normal kidney graft function and unimpaired urine flow through the reconstructed urinary tract, 18 months after transplantation. This report demonstrates that successful surgical reconstruction after complete necrosis of the renal pelvis in a grafted kidney can be achieved, although the long-term outcome of this graft-saving technique remains to be seen.
Notes:
S Ko, M H Dahlke, O Lauth, M D Jäger, A Deiwick, A Dinkel, T Tsui, K Wonigeit, H J Schlitt (2001)  Bone marrow aplasia induced by passenger leukocytes from heart allografts.   Exp Hematol 29: 3. 339-344 Mar  
Abstract: Organ allografts contain passenger leukocytes that are transferred to the recipient with the transplantation, but their functional relevance to the recipient's immune system is still controversial.
Notes:
P Piso, H Bektas, U Werner, H J Schlitt, S Kubicka, A Bornscheuer, M Manns, J Klempnauer (2001)  Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma.   Eur J Surg Oncol 27: 3. 286-290 Apr  
Abstract: The prognosis of patients with peritoneal carcinomatosis from gastrointestinal malignancies is poor. The aim of this study was to analyse the results of multimodality treatment for peritoneal carcinomatosis of appendiceal carcinoma.
Notes:
H Aselmann, H Wolfes, F Rohde, M Frerker, A Deiwick, M D Jäger, J Klempnauer, H J Schlitt (2001)  Quantification of alpha 1-fetoprotein mRNA in peripheral blood and bone marrow: a tool for perioperative evaluation of patients with hepatocellular carcinoma.   Langenbecks Arch Surg 386: 2. 118-123 Mar  
Abstract: Quantification of alpha 1-fetoprotein (AFP) mRNA in the blood using reverse transcriptase polymerase chain reaction (RT-PCR) could be a useful tool in monitoring the dynamics of minimal residual disease in patients with hepatocellular carcinoma (HCC). Since all available assays do not take into account the efficiency of cell separation, RNA extraction and reverse transcription, a competitive RT-PCR assay for quantification of AFP mRNA in relation to the housekeeping gene glyceraldehyde phosphate dehydrogenase (GAPDH) was established.
Notes:
C Tippner, B Nashan, K Hoshino, E Schmidt-Sandte, K Akimaru, K H Böker, H J Schlitt (2001)  Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course.   Transplantation 72: 6. 1122-1128 Sep  
Abstract: Routine transplant aspiration cytology (TAC) after liver transplantation gives detailed information that concerns immunologic events in the graft. TAC can be helpful for diagnosis of acute rejection, but it also detects morphological signs of rejection without clinical correlate ("subclinical rejection"). The aim of this study was to systematically evaluate factors that influence the development of early clinical and subclinical rejection and to analyze the relevance of these early immunologic processes for the long-term course. The study includes the course of 340 patients after liver transplantation between 1988 and 1995 in whom TAC was performed routinely and who were followed for a minimum of 3 years. TAC findings were correlated with the following various clinical parameters: (1) Overall early clinical rejection occurred in 17.4%, subclinical rejection in 59.1%, and no immune activation was seen in 23.5% of patients. (2) Incidence of early clinical and subclinical rejection was markedly influenced by type of immunosuppression. (3) Basic disease and extent of preservation injury had only a minor influence; there was a trend towards lower early rejection associated with more severe preservation damage, increased patient age, and early retransplantation. (4) Presence of early clinical or subclinical rejection was not associated with a higher incidence of chronic dysfunction. (5) Falsely indicated antirejection treatment was associated with inferior graft survival. Subclinical rejection is very frequent early after liver transplantation, requires no treatment, and has no long-term adverse effect. Incidence of early clinical rejection is mainly determined by initial immunosuppression; its occurrence has no negative long-term effects and may even be associated with a lower risk for later immunological complications. Thus, the incidence of early acute rejection is no adequate parameter for evaluating the quality of an immunosuppressive treatment protocol.
Notes:
C Heerwagen, M Schuster, A Bornscheurer, L Pape, E Kirchner, H J Schlitt, B Luettig, J Westermann (2001)  Rapid exchange of large numbers of donor- and host leukocytes after human liver transplantation.   Transpl Int 14: 4. 240-247 Aug  
Abstract: After liver transplantation, the release of donor leukocytes into the host and the uptake of host leukocytes by the graft is one of the earliest immunologic interactions between donor and host. Using three-color flow cytometry, these interactions were investigated in eight patients from 5 min-24 h after receiving HLA unmatched liver grafts. Five minutes after reperfusion, 5.0 % +/- 1.4 % of all blood leukocytes in the host were of donor origin, decreasing to 1.1 % +/- 0.8 % after 24 h. Donor granulocytes preferentially disappeared from the host circulation, whereas no differences were found between NK-cells and various B- and T cell subpopulations. Furthermore, host granulocytes were preferentially retained in the donor liver. Thus, despite extensive pre-operative perfusion, more than 10(9) donor leukocytes quickly leave the liver graft while host granulocytes preferentially accumulate there. A better understanding of the molecular mechanisms mediating these early interactions might help to develop new strategies for diagnosis and therapy of liver graft rejection.
Notes:
H J Schlitt, A Barkmann, K H Böker, H H Schmidt, N Emmanouilidis, J Rosenau, M J Bahr, G Tusch, M P Manns, B Nashan, J Klempnauer (2001)  Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.   Lancet 357: 9256. 587-591 Feb  
Abstract: Renal dysfunction is a major complication of long-term immunosuppressive therapy with calcineurin inhibitors (CNI) in liver-transplant recipients. We undertook a randomised study to assess the safety and efficacy of CNI withdrawal and replacement by mycophenolate mofetil.
Notes:
S Ko, M D Jager, T Y Tsui, A Deiwick, A Dinkel, F Rohde, M H Dahlke, O Lauth, K Wonigeit, H J Schlitt (2001)  Long-term allograft acceptance induced by single dose anti-leukocyte common antigen (RT7) antibody in the rat.   Transplantation 71: 8. 1124-1131 Apr  
Abstract: In clinical organ transplantation monoclonal antibodies (mAb) to different surface molecules of immunocompetent cells become integral parts of the immunosuppressive therapy. In this study, a mAb against the rat leukocyte common antigen CD45 (RT7) was tested for its immunosuppressive potency after a single perioperative injection.
Notes:
2000
A Barkmann, B Nashan, H H Schmidt, K H Böker, N Emmanouilidis, J Rosenau, M J Bahr, M W Hoffmann, M P Manns, J Klempnauer, H J Schlitt (2000)  Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil.   Transplantation 69: 9. 1886-1890 May  
Abstract: Renal dysfunction caused by treatment with the calcineurin inhibitors (CNI) is a major problem in the long-term course after liver transplantation.
Notes:
K J Oldhafer, H Lang, H J Schlitt, J Hauss, R Raab, J Klempnauer, R Pichlmayr (2000)  Long-term experience after ex situ liver surgery.   Surgery 127: 5. 520-527 May  
Abstract: Ex situ liver surgery allows liver resection and vascular reconstruction in patients who have liver tumors located at critical sites. Only a small series of studies about ex situ liver surgery is available in the literature. No long-term results have been published.
Notes:
D Högemann, G Stamm, H Shin, K J Oldhafer, H J Schlitt, D Selle, H O Peitgen (2000)  [Individual planning of liver surgery interventions with a virtual model of the liver and its associated structures].   Radiologe 40: 3. 267-273 Mar  
Abstract: BACKGROUND: In an interdisciplinary approach, HepaVision (MEVIS, Bremen), a software tool specifically developed for 3D visualization of the liver, was employed for individual planning of extensive liver resections and evaluation of living-relative donations. So far there is experience with more than 50 biphasic spiral CT examinations. RESULTS: The spatial relationship of large tumors to crucial hepatic structures, the demonstration and evaluation of anatomic variants regarding vascular supply and the risk stratification of liver failure by volumetric analysis on the basis of portal venous drainage supported precise indication for surgery. Surgical safety is increased by preoperative planning and simulation of necessary vessel reconstructions. By hiding selective areas of portal venous drainage or applying freely selectable clip planes, segmental as well as non-anatomical resections can be simulated and their effects analyzed. The virtual preoperative situs was confirmed intraoperatively in all 17 patients of our study population who underwent segmental liver resection for either a tumor or living-relative donation.
Notes:
T Y Tsui, A Deiwick, S Ko, H J Schlitt (2000)  Specific immunosuppression by postoperative infusion of allogeneic spleen cells: requirement of donor major histocompatibility complex expression and graft-versus-host reactivity.   Transplantation 69: 1. 25-30 Jan  
Abstract: Donor leukocytes may exert positive immunoregulatory effects on allograft acceptance. Most recent studies have focused on pretreatment protocols. In this study, the effect of postoperative infusion of donor leukocytes on graft survival and the phenotypic and functional requirements for infused cells were investigated in fully major histocompatibility complex (MHC)-mismatched rat heart transplant models.
Notes:
R Raab, H J Schlitt, K J Oldhafer, A Bornscheuer, H Lang, R Pichlmayr (2000)  Ex-vivo resection techniques in tissue-preserving surgery for liver malignancies.   Langenbecks Arch Surg 385: 3. 179-184 Apr  
Abstract: Some primary and secondary liver tumours are not absolutely irresectable, but cannot be resected using a conventional approach because of the limited warm ischaemia tolerance of the liver or poor accessibility of the tumour region. In such situations, the techniques of ex vivo liver surgery, pioneered by Rudolf Pichlmayr some 10 years ago, offer new chances for R0 resection. All the three different approaches, namely "in situ"-, "ante situm"-, and "ex situ" resection, require the use of measures originally developed for transplantation, such as hypothermic liver perfusion and veno-venous bypass. They differ mainly in the extent to which major vessels are divided in order to achieve optimal mobility of the organ. The results show that radical resection can be achieved accomplished in many cases. If necessary, complex vascular reconstructions can be performed. Although perioperative morbidity and mortality are high, there are a number of long-term survivors. Tumour recurrence, however, remains the main problem over the long term. In conclusion, ex vivo liver surgery is an important extension of surgical treatment possibilities. However, the procedure is suitable only for a small number of carefully selected patients and should be reserved for use in specialised centres. Furthermore, in view of the fact that the results are not yet optimal, additive and adjuvant treatment modalities are needed.
Notes:
A Weimann, H Varnholt, H J Schlitt, H Lang, P Flemming, C Hustedt, G Tusch, R Raab (2000)  Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma.   Br J Surg 87: 9. 1182-1187 Sep  
Abstract: Cholangiocellular carcinoma is an uncommon primary liver cancer, which may be mixed with hepatocellular carcinoma. A retrospective analysis was undertaken to evaluate the results of surgical treatment and to identify prognostic factors.
Notes:
K Akimaru, M Onda, H J Schlitt, T Tajiri (2000)  [Liver transplant aspiration cytology to monitor the intragraft events].   Rinsho Byori 48: 11. 1014-1021 Nov  
Abstract: Liver transplant aspiration cytology(TAC) contributes significantly to the differential diagnosis of transplanted liver graft dysfunction, since each of the possible causes induces characteristic cytological findings in the graft and peripheral blood. That is, TAC can differentiate various inflammatory changes as indicating acute rejection, viral infection, or bacterial infection. The key is the intensity of activated lymphocytes in the graft and in blood. Remarkable lymphocytic activation only in the liver graft indicates acute rejection, meanwhile in a case of viral infection the activation can be seen both in liver graft and blood. The patterns and degree of liver cell injury and cholestasis can also identify the reason for liver impairment. Several cases of acute rejection, viral infection, and subclinical acute rejection diagnosed by TAC were recognized on TAC slide preparations. Subclinical rejection, which means acute rejection appreciated only cytologically or histologically, can be followed without treatment unless the patient demonstrates jaundice and liver enzymes over 100 units. In a case of chronic rejection, TAC is not an appropriate method of diagnosis, because there are few infiltrating cells in the portal triad, and subsequently, no visible activated lymphocytes on TAC slides. Although TAC is not well accepted, it is an informative means preliminary to core biopsy, and its use is expected to become wide-spread in the future because it is a safe procedure with minimal invasiveness to patients, and useful for differential diagnosis. The use of TAC will lessen the frequency of performing more invasive core biopsy.
Notes:
P Piso, H J Schlitt, J Klempnauer (2000)  Stromal sarcoma of the stomach: therapeutic considerations.   Eur J Surg 166: 12. 954-958 Dec  
Abstract: To present our experience of the surgical treatment of primary gastric stromal sarcomas and to compare it with reported results.
Notes:
C Trautwein, M Possienke, H J Schlitt, K H Böker, R Horn, R Raab, M P Manns, G Brabant (2000)  Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation.   Am J Gastroenterol 95: 9. 2343-2351 Sep  
Abstract: Osteoporosis is frequently found in patients with cholestatic liver disease (primary biliary cirrhosis/primary sclerosing cholangitis) and chronic viral hepatitis. There is limited information about the long-term effect of liver transplantation (OLT) on bone metabolism. The aim of this study was to investigate the effect of liver transplantation on bone metabolism in patients with cholestatic and viral liver diseases.
Notes:
M Schult, J Küster, V Kliem, R Brunkhorst, B Nashan, K J Oldhafer, H J Schlitt (2000)  Native pyeloureterostomy after kidney transplantation: experience in 48 cases.   Transpl Int 13: 5. 340-343  
Abstract: Necrosis and stenosis of the ureter are severe complications after kidney transplantation and occur with mean incidence of 2,9-13,4 %. Several surgical techniques like simple nephrostomy or complex urinary tract reconstruction have been applied for repair. In this study, our experience with native pyeloureterostomy (NPUS) using the native ureter is presented. Between March 1978 and June 1996, 2,592 kidney transplantations were performed in our institution. In 48 patients (1,9%), secondary urinary tract reconstruction by NPUS was necessary. These patients were evaluated retrospectively by review of the case notes. At the time of operation the mean age was 45 +/- 14 years. Indications for NPUS were distal ureteral stenosis (n = 29), necrosis (n = 17), bleeding (n = 1) or iatrogenic lesion of the ureter (n = 1). The mean time period between transplantation and urinary tract reconstruction was 20 +/- 23 days (range: 1-90 days) for necrosis and 404 +/- 637 days (range: 14-2,385 days) for stenosis. A pyeloureterostomy was technically feasible in all patients using the recipient's ipsilateral ureter. In 40 out of 48 patients the graft developed a normal function postoperatively (follow up: 39 +/- 48 months). A graft nephrectomy was necessary only in one patient, because of complete pyelonnecrosis 6 days after NPUS. Two grafts were lost due to acute rejection. Data of five patients were not available > 15 years after successful reconstruction. We can conclude that NPUS is a safe and simple rescue technique for the treatment of distal ureteral complications after kidney transplantation. Therefore, this technique should be the therapy of choice when secondary reconstruction by re-ureteroneocystostomy is not possible.
Notes:
1999
K J Oldhafer, A Bornscheuer, N R Frühauf, M K Frerker, H J Schlitt, B Ringe, R Raab, R Pichlmayr (1999)  Rescue hepatectomy for initial graft non-function after liver transplantation.   Transplantation 67: 7. 1024-1028 Apr  
Abstract: Early retransplantation is the therapy of choice in patients with initial graft nonfunction (INF). In rare cases the patients' conditions deteriorate dramatically with severe cardiovascular and/or pulmonary insufficiency while on the waiting list for retransplantation. In this life-threatening situation removal of the graft and temporary portocaval shunt before allocation of a new liver proved to be effective. Our experience with this two-stage hepatectomy and subsequent liver transplantation in patients with complicated INF is reported.
Notes:
T Sato, A Deiwick, G Raddatz, K Koyama, H J Schlitt (1999)  Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): influence of cell numbers, subpopulations and cyclosporin.   Clin Exp Immunol 115: 2. 301-308 Feb  
Abstract: With organ allografts considerable numbers of donor-type mononuclear cells are transferred to the recipient, leading to bilateral immunological interactions between donor and recipient lymphocytes. To study such bilateral immune reactions in detail, human two-way MLC were performed. In this model proliferation kinetics, patterns of activation, and survival of the two populations were analysed, and the relevance of initial cell subset composition, relative cell numbers, and the effect of immunosuppression on this co-culture were evaluated. It could be demonstrated that with an initial 50:50 ratio of two populations of allogeneic cells one population dominated after 21 days of co-culture in 78 out of 80 combinations (97%) tested; the other population decreased markedly after an initially stable phase of 6-7 days. With unequal starting conditions the larger population dominated when resting cells were used, but small populations of preactivated cells or separated CD8+ cells could also dominate. Depletion of CD16+ natural killer (NK) cells and of CD2- cells (B cell and monocytes) had no effect on domination. Addition of cyclosporin delayed or blocked the domination process while addition of IL-2 accelerated it. Disappearance of one population was associated with detection of apoptotic cells. The findings indicate that co-cultures of allogeneic mononuclear cells are generally not stable for more than 1 week, but lead to active elimination of one population. CD8+ cells and particularly preactivated cells seem to play the most important role in that process, while NK cells are of less importance. Cyclosporin can prolong survival of allogeneic cells in co-culture. These observations suggest that under the conditions of clinical organ transplantation even small amounts of immunocompetent donor cells transferred by the graft may persist for some time and may, thereby, have the chance to exert immunomodulatory functions.
Notes:
H J Schlitt, A Weimann, J Klempnauer, K J Oldhafer, B Nashan, R Raab, R Pichlmayr (1999)  Peripheral hepatojejunostomy as palliative treatment for irresectable malignant tumors of the liver hilum.   Ann Surg 229: 2. 181-186 Feb  
Abstract: To evaluate the concept of surgical decompression of the biliary tree by peripheral hepatojejunostomy for palliative treatment of jaundice in patients with irresectable malignant tumors of the liver hilum.
Notes:
H J Schlitt, P N Meier, B Nashan, K J Oldhafer, K Boeker, P Flemming, R Raab, M P Manns, R Pichlmayr (1999)  Reconstructive surgery for ischemic-type lesions at the bile duct bifurcation after liver transplantation.   Ann Surg 229: 1. 137-145 Jan  
Abstract: To assess the feasibility, morbidity, mortality, and clinical success rate of surgical reconstruction of the biliary system in patients with ischemic-type biliary lesions in their liver graft.
Notes:
H J Schlitt, M Neipp, A Weimann, K J Oldhafer, E Schmoll, K Boeker, B Nashan, S Kubicka, H Maschek, G Tusch, R Raab, B Ringe, M P Manns, R Pichlmayr (1999)  Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation.   J Clin Oncol 17: 1. 324-331 Jan  
Abstract: Tumor recurrence is the major limitation of long-term survival after liver transplantation for hepatocellular carcinoma (HCC) or fibrolamellar carcinoma (FLC). Understanding tumor-biologic characteristics is important for selection of patients and for development of adjuvant therapeutic strategies.
Notes:
B Rodeck, R Kardorff, M Melter, H J Schlitt, K J Oldhafer (1999)  Auxiliary partial orthotopic liver transplantation for acute liver failure in two children.   Pediatr Transplant 3: 4. 328-332 Nov  
Abstract: Acute liver failure in children and adults is associated with a high mortality rate. At present the treatment of choice is orthotopic whole-liver transplantation. However, allogeneic liver transplantation necessitates lifelong immunosuppressive therapy, which is associated with substantial risks to the patient. Temporary auxiliary partial orthotopic liver transplantation has been developed recently as an alternative, enabling the native liver to regenerate while avoiding the risks of long-term immunosuppressive treatment. Here we describe two cases of partial orthotopic liver transplantation in children. Auxiliary partial orthotopic liver transplantation was performed in two boys (5 and 6 years old) suffering from acute liver failure of unknown origin. The native left lateral liver lobes (segment II and II) were removed and replaced by left lateral liver grafts from young blood-group-compatible adults. In the first child the native liver, which was 80% necrotic at time of transplantation, showed regeneration within two weeks and the partially necrotic graft could be surgically removed on day 15 after auxiliary transplantation. Four years after transplantation, the child is in excellent condition with normal liver function and does not require any treatment. In the second case the native liver (90% necrotic at time of transplantation) regenerated within 6 weeks of transplantation, at which time the transplanted liver was removed. The patient developed aplastic anemia and died 2 months after transplantation from candida sepsis. The conclusion was that auxiliary partial liver transplantation in childhood provides a valuable option to maintain liver function in acute liver failure until functional recovery of the native liver. The main advantage over whole-liver transplantation is the chance to avoid lifelong immunosuppression. However, there is a higher surgical risk. Therefore, auxiliary transplantation should be considered carefully in every case of acute liver failure in children.
Notes:
B Nashan, R Lück, V Kliem, R Brunkhorst, H J Schlitt, J Klempnauer (1999)  CMV in kidney transplantation: a single center experience over 22 years.   Clin Transpl 181-188  
Abstract: Analysis of a historic renal transplant population for risks of developing CMV disease demonstrated a low mortality (0.2%) and morbidity. In our population of 1,959 patients, 411 (21%) developed subclinical CMV infection and 220 (11%) had CMV disease which was severe in 41 (2%). Important factors for infection were baseline immunosuppression, indicating that triple therapy with the proliferation inhibitors, azathioprine and MMF, had significantly higher infection numbers in comparison to dual, CsA-based immunosuppression. The cumulative dose of steroids correlated strongly with an increased number of CMV infections and disease, as did the addition of ALG/ATG or OKT3 for either steroid-resistant rejections or induction therapy. While CMV serology had an impact on infection in cases of seropositive donors to seronegative recipients, seropositive patients, in general, demonstrated increased infection rates most likely due to reactivation of the virus. Prophylaxis had no impact on the incidence of infection but reduced the severity.
Notes:
G Marx, B Nashan, M Cobas Meyer, B Vangerow, H J Schlitt, S Ziesing, M Leuwer, S Piepenbrock, H Rueckoldt (1999)  Septic shock after liver transplantation for Caroli's disease: clinical improvement after treatment with C1-esterase inhibitor.   Intensive Care Med 25: 9. 1017-1020 Sep  
Abstract: The extent of complement and contact activation is related to outcome in sepsis. A low functional index of their main blocker C1-esterase inhibitor (C1-INH) is considered as a relative deficiency of C1-INH and might contribute to the development of fatal complications in the intensive care unit. The first results of therapeutic intervention with C1-INH concentrate in septic shock are promising. We report on our experience of C1-INH concentrate administration in a young woman with Caroli's disease as ultimate rescue therapy for septic shock with capillary leakage syndrome after combined liver and kidney transplantation. No focus of infection was detectable and thus surgical intervention was not indicated. Antibiotic therapy at that time included vancomycin, tobramycin, meropenem and fluconazol. Hemodynamic stabilization occurred within hours after administration of C1-INH concentrate. Simultaneously a reduction in vasopressor medication was possible and negative fluid balance was achieved.
Notes:
S Ko, A Deiwick, M D Jäger, A Dinkel, F Rohde, R Fischer, T Y Tsui, K L Rittmann, K Wonigeit, H J Schlitt (1999)  The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat.   Nat Med 5: 11. 1292-1297 Nov  
Abstract: With an organ transplant, hematopoietic donor cells are transferred to the recipient. To study the relevance of the resulting microchimerism for allograft acceptance, we analyzed a rat model of cyclosporine-induced tolerance for strongly incompatible heart allografts. Using a monoclonal antibody that detects a donor-specific CD45 allotype (RT7a), we selectively depleted donor leukocytes at different times after transplantation (days 0 or 18). Depletion was similarly effective at both times. However, only depletion on day 0 prevented tolerance induction and was associated with severe acute or chronic graft rejection. This indicates that passenger leukocytes have an essential immunomodulatory effect on the induction phase of allograft acceptance.
Notes:
H J Schlitt, R Brunkhorst, H H Schmidt, B Nashan, A Haverich, R Raab (1999)  Attitudes of patients before and after transplantation towards various allografts.   Transplantation 68: 4. 510-514 Aug  
Abstract: The presence of an allogeneic graft inside the body may have psychological impact on transplant patients. It was the aim of this study to evaluate the attitude of patients before and after different types of organ transplantation towards organ allografts.
Notes:
H J Schlitt, R Brunkhorst, A Haverich, R Raab (1999)  Attitude of patients toward transplantation of xenogeneic organs.   Langenbecks Arch Surg 384: 4. 384-391 Aug  
Abstract: The prospect of xenotransplantation has stimulated considerable hopes as well as major concerns. The question of whether or not patients accept xenografts is influenced not only by scientific facts but also by psychological factors. It was the aim of this study to analyze the attitudes of patients toward transplantation of xenogeneic organs and evaluate factors influencing these attitudes.
Notes:
H Lang, H J Schlitt, H Schmidt, P Flemming, B Nashan, G F Scheumann, K J Oldhafer, M P Manns, R Raab (1999)  Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients.   Langenbecks Arch Surg 384: 4. 370-377 Aug  
Abstract: Metastatic neuroendocrine pancreatic tumors have a poor prognosis. We have studied retrospectively the efficacy of liver transplantation as ultimate therapy of otherwise untreatable symptomatic neuroendocrine hepatic metastases originating in the pancreas.
Notes:
M Winkler, H J Schlitt (1999)  [Xenotransplantation of the liver].   Zentralbl Chir 124: 7. 621-627  
Abstract: The development of pigs transgenic for human regulators of complement activation resulted in the nearly total elimination of episodes of hyperacute rejection following discordant solid organ xenotransplantation. Following discordant heart or kidney transplantation, in subhuman primates, graft survival rates of up to several months can be observed. In contrast to these organs, the xenotransplantation of the liver is associated with the inherent problem of the immunological and metabolic compatibility of the large variety of xenoproteins generated. Based on a review of data mainly derived from experimental ex-vivo xenoliver perfusions in patients with hepatic coma, whole organ orthotopic or heterotopic liver xenotransplantation currently is not likely to become a relevant option for the treatment of patients with endstage liver failure. In contrast, clinical studies utilizing different forms of bioartificial liver assist devices are currently underway. Based on preliminary data published, this form of liver support therapy might enter the clinic in the near future.
Notes:
1998
R Pichlmayr, A Weimann, K J Oldhafer, H J Schlitt, G Tusch, R Raab (1998)  Appraisal of transplantation for malignant tumours of the liver with special reference to early stage hepatocellular carcinoma.   Eur J Surg Oncol 24: 1. 60-67 Feb  
Abstract: The enthusiasm to treat or even cure patients with unresectable hepatobiliary malignancy by total hepatectomy and liver transplantation has considerably diminished. Nowadays, due to organ-donor shortage, patients have to be selected with predictable likelihood for long-term survival. According to own experience and a review of the literature, liver transplantation may be considered in unresectable early stage hepatocellular and proximal bile duct carcinoma, the uncommon entities fibrolamellar carcinoma, epithelioid haemangioendothelioma and hepatoblastoma as well as in liver metastases from neuroendocrine tumours. At present, advanced stages of hepatocellular and proximal bile duct carcinoma, as well as intrahepatic bile duct carcinoma, haemangiosarcoma and metastases from nonendocrine tumours, should be excluded from transplantation. In order to cure the cancer-bearing disease, liver transplantation might be the ideal treatment for small but still resectable hepatocellular carcinoma with underlying cirrhosis. Our retrospective comparison of survival after resection and transplantation for early stage hepatocellular carcinoma does not reveal a significant difference. Although a tendency has been observed in favour of transplantation, resection of these tumours is still justifiable, not least because of donor organ shortage.
Notes:
K Hengst, B Nashan, W Avenhaus, H Ullerich, H J Schlitt, P Flemming, R Pichlmayr, W Domschke (1998)  Metastatic pancreatic VIPoma: deteriorating clinical course and successful treatment by liver transplantation.   Z Gastroenterol 36: 3. 239-245 Mar  
Abstract: Gastrointestinal neuroendocrine tumors are slowly growing and metastases are often limited to the liver. As a result of their favorable biological behavior these tumors have a relatively good prognosis even in metastatic stage. Due to a variety of therapeutic options patients with malignant neuroendocrine tumors may survive for extended periods of time up to ten years. Often a combination of different treatments and also alternation between the different therapeutic regimes is needed. A patient with excessive WDHA-syndrome and severe metabolic disturbances due to a pancreatic VIPoma with metastatic spread into the liver and abundant hormonal secretion is presented. Cytotoxic agents (streptozocin, 5-fluorouracil and adriamycin) were able to alleviate clinical symptoms and to control tumor growth for six years. Analogues of somatostatin (octreotide) and interferon alpha had been very useful in controlling clinical symptoms and tumor progress for 18 months. Cytotoxic agents or octreotide were not able, however, to achieve any permanent cure. Eventually, treatment failure occurred with dramatic progression of symptoms and tumor growth, unresponsive to any medical therapy. Consequently, total hepatectomy and liver transplantation together with extirpation of the pancreatic primary tumor was performed and succeeded in providing a normal life to the patient. In our opinion the overall outcome of patients with metastatic VIPoma may be improved best by maintaining the patients on medical therapy until treatment failure occurs. In case of extended hepatic metastases orthotopic liver transplantation might be considered for patients with symptomatic disease who no longer respond to conventional treatment modalities.
Notes:
A Weimann, L Bastian, W E Bischoff, M Grotz, M Hansel, J Lotz, C Trautwein, G Tusch, H J Schlitt, G Regel (1998)  Influence of arginine, omega-3 fatty acids and nucleotide-supplemented enteral support on systemic inflammatory response syndrome and multiple organ failure in patients after severe trauma.   Nutrition 14: 2. 165-172 Feb  
Abstract: This study investigated the influence of an enteral diet supplemented with arginine, omega-3 fatty acids, and nucleotides (Impact, Sandoz Nutrition, Berne, Switzerland) on the incidence of systemic inflammatory response syndrome (SIRS) and multiple organ failure (MOF) in patients after severe trauma. Thirty-two patients with an injury-severity score > 20 were included in this prospective, randomized, double-blind, controlled study. Primary endpoints were the incidence of SIRS and MOF. Secondary endpoints were parameters of acute phase and immune response as well as infection rate, mortality, and hospital stay. For statistical analysis 29 patients (test group n = 16, control n = 13) were eligible. In the test group, significantly fewer SIRS days per patient were found during 28 d. The difference was highly significant between d 8-14 (P < 0.001). MOF score was significantly lower in the test group on d 3 and d 8-11 (P < 0.05). Acute phase parameters showed lower C-reactive protein serum levels (significant on D day 4) and fibrinogen plasma levels (significant on d 12 and 14; P < 0.05). HLA-DR expression on monocytes showed significantly higher fluorescence activity on d 7. No significant difference was found for T-lymphocyte CD4/CD8 ratio, interleukin-2 receptor expression, infection rate, mortality (2/16 vs. 4/13), and hospital stay. The results of the study provide further support for beneficial effects of arginine, omega-3-fatty acids and nucleotide-supplemented enteral diet in critically ill patients.
Notes:
J Radermacher, M Meiners, C Bramlage, V Kliem, M Behrend, H J Schlitt, R Pichlmayr, K M Koch, R Brunkhorst (1998)  Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.   Transpl Int 11: 1. 3-10  
Abstract: This prospective study investigated hypertension and renal vasoconstriction developing during the 1st year after renal transplantation in patients randomly allocated to treatment with FK 506 (n = 28) or CyA (n = 13). Starting doses were 0.2-0.3 mg/kg per day for FK 506 and 5-8 mg/kg per day for CyA: doses were subsequently adjusted to trough levels (5-15 ng/ml for FK 506 and 100-150 ng/ml for CyA). We compared 24-h ambulatory blood pressure measurement, antihypertensive treatment, serum creatinine, and resistance index (RI), measured by Doppler ultrasound at the level of the interlobar artery. Until month 2 of treatment, FK 506-treated patients had a significantly lower RI (8%) and better renal graft function, as evidenced by significantly lower serum creatinine values. Some 13% of FK 506-treated patients, compared to 70% of CyA-treated patients (P < 0.01), needed additional antihypertensive drugs after transplantation to keep blood pressure stable. FK 506 treatment, at the above-mentioned dosages, was associated with a significantly higher number of infections (urinary tract infection, pyelonephritis, and pneumonia). We conclude that CyA produces greater renal vasoconstriction and systemic hypertension than FK 506, as reflected in higher renal interlobar artery RI values and a greater need for antihypertensive treatment. After 2 months of treatment and a reduction in CyA trough levels, the renal effects (i.e., lower RI and lower creatinine values), but not the systemic hypertensive effects, disappear.
Notes:
M Caselitz, S Wagner, A Chavan, M Gebel, J S Bleck, A Wu, H J Schlitt, M Galanski, M P Manns (1998)  Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease).   Gut 42: 1. 123-126 Jan  
Abstract: Arteriovenous malformations of the liver in Osler's disease may present as high output cardiac failure. A few case reports suggested that treatment with arterial embolisation may have beneficial effects in such patients.
Notes:
G Raddatz, A Deiwick, T Sato, H J Schlitt (1998)  Inhibition of cytotoxic alloreactivity by human allogeneic mononuclear cells: evidence for veto function of CD2+ cells.   Immunology 94: 1. 101-108 May  
Abstract: In animal models of organ transplantation, infusion of donor-derived leucocytes or bone marrow cells can support tolerance induction. To date, little is known about the suppressive effects of human allogeneic mononuclear cells on alloreactivity in the human system. To study this, mixed leucocyte cultures (MLC) were incubated in the presence and absence of viable allogeneic mononuclear cells (MNC) (modulator cells) of stimulator/donor origin, and the cytotoxic and proliferative potential of the resulting effector cells was determined. The experiments showed that: viable allogeneic MNC from bone marrow and from lymph nodes and peripheral blood (PBMC) were able to suppress allospecific cytotoxicity by an average of 60%; that allospecific as well as non-specific inhibitory effects could be observed with unseparated PBMC; that CD2+ PMNC showed predominantly allospecific inhibition of cytotoxicity with little effect on proliferation whereas CD2- PBMC showed non-specific inhibitory effects (both for cytotoxicity and proliferation), which could be eliminated by indomethacin; that addition of interleukin-2 (IL-2) up to 50 U/ml to the MLC could not reverse the inhibitory effect; and that selective removal of CD8+ cells from the CD2+ modulator population diminished the specific inhibitory effect only partially. These findings demonstrate that viable human MNC from different compartments can have a marked suppressive effect on alloreactivity in vitro. For peripheral blood mononuclear cells (PBMC) the data suggest that various mechanisms can contribute to allosuppression, including specific suppressive veto effects by CD2+ cells. Such inhibitory effects might be applicable in vivo for down-regulating allospecific cytotoxicity and to facilitate the acceptance of allografts.
Notes:
O K Eberhard, I Langefeld, E R Kuse, F M Brunkhorst, V Kliem, H J Schlitt, R Pichlmayr, K M Koch, R Brunkhorst (1998)  Procalcitonin in the early phase after renal transplantation--will it add to diagnostic accuracy?   Clin Transplant 12: 3. 206-211 Jun  
Abstract: The determination of serum procalcitonin (PCT) was tested for its utility in detecting invasive bacterial infection and acute rejection during the first 6 wk after kidney transplantation. Fifty-seven kidney graft recipients were prospectively included in the study. In 13/57 patients, 16 episodes of acute biopsy-proven rejection occurred and were treated with high-dose steroids (n = 14) or with OKT3 (n = 2). Seventeen out of 57 patients experienced 19 invasive bacterial infections; 2/57 had partial graft necrosis due to malperfusion. Twenty-five out of 57 graft recipients experienced an uncomplicated postoperative course. A total of 116 samples were analyzed and the following data obtained: PCT, C-reactive protein (CRP), white blood cell (WBC) count, corresponding body temperature and serum creatinine. Procalcitonin values for patients with rejection did not differ significantly from those of the healthy transplant recipients (p = 0.47). In contrast, PCT was clearly elevated with invasive bacterial infection or partial graft necrosis (p < 0.01). OKT3 treatment of rejection led to a more than 10-fold increase in PCT. C-reactive protein, unlike PCT, was elevated to a variable extent in patients with graft rejection, though CRP values were significantly more elevated in patients with infection than in those with rejection (p < 0.01). The specifity for detection of invasive bacterial infection was 0.7 for PCT and 0.43 for CRP, whereas sensitivity was 0.87 for PCT and 1.0 for CRP. There was no correlation between PCT and serum creatinine (r = 0.06). Haemodialysis did not lower PCT serum concentrations. Procalcitonin values rose postoperatively to peak levels on the first and second days and mostly declined to normals within 1 wk. In conclusion PCT, not being influenced by acute kidney graft rejection but serving as a specific indicator of systemic bacterial infection, could help to discriminate between both types of inflammation.
Notes:
E G Rambusch, B Nashan, H L Tillmann, K H Böker, H J Schlitt, H Maschek, R Raab, M P Manns (1998)  [De novo hepatitis B infection after liver transplantation--evidence for the need of active hepatitis B vaccination of liver transplantation candidates].   Z Gastroenterol 36: 12. 1027-1035 Dec  
Abstract: Liver transplantation (LTX) is a generally accepted therapy in the treatment of acute and chronic end-stage liver diseases. Recurrent and de-novo hepatitis B and C virus infection following liver transplantation have been shown.
Notes:
A Chavan, M Galanski, S Wagner, M Caselitz, H J Schlitt, K F Gratz, M Manns (1998)  Hereditary hemorrhagic telangiectasia: effective protocol for embolization of hepatic vascular malformations--experience in five patients.   Radiology 209: 3. 735-739 Dec  
Abstract: To develop a hepatic artery embolization protocol and investigate its efficacy in a prospective study treating patients with hereditary hemorrhagic telangiectasia and predominant hepatic involvement.
Notes:
K J Oldhafer, A Chavan, N R Frühauf, P Flemming, H J Schlitt, S Kubicka, B Nashan, A Weimann, R Raab, M P Manns, M Galanski (1998)  Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?   J Hepatol 29: 6. 953-959 Dec  
Abstract: Hepatic artery chemoembolization was introduced in the treatment of patients with unresectable hepatocellular carcinoma waiting for liver transplantation. The rationale for this preoperative treatment was to control tumor growth during the waiting period and to improve long-term survival. This study aimed to investigate whether preoperative chemoembolization not only induces marked tumor necrosis but also has a survival benefit.
Notes:
T Kiuchi, K J Oldhafer, H J Schlitt, B Nashan, A Deiwick, K Wonigeit, B Ringe, K Tanaka, Y Yamaoka, R Pichlmayr (1998)  Background and prognostic implications of perireperfusion tissue injuries in human liver transplants: a panel histochemical study.   Transplantation 66: 6. 737-747 Sep  
Abstract: Hepatic graft reperfusion is associated with inflammatory processes of unknown relevance to the fate of graft. This study aimed to clarify this relevance by histochemical analyses of human hepatic grafts.
Notes:
H L Tillmann, S Heringlake, C Trautwein, D Meissner, B Nashan, H J Schlitt, J Kratochvil, J Hunt, X Qiu, S C Lou, R Pichlmayr, M P Manns (1998)  Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection.   Hepatology 28: 2. 379-384 Aug  
Abstract: GB virus C (GBV-C) is a newly discovered RNA virus related to the Flaviviridae family. Although GBV-C is not yet associated with any cause of liver disease, a humoral immune response against the GBV-C envelope 2 (E2) protein has been observed. Therefore, we studied the prevalence and clinical relevance of GBV-C RNA and anti-E2 antibodies in patients undergoing orthotopic liver transplantation (OLT). In addition, we tested whether the prevalence of anti-E2 antibodies may protect against GBV-C infection. Of the 182 liver recipients included in this study, 117 of these were evaluated for GBV-C recurrence or de novo infection. GBV-C RNA was detected in sera or plasma using single-tube, reverse-transcriptase polymerase chain reaction, and anti-E2 antibody was detected by enzyme immunoassay (EIA). Cumulative patient and graft survival was tested by using Kaplan-Meier analysis. The independence of prognostic values was assessed by using Cox regression analysis. Before OLT, GBV-C RNA and anti-E2 were detected in 4.0% to 28.6% and 10.0% to 68.8%, respectively, of patients suffering from different forms of chronic liver diseases. GBV-C reinfection after OLT was determined in 85.7%. Of the patients without evidence of exposure to GBV-C before OLT, 30 of 65 (46.2%) became GBV-C RNA positive after OLT. None of the 38 patients who were anti-E2 antibody positive before OLT became GBV-C RNA positive after OLT. Neither patient nor graft survival was significantly affected by the presence of either GBV-C RNA or anti-E2 antibody before OLT. Our data indicate that 1) GBV-C RNA positive patients have a high risk of reinfection after OLT, and 2) the presence of anti-E2 antibodies before OLT is associated with an absence of GBV-C infection after OLT, which may indicate a protective role of anti-E2 antibodies.
Notes:
1997
Pichlmayr, Weimann, Tusch, Schlitt (1997)  Indications and Role of Liver Transplantation for Malignant Tumors.   Oncologist 2: 3. 164-170  
Abstract: PURPOSE: The indication for liver transplantation in malignant liver tumors has been controversial due to disappointing results and shortage of donor organs. The authors evaluated the experience and results of a single center in order to define present indications and selection criteria in hepatobiliary malignancy. PATIENTS AND METHODS: Retrospective analysis of 212 patients who underwent liver transplantation for malignant tumors between 1972 and 1995: Primary hepatobiliary tumors: hepatocellular carcinoma, n = 124 (with underlying cirrhosis, n = 86; fibrolamellar subtype, n = 8); intrahepatic bile duct (cholangiocellular) carcinoma, n = 24; proximal bile duct carcinoma, n = 29; other uncommon entities (n = 15); secondary liver tumors: neuroendocrine, n = 11, and nonendocrine, n = 9. RESULTS: Survival rates in primary liver cancer were correlated to International Union Against Cancer (UICC) tumor stage. For hepatocellular and proximal bile duct carcinoma significantly better outcome was found in UICC-tumor stage I and II versus III and IV. No long-term survival was found after transplantation for intrahepatic bile duct carcinoma, hemangiosarcoma and nonendocrine liver metastases. Comparison of transplant and resected patients with hepatocellular carcinoma stage I and II with underlying cirrhosis showed better survival after transplantation: 1-, 3-, 5-year survival rate of 83.3% versus 76.9%, 75.8% versus 44.0%, 60.6% versus 44.0%, and median survival 96.5 versus 23.2 months. Although this difference was not significant, no patient died from tumor recurrence in the transplant group versus three in the resection group. DISCUSSION AND CONCLUSIONS: Patients with malignant tumors can be selected for transplantation with predictable likelihood for long-term survival. According to the present data, liver transplantation can be considered in unresectable UICC-stage II hepatocellular and proximal bile duct carcinoma, the uncommon entities fibrolamellar carcinoma, epitheliod hemangioendothelioma and hepatoblastoma as well as liver metastases from neuroendocrine tumors. UICC-stage II and IV hepatocellular carcinoma as well as intrahepatic bile duct carcinoma, hemangiosarcoma and metastases from nonendocrine tumors should be excluded from transplantation alone. For hepatocellular carcinoma, multimodality treatment protocols have had a proven impact on the prevention of early recurrence and prolongation of survival. There is evidence that liver transplantation in still resectable hepatocellular carcinoma with underlying cirrhosis might be more appropriate in order to cure the cancer-bearing disease.
Notes:
H J Schlitt, H Rosenthal, K Böker, M Manns, R Pichlmayr (1997)  [Therapy of persistent bleeding esophageal varices using intrahepatic portosystemic stent shunt and immediate liver transplantation].   Chirurg 68: 4. 385-388 Apr  
Abstract: A 41-year-old patient with liver cirrhosis due to autoimmune hepatitis received an emergency transjugular portosystemic stent shunt for uncontrolled acute variceal hemorrhage. Because of markedly impaired liver function, liver transplantation was considered to be indicated and was performed on the following day. Intraoperatively, one of the intrahepatic metal stents migrated unnoticed into the pulmonary artery. The postoperative course was uncomplicated and the displaced stent was left in situ. Eighteen months after the transplantation the patient is well with normal liver function and no pulmonary problems.
Notes:
H Lang, K J Oldhafer, A Weimann, H J Schlitt, G F Scheumann, P Flemming, B Ringe, R Pichlmayr (1997)  Liver transplantation for metastatic neuroendocrine tumors.   Ann Surg 225: 4. 347-354 Apr  
Abstract: This article describes the experience with liver transplantation in patients with irresectable neuroendocrine hepatic metastases.
Notes:
H Lang, H J Schlitt, M P Manns, R Pichlmayr (1997)  [Surgery in immunosuppressed patients with emergency or elective indications].   Chirurg 68: 7. 675-680 Jul  
Abstract: Immunosuppressive therapy and its influence on perioperative pathophysiology present special challenges in the event of surgical intervention. Immunosuppressive agents alter the patient's response to surgical stress and infectious complications. The often masked signs, even in the case of severe infection, require a high index of suspicion to establish the diagnosis. This may result in a fatal delay of therapy. In addition, the immunosuppressed state increases the patient's susceptibility to infection and leads to an impairment of wound healing. Therefore, careful perioperative clinical monitoring of the patient and complete control of the immunosuppressive therapy are mandatory. Elective operations in immunosuppressed patients should be performed with special caution regarding the potential perioperative risks for the patient and the graft. On the other hand, if there is evidence of, for example, an acute abdominal event, a more aggressive approach is required to rapidly establish the diagnosis and institute appropriate therapy. From the surgical point of view, special emphasis should be placed on wound closure and on anastomotic sutures when operating on a patient receiving immunosuppressive therapy.
Notes:
C Ohmacht, V Kliem, M Burg, B Nashan, H J Schlitt, R Brunkhorst, K M Koch, J Floege (1997)  Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss.   Transplantation 64: 10. 1493-1496 Nov  
Abstract: Although most transplanted patients with underlying IgA nephropathy (IgAN) develop histological recurrence, its clinical relevance is considered low.
Notes:
M Ueda, J Hundrieser, M Hisanaga, K Tanaka, K Wonigeit, R Pichlmayr, H J Schlitt, Y Yamaoka (1997)  Development of microchimerism in pediatric patients after living-related liver transplantation.   Clin Transplant 11: 3. 193-200 Jun  
Abstract: Microchimerism has been suggested to play an important role in the long-term acceptance of allogeneic organ grafts by transplant patients and for the maintenance of a state of donor-specific low responsiveness. In order to elucidate the kinetics of the development of chimerism we have performed a follow-up analysis in 10 pediatric patients with living-related liver transplantation (LRLTx). Blood samples obtained during the first 6 months and at 18 months post-transplant and skin biopsies taken at one month were analysed for the presence of donor cells by PCR using donor-specific HLA-DRB1 primer pairs or primers for a Y chromosome-specific sequence. Furthermore 13 long-term patients more than 2 yr after LRLTx were studied at two different time points. In the follow-up studies donor cells could be demonstrated in the blood of all patients immediately after transplantation. After a gradual decline all patients became chimerism-negative for several weeks or months. At 6 months, however, in five of eight patients tested and at 18 months in six of nine patients donor cells had reappeared. This biphasic pattern in the development of chimerism is proposed to reflect the occurrence of different donor-derived cell populations in the recipient. The population giving rise to the first wave of chimerism probably represents matured cells with a limited lifespan which are released from the graft into the circulation of the recipient during the first weeks after transplantation. The population of cells occurring with the second wave of chimerism is likely to have been generated by donor-derived cells with stem cell potential located either in the graft or in the hematopoetic organs of the recipient after emigration from the graft. This model may be able to explain fluctuations in the incidence and degree of microchimerism described in other patient populations during the first year post-transplant. Of the 13 long-term patients, chimerism could be demonstrated in 11. In seven patients it was detected in both blood and skin, in three patients the results obtained for blood and skin were discordant. In one patient only blood was analysed. It is not clear whether the negative results really reflected the absence of chimerism or whether the number of donor cells was below the level of detectability.
Notes:
M Haubitz, V Kliem, K M Koch, B Nashan, H J Schlitt, R Pichlmayr, R Brunkhorst (1997)  Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients.   Transplantation 63: 9. 1251-1257 May  
Abstract: In patients with autoimmune diseases such as vasculitis or systemic lupus erythematosus (SLE), end-stage renal disease develops in a high percentage of patients, and kidney transplantation has become a therapeutic option. However, only limited data about the prognosis and outcome after kidney transplantation are available.
Notes:
1996
M Hisanaga, J Hundrieser, K Böker, K Uthoff, G Raddatz, T Wahlers, K Wonigeit, R Pichlmayr, H J Schlitt (1996)  Development, stability, and clinical correlations of allogeneic microchimerism after solid organ transplantation.   Transplantation 61: 1. 40-45 Jan  
Abstract: To assess the development, stability, and clinical relevance of donor-type microchimerism, skin and blood were analyzed in heart (n = 53) and liver (n = 18) transplant recipients by nested polymerase chain reaction. Microchimerism was detectable in 40 (75%) and 13 (72%) patients after heart and liver transplantation, respectively. In heart transplantation, chimerism-positive patients showed a lower frequency of acute rejection as compared with negative patients, although this was only of borderline statistical significance. Repeated intraindividual analyses demonstrated variable patterns of microchimerism over time, but changes did not correlate to the clinical state. In liver transplantation, chimeric state showed no clear correlation with the patients' immunological situation. Our results demonstrate that peripheral microchimerism frequently develops after different types of organ transplantation and represents a dynamic process but without diagnostic value to predict the immunological risk for individual patients.
Notes:
H J Schlitt, A Obed, K J Oldhafer, M P Manns, R Pichlmayr (1996)  [Liver transplantation in elderly patients: indications, risks and results].   Langenbecks Arch Chir Suppl Kongressbd 113: 519-521  
Abstract: This study analyzes the course of 62 patients aged over 60 years (i.e., 7% of all recipients) which were liver transplanted over the last 10 years. The data show that the results of transplantation in patients with malignant tumors (n = 25) are unfavorable (20% 5-year survival), while good results could be obtained in patients with benign indications (n = 37), including mainly posthepatitic cirrhosis, but also three fulminant liver failures (75% 5-year survival). Causes of death were mainly septic complications in the early phase and tumor recurrence in patients with malignant disease.
Notes:
B Nashan, G Tusch, H J Schlitt, R Pichlmayr (1996)  [Liver transplantation in patients with primary sclerosing cholangitis. Determining timing with reference to risk of malignancy].   Langenbecks Arch Chir Suppl Kongressbd 113: 410-412  
Abstract: Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease associated with hepatobiliary malignancies which are in the majority of cases not known prior to transplantation. Applying the Mayo PSC natural history model, patients can be classified in low, medium and high risk groups; particularly patients at medium and high risk are in danger of developing malignancies in a PSC setting. Therefore, regular scoring of patients using the above-mentioned model is suggested, and transplantation should be performed at scores above 4.
Notes:
B Nashan, H J Schlitt, R Schwinzer, B Ringe, E Kuse, G Tusch, K Wonigeit, R Pichlmayr (1996)  Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.   Transplantation 61: 4. 546-554 Feb  
Abstract: The immunosuppressive effect of a monoclonal antibody (moAb), BT563, directed to the alpha-chain of the IL-2R (CD25), was analyzed in a prospective nonrandomized trial and a prospective randomized trial. Primary objectives were evaluation of the incidence of acute rejections and infections; secondary objectives were safety and tolerability of the moAb. A total of 28 patients were enrolled (phase II) to receive 10 mg/day of BT563 (12 days) as immunoprophylaxis in combination with cyclosporine, azathioprine, and low-dose steroids. Subsequently 32 patients were randomly assigned (phase III) to receive BT563 (10 mg/day) for 12 days or ATG (5 mg/kg/day) for 7 days in addition to cyclosporine and low-dose steroids. No side effects of the BT563 treatment were noted. The actuarial survival was 82% at 12 months in the phase II trial and 92% at 12 months in both arms of the phase III trial. There was one acute rejection in the phase II trial. No acute rejections were noted in the BT arm of the phase III trial and 5 acute rejections were treated in the ATG arm. In the phase II trial 7 infectious episodes were observed, while one infection was seen in the BT arm and 7 in the ATG arm of the triple immunosuppression phase III trial. In all patients circulation of coated CD25+ lymphocytes was observed during BT563 treatment; there was no evidence of depletion or modulation of CD25+ cells. Mean serum levels of BT563 ranged from 1.6 to 7.6 microgram/ml throughout the therapy. An antimurine response was seen in 82% (phase II) and 100% (phase III) of the patients. Antirabbit antibodies were found in 56% of the patients treated with ATG. Analysis of the antimurine response specificity revealed in 56% blocking anti-isotypic antibodies and only in 3% of the patients an anti-idiotypic response. The data of the study presented suggest that therapy with an anti IL-2R moAb is at least equal to ATG application according to the incidence of acute rejections and infections.
Notes:
H Lang, K J Oldhafer, H J Schlitt, G F Scheumann, B Ringe, R Pichlmayr (1996)  [Is liver transplantation as surgical therapy concept in metastases of neuroendocrine tumors justified?].   Langenbecks Arch Chir Suppl Kongressbd 113: 416-418  
Abstract: Between 1982 and February 1996 11 patients underwent liver transplantation for irresectable neuroendocrine hepatic metastases. The operative mortality was one of 11, while two patients died due to sepsis respectively tumor recurrence 7 and 68 months after transplantation. Eight patients are alive with a median survival of 55 months (range from 10 days to 8.5 years). In three patients there is no evidence of tumor and the longest disease-free survival is 102 months after LTx. These results suggest that liver transplantation represents a justified treatment for irresectable hepatic metastases arising from neuroendocrine tumors.
Notes:
P Liebau, E Kuse, M Winkler, H J Schlitt, K Oldhafer, W Verhagen, J Flik, R Pichlmayr (1996)  Management of herpes simplex virus type 1 pneumonia following liver transplantation.   Infection 24: 2. 130-135 Mar/Apr  
Abstract: Interstitial pneumonia caused by Herpes simplex virus type 1 (HSV-1) is a severe complication of orthotopic liver transplantation (LTX). The records of patients were reviewed who had an LTX at the age of 16 years or older between 1991 and 1994 with a mean follow-up of 21 months (range, 10 to 44 months). Six patients were included who had fever of > 38 degrees C, deterioration of arterial blood gases, radiological evidence of interstitial pneumonia and proof of HSV-1 in bronchoalveolar lavage fluid. All patients were anti-HSV-IgG positive before LTX. All patients were successfully treated with intravenous acyclovir, mechanical ventilation and reduced immunosuppression. Three patients who received cyclosporin A had a rejection which was successfully treated by switching to FK 506. Four patients were discharged in good health. One patient died 36 months after LTX of an unrelated cause. One patient died of urosepsis on postoperative day 139. Acyclovir together with mechanical ventilation and reduced immunosuppression proved to be an effective treatment for HSV-1 pneumonia following LTX.
Notes:
B Nashan, H J Schlitt, G Tusch, K J Oldhafer, B Ringe, S Wagner, R Pichlmayr (1996)  Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation.   Hepatology 23: 5. 1105-1111 May  
Abstract: Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease associated in 10% to 36% of those with hepatobiliary malignancies, which are, in the majority of cases, not known prior to transplantation. Diagnosis of carcinomas in a PSC setting at an early stage has not yet been achieved, because there are no differences in the age of patients or clinical course, particularly with regard to the time between diagnosis of PSC and detection of carcinomas. To assess optimal timing for transplantation in patients with PSC, we applied the Mayo survival model to 48 patients receiving transplants for that disease in our center between 1972 and 1994. Of these patients, 10 had a biliary malignancy, which was incidental in 9. According to the Mayo model, low-, moderate-, and high-risk groups of patients could be formed. The actuarial patient survivals at 1 and 7 years were 100% and 100% (low risk), 68.6% and 68.6% (moderate risk), and 54.6% and 46.8% (high risk), respectively. Patients with a biliary malignancy had a 30% survival at 1 year; none survived 6 years. Local recurrence of the tumor was found in 3 patients, 2 of them with low tumor stages at the time of transplantation. Analysis of the Mayo Model risk scores demonstrated a marked increase in the incidence of biliary malignancies at a score above 4.4. All patients with tumors were found to have a score above 4. Moreover, the prevalence rate rose from 14.3% in the low-risk group to 33.3% in the moderate-risk group. There was no difference in the clinical courses at 6 to 12 months prior to transplantation; in particular, the bilirubin levels (PSC alone, 250 +/- 230 mumol/L; PSC with carcinoma, 288 +/- 182 mumol/L) did not differ significantly (P > .05) between both patient groups. Because the outcome after transplantation is poor even in patients with low-grade malignancies, early timing of transplantation in patients with PSC is suggested to prevent formation of biliary malignancies. Therefore, regular scoring of patients with the Mayo Model risk score is suggested, and transplantation should be taken into consideration at scores above 4.
Notes:
O K Eberhard, V Kliem, K Oldhafer, H J Schlitt, R Pichlmayr, K M Koch, R Brunkhorst (1996)  How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation.   Transplantation 61: 9. 1345-1349 May  
Abstract: Nineteen patients with biopsy-confirmed ongoing acute rejection of renal allografts were converted from standard immunosuppression to FK506. Eight grafts showed vascular rejection and 11 had cellular rejection on biopsy. All patients had already received intravenous high-dose steroid treatment. Ten patients also had additional OKT3 rescue therapy. Initial FK506 doses were 0.13 +/- 0.06 mg/kg/day; the FK506 whole blood trough level after 3 days of treatment was 9.3 +/- 4.5 ng/ml. After conversion to FK506 all but four patients also received azathioprine, 1.5-2 mg/kg/day, and all patients received oral prednisolone. Concomitant with initiation of FK506, an anti-infective prophylaxis was prescribed, consisting of ganciclovir and trimethoprim/sulfamethoxazole. Sixteen out of 19 of the grafts (84%) were rescued successfully, including two grafts of patients already on hemodialysis at the time of conversion. Graft function of the responders improved from an average serum creatinine level of 364 +/- 109 mumol/L to 154 +/- 49 mumol/L. Of the patients receiving high-dose steroids alone prior to FK506 initiation, 8/9 responded to FK506 treatment, compared with 8/10 of those who had also received OKT3. During the mean follow-up of 35 weeks after conversion, no clinically apparent cytomegalovirus infection and no pneumonia were seen. Treatment with FK506 may successfully suppress ongoing acute rejection, even if antilymphocyte preparations have failed. FK506 can be used at a lower dose than so far recommended without impairing the antirejection potential. An additional anti-infective prophylaxis seems effective in preventing severe complications in the first months after rejection therapy.
Notes:
E R Kuse, M Meyer, R Constantin, K Oldhafer, H J Schlitt, P Schulz-Knappe, H J Uberbacher, R Pichlmayr, W G Forssmann (1996)  [Urodilatin (INN: ularitide). A new peptide in the treatment of acute kidney failure following liver transplantation].   Anaesthesist 45: 4. 351-358 Apr  
Abstract: Acute renal failure (ARF) is a serious complication following liver transplantation. Many therapeutic regimens have been used so far but with limited success. Urodilatin (URO) is a new member of the atrial natriuretic peptide (ANP) family. When administered intravenously, URO induces strong diuresis and natriuresis with tolerable hemodynamic side effects. Preliminary non-controlled clinical studies demonstrate beneficial effects using URO as a therapeutic agent in patients suffering from ARF following heart and liver transplantation (HTx, LTx). These results prompted us to initiate this first controlled clinical trial to investigate whether URO infusion can improve renal function in patients with emerging ARF following LTx.
Notes:
H Bektas, H J Schlitt, K Böker, R Brunkhorst, K J Oldhafer, R Pichlmayr (1996)  [Indications for liver transplantation in severe amanita phalloides mushroom poisoning].   Chirurg 67: 10. 996-1001 Oct  
Abstract: The clinical course of 12 patients with mushroom poisoning was evaluated in order to define the parameters considered to be relevant to the indication for liver transplantation. Eight patients recovered under conservative therapy; one patient died due to pre-existing, concomitant cardiopulmonary disease. In three patients transplantations had to be performed because of severe liver failure. On admission, the transplanted patients had a decreased Quick's test score and factor V value (< 10%). The peak of liver enzymes, serum bilirubin, serum creatinine, partial thromboplastin time and azotemia were not of any prognostic value. Main indications for liver transplantation were a very low initial Quick's test score and factor V value (both < 10%) and their inadequate response under substitution therapy. The development of encephalopathy and renal failure were further parameters indicating poor prognosis.
Notes:
1995
I Lautenschlager, B Nashan, H J Schlitt, B Ringe, K Wonigeit, R Pichlmayr (1995)  Early intragraft inflammatory events of liver allografts leading to chronic rejection.   Transpl Int 8: 6. 446-451  
Abstract: In this retrospective study, we have investigated the early intragraft inflammatory events of 12 liver allografts leading to chronic rejection. The cytological findings and clinical follow-up were analyzed in detail. Nine patients underwent at least one typical lymphoid activation of acute rejection, and three of them were treated more than once. Diagnosis of rejection was based on biopsy histology, cytology and liver dysfunction. In addition to the acute rejections, cytological analysis demonstrated in 11 of 12 grafts an unidentified lymphoid episode that differed from that of rejection. These lymphoid responses were associated with viral infections; cytomegalovirus (CMV) infection in 10 of 12 patients, hepatitis C virus (HCV) infection in 2 of 12 patients, 1 combined with CMV, and hepatitis B virus (HBV) infection in 1 patient. Graft dysfunction was still seen at the end of the follow-up. Thus, intragraft inflammation caused either by acute rejection or by viral infections may be involved in the induction of chronic rejection.
Notes:
H J Schlitt, S Schäfers, A Deiwick, K U Eckardt, T Pietsch, W Ebell, B Nashan, B Ringe, K Wonigeit, R Pichlmayr (1995)  Extramedullary erythropoiesis in human liver grafts.   Hepatology 21: 3. 689-696 Mar  
Abstract: Extramedullary erythropoiesis in the adult is very rare and is generally confined to situations of severe bone marrow irritation or replacement. In this study, we describe the occurrence of intrahepatic erythropoiesis in patients who have received a liver allograft and who have no evidence of bone marrow dysfunction. By routinely performed transplant aspiration cytology (TAC), marked intrahepatic erythropoiesis could be detected in 39 of 312 patients (12.5%) with liver allograft. In 19 patients, including 5 of 8 (63%) after combined liver and kidney transplantation, intrahepatic erythropoiesis occurred within the first 3 weeks after surgery. Twenty patients showed intrahepatic erythropoiesis between 3 weeks and 4 months after transplantation. Erythropoiesis was usually transient, lasting between 1 and 3 weeks. Cytologically, mature as well as immature erythroblasts of GlyA+ CD36+ CD45- phenotype could be detected in the grafts, whereas they were absent in blood; histologically, the cells could be localized to the sinusoids of the liver. There was no clear correlation of preoperative or postoperative hemoglobin levels, graft function, kidney function, and immunosuppressive medication with the presence or absence of erythropoiesis. Moreover, serum levels of erythropoietin (EPO) and stem cell factor (SCF) in patients with and without intrahepatic erythropoiesis in the early postoperative phase did not show significant differences. These findings show that intrahepatic erythropoiesis can occur transiently in human liver allografts and suggest that systemic stimuli as well as local factors may contribute to it.
Notes:
G Steinhoff, M Behrend, N Richter, H J Schlitt, J Cremer, A Haverich (1995)  Distinct expression of cell-cell and cell-matrix adhesion molecules on endothelial cells in human heart and lung transplants.   J Heart Lung Transplant 14: 6 Pt 1. 1145-1155 Nov/Dec  
Abstract: Intercellular reactions and cell-matrix interactions are mediated by a number of specific adhesion molecules. For the intravascular reactivity of leukocytes and thrombocytes the endothelial expression of adhesion ligand molecules is of main importance. This condition may be of special relevance for the organ-specific manifestation of immune reactions in heart and lung transplants. The question was investigated as to whether organ-specific differences exist on arterial, venous, and capillary endothelial lining cells in heart and lung transplants and whether this condition is modified during transplant rejection. Transplant biopsy specimens of 24 heart transplant recipients (n = 303) and lung transplant recipients who underwent retransplantation for rejection (n = 4), as well as normal heart (n = 7) and lung tissue (n = 4), were studied. Cell-cell adhesion molecules (intercellular adhesion molecule-1 (CD54) and -2; LFA-3; CD31; vascular cellular adhesion molecule-1; neural cellular adhesion molecule; E-/P-selectin; CD44) and cell-matrix adhesion molecules (very late antigen-1 through -6; CD51) were studied on cryostat sections by means of standard immunohistology.
Notes:
R Pichlmayr, A Weimann, K J Oldhafer, H J Schlitt, J Klempnauer, A Bornscheuer, A Chavan, E Schmoll, H Lang, G Tusch (1995)  Role of liver transplantation in the treatment of unresectable liver cancer.   World J Surg 19: 6. 807-813 Nov/Dec  
Abstract: Resection remains the treatment of choice in liver cancer. In order to avoid liver transplantation in conventionally unresectable tumors ex-situ ("bench" procedure), in-situ and ante-situm resection technique should be preferred whenever feasible. Despite the deficiency of donor organs, a single center experience with 198 patients reveals that liver transplantation continues its role as a therapeutic option for selected patients. At present "favorable" indications for transplantation are International Union against Cancer (UICC) - stage II hepatocellular carcinoma as well as the subtype fibrolamellar carcinoma, uncommon tumors such as epitheloid hemangioendothelioma, hepatoblastoma, and liver metastases from neuroendocrine tumors. Due to unsatisfying results, intrahepatic bile duct-, stage III and IV hepatocellular carcinoma, hemangiosarcoma, and liver metastases from nonendocrine primaries should be excluded from liver transplantation alone. For these advanced tumors, especially in cases of extrahepatic involvement, a combination of liver transplantation and multivisceral resection has been proven feasible. However, a significant improvement in patient survival may only be expected only by currently investigated multimodality treatment protocols which will require further randomized studies.
Notes:
N Richter, G Raddatz, T Graeter, H J Schäfers, H J Schlitt (1995)  Allogeneic lymphocyte chimerism after clinical lung transplantation.   Transpl Immunol 3: 1. 74-80 Mar  
Abstract: Donor lungs contain large amounts of passenger leukocytes which are transferred to the recipient by organ transplantation. In this study we have analysed the fate of these cells and have studied the populations of donor leucocytes detectable in the blood circulation of ten lung transplanted patients during the first postoperative weeks. To this aim we have applied immunocytological as well as flow cytometric analyses using monoclonal antibodies against polymorphic HLA class I antigens that differed between donor and recipient as well as antibodies against cell differentiation markers. The results demonstrate that donor cells can be detected in the circulation of all lung transplanted patients but there is a considerable interindividual variability between 0.9% and 17.5% (mean 5.1%) on postoperative day 3. Cells were usually detectable for 2-4 weeks and had disappeared in all patients after 1 month. The circulating donor cells consisted exclusively of lymphocytes. T cells were the predominant population, most of which seemed to be CD45R0+, but B and NK (natural killer) cells were also present. Probably due to the small numbers of patients studied no correlation between clinical parameters and the extent of donor lymphocyte persistence; there were no clinical graft-versus-host reactions. The findings demonstrate the regular existence of a transient (macro)chimerism due to passenger lymphocytes in the early phase after lung transplantation. The immunological function and the relation between this phenomenon and the long-term microchimerism which frequently develops after solid organ transplantation remain unclear.
Notes:
B Nashan, R Schwinzer, H J Schlitt, K Wonigeit, R Pichlmayr (1995)  Immunological effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients.   Transpl Immunol 3: 3. 203-211 Sep  
Abstract: The immunological effects of therapeutic monoclonal antibodies (mAbs) depend upon their interaction with the target structure as well as the isotype of the mAb which is responsible for the binding to Fc receptors of accessory cells. The aim of the presented analysis was the evaluation of the in vivo immunosuppressive effect of BT 563, a mAb directed to the alpha-chain of the interleukin-2 receptor (IL-2R). Thirty-eight patients following liver transplantation were treated prophylactically for 12 days with 10 mg/day BT 563 (clinical phase II and III study). As baseline immunosuppression cyclosporin (CyA) and low dose steroids were administered. BT 563 levels, lymphocyte subpopulations, levels of soluble CD25 and Fc receptor polymorphism were evaluated and compared to the clinical outcome. Preoperatively in all patients a small subset of CD45R0+ cells expressed CD25 with detectable density. These cells were coated by BT 563. There was no evidence for depletion of IL-2R+ cells or modulation of the IL-2R. During therapy stable levels of the soluble IL-2R were measured in patient sera. Throughout the therapy high levels of unbound BT 563 were found in sera, suggesting that IL-2R newly expressed on cells activated by the allograft could also be inhibited by BT 563. No acute rejections were observed in these patients and no side effects of BT 563 were noted. There were only minor bacterial infections, while mycotic or viral infections did not appear. Administration of BT 563 together with CyA and low dose steroids to liver allografted patients represents a safe and effective protocol. Its action is likely to be mediated by turning off the pathway of signal transduction of the IL-2R in T-cells by the antibody while IL-2 gene transcription is simultaneously modified by CyA and steroids. The addition of all three immunosuppressive mechanisms is suggested to lead to a state of anergy during mAb application that is reversible at the end of antibody therapy but does not lead to rebound rejections. Analysis of the phenotype of CD25+ cells showed that they preferentially belonged to the CD45R0+ cell type. Thus we assume that BT 563 specifically turns off preactivated cells enabling rather selective and effective immunoprophylaxis in liver allografted patients.
Notes:
H J Schlitt, H J Tischler, B Ringe, G Raddatz, H Maschek, H Dietrich, E Kuse, R Pichlmayr, H Link (1995)  Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation--clinical and immunological considerations.   Bone Marrow Transplant 16: 3. 473-478 Sep  
Abstract: Veno-occlusive disease (VOD) is a frequent complication early after bone marrow transplantation. In cases of severe liver failure treatment by allogeneic liver transplantation is possible. We report the clinical and immunological course of a patient after bone marrow transplantation for AML and subsequent allogeneic liver transplantation for severe hepatic VOD. After liver transplantation the patient recovered well clinically. Early after liver transplantation he had large numbers of liver donor T and NK lymphocytes in his circulation. He had no liver graft rejection, but he developed mild acute GVHD which was caused by liver graft-derived T lymphocytes. Two years after transplantation he had persistent microchimerism with donor liver cells detectable in his bone marrow. Now 36 months after transplantation, the patient has no evidence of recurrent leukemia, stable liver function, and no signs of graft-versus-host disease or bone marrow dysfunction.
Notes:
B Ringe, K Böker, H J Schlitt, J Sproviero, J Hundrieser, H L Tillmann, A Chavan, P Flemming, M Galanski, R Pichlmayr (1995)  Recurrence of hepatitis B virus cirrhosis and hepatocellular carcinoma: an indication for retransplantation?   Clin Transplant 9: 3 Pt 1. 190-196 Jun  
Abstract: Hepatitis B virus reinfection as well as recurrence of hepatocellular carcinoma are frequent complications in liver allograft recipients. This is the report of a patient who had two liver transplantations with a 6-year interval, both for the same indication-postnecrotic cirrhosis and liver cancer. Following first and second transplantation, hepatitis B reinfection occurred at 12 and 6 months, and allograft cirrhosis developed after 20 and 10 months, respectively. Intrahepatic recurrence of hepatocellular carcinoma was found after 69 months. Two years following retransplantation, the patient is tumor-free, and has normal graft function. In selected patients with hepatitis B-related liver disease, and hepatocellular carcinoma liver replacement is indicated when combined with effective immunoprophylaxis, and other adjuvant therapy. Late recurrence of both diseases is unusual, and retransplantation may come into question.
Notes:
T Kiuchi, H J Schlitt, K J Oldhafer, B Nashan, B Ringe, T Kitai, A Tanaka, K Wonigeit, Y Yamaoka, R Pichlmayr (1995)  Backgrounds of early intragraft immune activation and rejection in liver transplant recipients. Impact of graft reperfusion quality.   Transplantation 60: 1. 49-55 Jul  
Abstract: In solid organ transplantation, acute rejections are most frequent during the first weeks. The aim of this study was to investigate the relationship between graft reperfusion injury and later immune responses against the graft. Intragraft immune activation was routinely monitored by transplant aspiration cytology in 47 recipients of hepatic allografts. As a parameter of reperfusion quality, oxygen saturation of hemoglobin (SO2) in hepatic tissue was determined intraoperatively by a near-infrared spectroscopy. Grafts that presented aspiration cytology scores of 2 or more (i.e., more than 10% of lymphocytes activated) at 1 week after operation (group I, n = 14) were associated with a higher heterogeneity of hepatic tissue SO2 at the end of operation (coefficient of variation in 12 points 18.3 +/- 18.3%, mean +/- SD) than grafts with no or very mild intragraft immune activation (group II, n = 33, 9.2 +/- 4.2%; P < 0.01). Group I was also accompanied by higher postoperative peak glutamic oxalacetic transaminase level (corrected by graft size, P < 0.05) and higher donor age (43.9 +/- 12.9 vs. 32.6 +/- 13.9 years, P < 0.02). Heterogenous reperfusion (P < 0.01), higher peak glutamic oxalacetic transaminase level (P < 0.01), and higher donor age (P < 0.05) were also associated with clinical rejection at 1 week (n = 10), but not with later-onset rejection (n = 11). These data suggest that intragraft immune activation and clinical rejection in the early phase after hepatic engraftment are strongly influenced by graft injury, which can be recognized early after reperfusion.
Notes:
1994
N Richter, G Raddatz, G Steinhoff, H J Schäfers, H J Schlitt (1994)  Transmission of donor lymphocytes in clinical lung transplantation.   Transpl Int 7: 6. 414-419  
Abstract: Passenger mononuclear cells in organ grafts are known to influence the alloimmune response to the graft. To assess their relevance in clinical lung transplantation, we studied the amount, distribution, cell types, and surface marker expression of mononuclear cells in human donor lungs. Two major compartments of mononuclear cells could be differentiated: lymph nodes containing resting T and B lymphocytes, and the lung tissue itself, containing mainly activated lymphocytes as well as monocytes/macrophages. Tissue-associated mononuclear cells make up 20-40 x 10(9) cells per lung, about 30-50% of which are lymphocytes. Tissue-associated lymphocytes are predominantly T and NK cells; most of the T cells are CD8+ CD45R0+ and express HLA-DR. Strong expression of the adhesion molecules LFA-1 and ICAM-1 is present on infiltrating cells as well as on resident cells of the organ. Moreover, the lymphocytes inside the lung tissue are functionally highly active, with a strong stimulatory as well as alloreactive potency. Thus, large numbers of allogeneic mononuclear cells and particularly large numbers of functionally active lymphocytes are obviously transmitted by human lung allografts. The immunological in vivo relevance of these cells after lung transplantation may include allostimulation and graft-versus-host activity, but also beneficial immunomodulatory effects.
Notes:
K J Oldhafer, G Gubernatis, H J Schlitt, B Rodeck, K Böker, R Pichlmayr (1994)  Auxiliary partial orthotopic liver transplantation for acute liver failure: the Hannover experience.   Clin Transpl 181-187  
Abstract: APOLT has been developed both to enable the native liver to regenerate in acute liver failure and to avoid the risks of long-term immunosuppressive therapy. We present our experience with APOLT in 4 patients with acute liver failure. The patients were 33, 18, 5, and 34 years of age, respectively. The causes of hepatic failure were: one HELLP syndrome, one paracetamol intoxication, and 2 causes which remained undetermined. All patients were in coma before transplantation. First symptoms had occurred 13, 2, 30, and 20 days prior to APOLT, respectively. In all cases, segments II and III of the recipient's own liver were resected before implanting the auxiliary liver orthotopically. The auxiliary graft consisted of segments II and III in 2 cases and of II, III, and IV in the other 2 patients. The auxiliary graft showed good initial function in all cases. All 4 patients are alive 5 years, 15 months, 6 months, and one month after transplantation. In the last patient, an arterial thrombosis of the graft on the 5th postoperative day required retransplantation. The immunosuppressive therapy could be stopped in 3 cases and the graft was removed in 2 patients 15 and 40 days after APOLT, respectively. This shows that APOLT represents an effective treatment for patients with acute liver failure, which enables restoration of native liver function. Thus, APOLT should be considered in every patient with acute and potentially reversible liver failure in whom a transplantation is indicated.
Notes:
H J Schlitt, J Hundrieser, M Hisanaga, K Uthoff, M Karck, T Wahlers, K Wonigeit, R Pichlmayr (1994)  Patterns of donor-type microchimerism after heart transplantation.   Lancet 343: 8911. 1469-1471 Jun  
Abstract: Allogeneic microchimerism of donor-type has been demonstrated in stable patients in the long-term after organ transplantation. We have analysed microchimerism in skin and blood of 47 heart-transplanted patients after transplantation with polymerase-chain-reaction amplification specific for donor HLA-DRB1. Microchimerism was detectable in 50% of the patients in the first 6 months, in 100% between 6 months and 2 years, and in 58% in the third postoperative year or later. The state of chimerism was not related to acute or chronic rejections. Patterns of microchimerism after heart transplantation may be dynamic, but any association with clinical and immunological variables remains to be elucidated.
Notes:
T Kiuchi, H Kato, S Kanaya, B Nashan, H J Schlitt, T Inamoto, B Ringe, K Ozawa, R Pichlmayr (1994)  Spontaneous proliferation of peripheral blood lymphocytes as an indicator of intragraft immune activation in liver transplant patients.   Clin Transplant 8: 4. 382-387 Aug  
Abstract: The presence of activated lymphocytes in the blood of transplant recipients is considered to be a marker of an ongoing immune process. In this study, the clinical utility of spontaneous proliferation (SP) of peripheral blood mononuclear cells (PBMC) as a marker of in vivo activation was evaluated by in vitro [3H]thymidine incorporation in 22 patients in the 1st month after liver transplantation. Also immune activation in the graft was monitored by transplant aspiration cytology (TAC-A). In the study period, there were only 2 mild episodes of clinical acute rejection, where SP of PBMC was 1290 and 1541 cpm (vs. 99 cpm averaged in healthy controls). Though SP of PBMC was also increased in systemic infections, a significant positive correlation was observed between SP of PBMC and TAC-A score. In all episodes where TAC-A score was elevated to above 2, SP of PBMC was simultaneously increased to more than 1000 cpm. In 8 patients prophylactically treated with the anti-interleukin-2-receptor antibody, BT563, SP of PBMC was significantly lower compared to 7 patients treated with antithymocyte globulin. It is suggested that SP can be a reliable parameter of the in vivo activation of lymphocytes, which accompanies immune activation in liver graft, and is potentially useful as a sensitive, although rather non-specific, and non-invasive monitoring of intragraft alloresponse.
Notes:
I Lautenschlager, B Nashan, H J Schlitt, K Hoshino, B Ringe, H L Tillmann, M Manns, K Wonigeit, R Pichlmayr (1994)  Different cellular patterns associated with hepatitis C virus reactivation, cytomegalovirus infection, and acute rejection in liver transplant patients monitored with transplant aspiration cytology.   Transplantation 58: 12. 1339-1345 Dec  
Abstract: Fine-needle aspiration biopsy (FNAB) is a routine diagnostic tool used for the monitoring of the graft during the first postoperative weeks after liver transplantation. The cellular pattern of acute liver rejection is typical in transplant aspiration cytology (TAC), documented and published by several authors. The lymphoid response associated with various viral infections may, however, provide differential diagnostic problems in the cytological monitoring. In this study, we have investigated in detail the cellular pattern of lymphoid response associated with hepatitis C virus (HCV) reactivation, and compared it with the pattern of cytomegalovirus (CMV) infection and with the typical diagnostic findings of acute cellular rejection. HCV reactivation was associated with rather mild total inflammation in the graft (4.5 +/- 1.5 CIU at the peak). The inflammatory infiltrate consisted mainly of small lymphocytes (3.1 +/- 0.2 CIU at the peak), with only occasional activated cells and without lymphoid blast response. No lymphoid activation was seen in the blood. CMV infection was associated with a mild immune response (3.9 +/- 0.4 CIU at the peak) recorded as a slight lymphoid activation and occasional blast cells both in blood and in the graft together with lymphocytosis in the graft (2.4 +/- 0.7 CIU at the peak). The typical findings of acute rejection were easily distinguished from the cellular pictures of both viral infections. The rejections were lymphoid blast (3.6 +/- 3.4 CIU at the peak) and activated lymphocyte (3.5 +/- 2.6 at the peak), dominated by a high peak of total inflammation (9.3 +/- 7.0 CIU). No blast cells and only a few activated cells were seen in the blood during rejection episodes. Thus, the cellular patterns of HCV reactivation and CMV infection differed slightly from each other, but significantly from that of acute liver allograft rejection monitored with the FNAB cytology.
Notes:
1993
B Trautmann, H J Schlitt, E G Hahn, M Löhr (1993)  Isolation, culture, and characterization of human pancreatic duct cells.   Pancreas 8: 2. 248-254 Mar  
Abstract: To establish a suitable control for pancreatic tumor cell lines, we have isolated and cultured primary human pancreatic duct cells from transplant donors. Duct cells were isolated by dissecting the main pancreatic duct and first-degree branches and enzymatic digestion. Aggregates of cells were cultured for 1 up to 5 weeks and monitored for changes in morphology and growth by phase contrast microscopy. Contaminating fibroblasts were mechanically removed from day 4 on and by cloning of epithelial cells. Cultured cells were characterized by phase contrast microscopy, electron microscopy, and immunofluorescence with antibodies against intermediate filaments (cytokeratins, vimentin, desmin), mucins (Du-Pan-2, CA 19-9), carbonic anhydrase II, acinar cell enzymes (amylase, lipase, trypsin), and islet cells. About 90% of the cultured cells could be identified as ductal epithelial cells by their expression of cytokeratins, mucins, and carbonic anhydrase II. These cells showed the ultrastructural features of duct cells. After 3-5 weeks of culture, most of the cultured cells showed co-expression of cytokeratins and vimentin in addition to duct cell markers. About 10% of cells were contaminating fibroblasts (vimentin positive, cytokeratin negative). The cultured normal human duct cells as the postulated cells of origin of the pancreatic adenocarcinoma may serve as a useful control for cultured pancreatic tumor cell lines.
Notes:
H J Schlitt, R Schwinzer, K Wonigeit (1993)  Responsiveness for mouse IgG2b antibodies to the human alpha/beta T-cell receptor/CD3 complex: evidence for genetic determination and low grade antibody cross-linking not mediated by known Fc gamma receptors.   Scand J Immunol 37: 3. 329-336 Mar  
Abstract: Mouse IgG2a and IgG3 antibodies directed to the human T-cell receptor/CD3 complex stimulate peripheral blood mononuclear cells in almost all individuals. By contrast, responder and non-responder individuals exist for the stimulatory effect of mouse IgG1 and IgG2b antibodies. Whereas responsiveness to IgG1 antibodies is rather frequent (60-70%) and is known to be determined by an Fc gamma RII polymorphism on the accessory cells, little is known about the underlying factors of the rare (6%) IgG2b responsiveness. In this study it is shown that (1) IgG2b responsiveness is genetically determined with a dominant pattern of inheritance; (2) IgG2b responsiveness is determined by a radioresistant feature of responder accessory cells which can be substituted by artificial cross-linking, but not by IL-1 beta or IL-2; (3) stimulation of peripheral blood mononuclear cells of an IgG2b responder by IgG2b antibodies requires rather high antibody concentration compared with stimulation by IgG2a antibodies; (4) the stimulation leads to proliferation and IL-2 receptor expression, but no measurable IL-2 production; (5) antibody binding to known Fc gamma receptors (Fc gamma RI, Fc gamma RII, Fc gamma RIII) is not involved in the stimulatory effect of the IgG2b antibodies in responders. These results demonstrate that responsiveness to IgG2b antibodies against the TcR/CD3 complex depends on a genetically determined feature of accessory cells that is not identical with any of the known Fc gamma receptors. Most likely, the stimulatory effect observed in IgG2b responders is explained by a low grade cross-linking of the antibody by a not yet identified polymorphic structure on the surface of accessory cells.
Notes:
H J Schlitt, G Raddatz, G Steinhoff, K Wonigeit, R Pichlmayr (1993)  Passenger lymphocytes in human liver allografts and their potential role after transplantation.   Transplantation 56: 4. 951-955 Oct  
Abstract: Rare cases of graft-versus-host disease after liver transplantation indicate that donor lymphocytes may be transferred to the recipient by human liver grafts. In this study, we have analyzed the number and subpopulations of donor lymphocytes transferred by liver grafts in order to evaluate the potential relevance of these cells after transplantation. Therefore, mononuclear cells were isolated from the tissue of perfused human donor livers and from the associated lymph nodes. The number of lymphocytes, their location, and surface marker expression were determined by immunostaining. The majority of lymphocytes transferred by the grafts were found within the liver tissue (5.3 +/- 2.9 x 10(9) cells). These lymphocytes are mainly T and NK cells, predominantly CD8+, are partially activated (28% HLA-DR+), and show strong adhesion molecule expression (88% LFA-1(3+)). In addition, 20-500 x 10(6) of resting lymphocytes, predominantly T and B cells, are transmitted by lymph nodes. These findings demonstrate that considerable numbers of donor lymphocytes of distinct phenotype are regularly transmitted to the recipient by human liver grafts and may be of functional relevance after transplantation.
Notes:
H J Schlitt, H Kanehiro, G Raddatz, G Steinhoff, N Richter, B Nashan, B Ringe, K Wonigeit, R Pichlmayr (1993)  Persistence of donor lymphocytes in liver allograft recipients.   Transplantation 56: 4. 1001-1007 Oct  
Abstract: Occasional cases of graft-versus-host disease after liver transplantation indicate a transfer of donor lymphocytes by human liver grafts. However, little is known about the usual fate and potential function of passenger lymphocytes in clinical liver transplantation. In this study, we have analyzed liver graft recipients for the presence of donor lymphocytes in the early course after transplantation. The presence of such cells in blood, the graft, and, occasionally, the skin was studied by the use of mAb to polymorphic HLA class I determinants and double-staining techniques in flow cytometry and immunocytology. The findings were compared with the clinical courses and with the results of routine graft biopsies. Within the first week after transplantation, in all 16 patients, between 1% and 24% donor lymphocytes (T, NK, and B cells) were detectable in blood, and in 14 of 22 patients (64%), between 2% and 23% donor T cells were found in the graft. After more than 2 weeks, donor cells were still present in blood in 2 of 14 patients at very low numbers. The presence of donor lymphocytes in the graft was associated with intragraft immune activation in 5 of 15 patients, but no clinical rejection occurred in these cases; mild graft-versus-host disease was observed in one patient. These findings demonstrate that donor lymphocytes regularly persist in liver-grafted patients for some time; this transient mixed lymphoid chimerism is only rarely associated with clinical graft-versus-host disease and some evidence even suggests that these donor-derived lymphocytes may exert beneficial immunomodulatory properties.
Notes:
1992
R Schwinzer, H J Schlitt, K Wonigeit (1992)  Monoclonal antibodies to common epitopes of the human alpha/beta T-cell receptor preferentially activate CD45RA+ T-cells.   Cell Immunol 140: 1. 31-41 Mar  
Abstract: The murine monoclonal antibody BMA 031 (IgG2b) is directed to a monomorphic epitope on the human alpha/beta T-cell receptor. In contrast to anti-CD3 antibodies of the IgG2b isotype, BMA 031 is able to induce a proliferative response in T-cells from IgG2b low responders. This response occurs independently of cross-linking conditions indicating that the mode of activation differs from stimulation by the anti-CD3 antibody OKT3 (IgG2a) which strictly depends on cross-linking conditions. to further characterize the stimulatory potential of the two antibodies we studied the lymphocyte subsets responsive to stimulation by BMA 031 and OKT3. In CD45RA+ cells both antibodies exhibited similar effects. They induced weak expression of the 55-kDa chain of the interleukin-2 receptor (CD25), virtually no interleukin-2 secretion, but nevertheless strong proliferation. In CD45R0+ cells OKT3 and BMA 031 showed markedly different effects. OKT3 stimulated strong CD25 expression, strong interleukin-2 production, and marked proliferation. In contrast, CD45R0+ cells stimulated by BMA 031 showed only weak CD25 expression but neither interleukin-2 production nor proliferation. These data suggest that CD45RA+ and CD45R0+ cells differ in their capability to produce interleukin-2 upon stimulation via the CD3/T-cell receptor complex and also in the requirement for interleukin-2 to mount a proliferative response. The differential effect of OKT3 and BMA 031 in CD45R0+ cells probably results from the failure of BMA 031 to trigger interleukin-2 production which may be a consequence of its inability to induce CD3/T-cell receptor cross-linking in IgG2b low responders BMA 031 is therefore a useful tool for the selective activation of CD45RA+ cells in these individuals.
Notes:
H J Schlitt, B Nashan, P Krick, B Ringe, C Wittekind, K Wonigeit, R Pichlmayr (1992)  Intragraft immune events after human liver transplantation. Correlation with clinical signs of acute rejection and influence of immunosuppression.   Transplantation 54: 2. 273-278 Aug  
Abstract: Evaluation of graft morphology is regarded as a cornerstone for diagnosis of acute liver graft rejection. Here we have studied the clinical relevance of biopsy findings obtained either by aspiration cytology or by histology in the first month after human liver transplantation, and have assessed the influence of immunosuppressive induction treatment on the incidence of morphological and clinical rejection. Results of 865 aspiration biopsies (TAC) and 155 core biopsies in 141 patients were correlated with the retrospective clinical diagnosis concerning the presence or absence of acute rejection. This analysis demonstrated that there are almost no false negative findings either in cytology or in histology (less than 0.1% of negative biopsies). In contrast, with both methods a large number of positive biopsy results were obtained that were without clinical correlate ("false positive" biopsies; 46% and 41% of positive cytologies and histologies, respectively). The rates of clinical and morphological acute rejections were differently influenced by the type of immunosuppressive induction protocol used. The incidence of clinical rejection was particularly low with a quadruple drug regimen when cyclosporine therapy was started immediately after transplantation (29% vs. 62% when introduction of cyclosporine was delayed for 2-5 days). Morphological rejections were similarly frequent with immediate and delayed introduction of cyclosporine at 2 mg/kg during quadruple therapy (65-75%) and were only reduced with initial high dose cyclosporine treatment (5 mg/kg) (35%). Antirejection treatment was not required in patients with morphological evidence of rejection but without clinical symptoms. The study demonstrates that cytology and histology are similarly reliable for exclusion and similarly unreliable for diagnosis of clinical acute rejection. The clinical relevance of positive biopsy findings is strongly influenced by the basic immunosuppressive treatment. Certain types of induction treatment can obviously alter the alloresponse in a way that no graft damage occurs despite the presence of marked intragraft immune activation. "False-positive" biopsy findings, therefore, seem to represent a qualitatively modified and self-limited type of intragraft alloresponse that is without clinical consequences ("incomplete" or "subclinical" rejection).
Notes:
1991
U Christians, K Kohlhaw, J Budniak, J S Bleck, R Schottmann, H J Schlitt, V M Almeida, M Deters, K Wonigeit, R Pichlmayr (1991)  Ciclosporin metabolite pattern in blood and urine of liver graft recipients. II. Influence of cholestasis and rejection.   Eur J Clin Pharmacol 41: 4. 291-296  
Abstract: The pattern of metabolites of ciclosporin in blood and 24 h-urine of 58 liver graft recipients was routinely monitored by HPLC from transplantation until discharge from hospital. Liver function and ciclosporin metabolite pattern in patients with an uncomplicated clinical course and in those with cholestasis or acute rejection were compared. During cholestasis M19 and M1A, and during acute rejection M19, in blood were significantly elevated compared to the control group. Blood M19 was significantly correlated with bilirubin concentration and gamma-glutamyl transferase activity in serum, and M1A with the serum bilirubin concentration. Analysis of the metabolite pattern over the observation period showed higher concentrations of M19 and M1A in blood from patients with cholestasis and acute rejection than in the control group; concentrations were lower in the rejection group than in the cholestasis group. The metabolite pattern in 24 h-urine showed similar alterations in ciclosporin metabolite pattern to those in blood. Cholestasis and rejection shift the ciclosporin metabolite pattern in blood and urine to higher concentrations of M19 and M1A, whereas the concentrations of other metabolites and ciclosporin were not significantly affected.
Notes:
U Christians, K Kohlhaw, J Budniak, J S Bleck, R Schottmann, H J Schlitt, V M Almeida, M Deters, K Wonigeit, R Pichlmayr (1991)  Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity.   Eur J Clin Pharmacol 41: 4. 285-290  
Abstract: Blood ciclosporin (Cs) metabolite pattern in 58 liver grafted patients was routinely monitored by HPLC from the first Cs dose after transplantation until discharge from hospital. Eighteen patients with normal kidney function were allocated to Group I and 14 patients in Group II suffered Cs nephrotoxicity during their clinical course. There were no significant differences between both groups in blood Cs level, kidney function before transplantation, liver function or co-administration of other potentially nephrotoxic drugs. A correlation matrix involving both groups showed a significant correlation between the blood concentration of metabolite M1c9 and serum creatinine and urea, and an inverse correlation with creatinine clearance. During a nephrotoxic episode the blood concentrations of metabolites M1c9 and M1A were significantly elevated in patients in Group II. Analysis of the time course revealed significantly higher blood levels of M19 and M1c9 in Group II patients compared with those in Group I for the first 10 days after transplantation. Serum creatinine and urea concentrations remained significantly elevated, the creatinine clearance being significantly reduced throughout the period of observation. The elevated blood concentrations of ciclosporin metabolites M1c9 and M19 during nephrotoxic episodes suggest that these metabolites are associated with ciclosporin nephrotoxicity. It could not be decided if the elevated metabolite concentrations were the result of and/or the reason for impaired kidney function.
Notes:
J S Bleck, H J Schlitt, U Christians, R Schottmann, C Thiesemann, S Strohmeyer, K Kohlhaw, K Wonigeit, R Pichlmayr, K F Sewing (1991)  Ciclosporin metabolite pattern in blood and urine of kidney graft patients in relation to liver function.   Eur J Clin Pharmacol 40: 6. 565-569  
Abstract: Ciclosporin, an immunosuppressant, is metabolized by the liver cytochrome P450 system. Changes in the pattern of its metabolites in blood and urine in patients with disturbed liver function have been studied. Forty seven kidney graft patients receiving 2.9 mg/kg/d ciclosporin b.i.d., and no additional medication that would interfere with ciclosporin metabolism, were allocated to three groups according to liver function: I with normal liver function (n = 19), II with elevated liver enzyme activity or bilirubin concentration in serum (n = 20), and III with cholestasis (n = 8). Ciclosporin and 17 metabolites were determined in blood and 24 h-urine. In blood the trough concentrations of metabolites M19 and M1A were significantly higher in group III than in groups I and II. The total quantity of metabolites excreted in 24 h-urine was significantly different for H230, M4N69 and M1A (group III greater than I = II). Renal excretion of the daily dose of ciclosporin in patients in group I was 2.7%, group II 3% and group III 5.7%. In group III compared to group I the ciclosporin metabolite pattern was shifted to a relatively higher concentration of M19 in blood and of H 230, M19 and M1A in urine. Since high ciclosporin metabolite concentrations appear to be associated with nephrotoxicity, the metabolite pattern in patients with impaired liver function should be monitored.
Notes:
H J Schlitt, U Christians, J Bleck, K Kohlhaw, B Ringe, H Bunzendahl, K F Sewing, K Wonigeit, R Pichlmayr (1991)  Contribution of cyclosporin metabolites to immunosuppression in liver-transplanted patients with severe graft dysfunction.   Transpl Int 4: 1. 38-44 Apr  
Abstract: The aim of this study was to analyse the immunosuppressive contribution of cyclosporin metabolites in liver-grafted patients. Therefore the immunosuppressive potency of 17 metabolites, alone and in combination, was tested in human mixed lymphocyte cultures, and the results were correlated with metabolite blood levels in liver-grafted patients. Of the 17 metabolites tested only six highly lipophilic metabolites showed a detectable immunosuppressive activity of up to 10% of the activity of cyclosporin; the effect of combining metabolites was additive. For calculation of the in vivo activity, blood levels of seven major cyclosporin metabolites were determined in liver-grafted patients with normal liver function (group A, 43 episodes) and with severe hyperbilirubinaemia (group B, 66 episodes). Both patient groups had comparable levels of parent drug (122.9 +/- 17.4 vs. 111.1 +/- 23.5 ng/ml by HPLC) and similar blood levels of the highly lipophilic metabolites 17, 1 and 18. By contrast, blood levels of the less lipophilic metabolites 8, 9, 26 and 203-218 were substantially increased in group B (P less than 0.05). High overall metabolite blood levels in group B were also indicated by a non-specific monoclonal RIA (520 +/- 199 ng/ml for group A vs. 1318 +/- 407 ng/ml for group B). Despite the very high levels in group B, however, the overall contribution of the metabolites to immunosuppression was similar in both groups (12.6 +/- 5.0% for group A vs. 13.8 +/- 5.6% for group B). These findings indicate that, despite a marked accumulation of cyclosporin metabolites in patients with severe cholestatic liver dysfunction, their immunosuppressive contribution remains low.(ABSTRACT TRUNCATED AT 250 WORDS)
Notes:
R Schwinzer, H Sommermeyer, H J Schlitt, R E Schmidt, K Wonigeit (1991)  Activation of human thymocytes by antibodies to the CD3/T-cell receptor complex: triggering of different epitopes results in different signals.   Cell Immunol 136: 2. 318-328 Sep  
Abstract: Monoclonal antibodies (mAb) against the CD3/T cell receptor (TcR) complex were analyzed for their ability to activate human thymocytes. In addition to mAb detecting epitopes on the CD3 complex (OKT3, BMA 030) the activation potential of recently developed mAb against common epitopes on the alpha/beta T-cell receptor (anti-TcR mAb: BMA 031, BMA 032) was evaluated. Several differences were observed between the two types of mAb: (a) Binding of the tested anti-CD3 mAb to thymocytes resulted in a rapid increase in the level of cytoplasmic free calcium ions [Ca2+]i, whereas no significant changes in [Ca2+]i were detected in thymocytes stimulated with BMA 031 or BMA 032. (b) Induction of effective proliferation induced by mAb OKT3 depended on exogenous IL-2 and in addition on the presence of accessory cells or phorbol-ester. Proliferation induced by BMA 031 only required exogenous IL-2. (c) OKT3 but not BMA 031 inhibited proliferation of thymocytes induced via the CD2 molecule. These studies indicate that anti-CD3 and anti-TcR mAb transduce different signals in thymocytes. Since the two types of mAb are directed to the same molecular complex the observed differences also support the idea that there are functionally different compartments in the CD3/TcR complex which may activate different signaling pathways.
Notes:
H J Schlitt, U Werner, P Schandelmaier, C Krettek, K Dreinhöfer, J Hauss, R Pichlmayr (1991)  [Acute posttraumatic lung failure. Its treatment through pressure-limited respiration and continuous postural change].   Dtsch Med Wochenschr 116: 34. 1257-1264 Aug  
Abstract: Nine patients (4 women and 5 men; mean age 31 [20-48] years) with severe posttraumatic adult respiratory distress syndrome (ARDS) were treated with continuous postural change (kinetic bed) and pressure-limited ventilation. Seven patients survived; only one patient died as a result of pulmonary insufficiency. As compliance was markedly reduced (less than 20 ml/cm H2O), low stroke volumes (up to 380 ml) and high respiratory rate (up to 45/min) were employed to keep airway peak pressure below 40 mmHg. Kinetic treatment lasted for a mean of 14 (2-28) days; artificial ventilation was maintained for 31 (9-49) days. Practical problems of the method are the intensive nursing care required for the kinetic bed and the risk of decubitus ulcers, as well as disconnection of infusion tubing. The results indicate that kinetic treatment with pressure-limited ventilation constitutes a low-risk and, in many cases, effective treatment of severe ARDS.
Notes:
H J Schlitt, B Nashan, B Ringe, H Bunzendahl, C Wittekind, K Wonigeit, R Pichlmayr (1991)  Differentiation of liver graft dysfunction by transplant aspiration cytology.   Transplantation 51: 4. 786-793 Apr  
Abstract: Episodes of graft dysfunction are frequently observed after liver transplantation and can be due to different causes requiring specific therapy. In this study the usefulness and reliability of liver transplant aspiration cytology (TAC) for differential diagnosis of liver graft dysfunction is assessed. Out of more than 1500 TACs performed, 292 TACs, taken during episodes of liver dysfunction due to retrospectively defined causes, were analyzed. Immune activation and parenchymal damage in the aspirates were determined cytologically. In 63 episodes of acute rejection, marked immune activation was present in aspirate but not in blood, with varying degrees of hepatocyte damage and cholestasis. No or only minimal immune activation was observed in 86 cases of toxic, ischemic, or septic liver damage, but considerable parenchymal damage and cholestasis were observed. In 3 cases of hepatitis slight-to-moderate immune activation with large granular lymphocytes was found in the aspirate, while 17 cases of viral infection presented with slight-to-moderate immune activation in aspirate and blood. After successful treatment the cytologic patterns normalized, except when the cause of liver dysfunction persisted. Moreover, typical patterns of parenchymal changes were found for preservation damage of the liver (n = 108), fatty degeneration (n = 3), obstructive cholestasis (n = 5), and acute arterial ischemia (n = 2). One case of moderate subcapsular hematoma was the only complication observed (less than 0.1%). Thus, liver TAC is an easy, safe, and clinically useful method for differential diagnosis of liver graft dysfunction. In particular, differentiation between acute rejection and nonimmunologic causes of dysfunction is very reliable, but hepatitis and viral infections also present distinctive patterns in liver TAC.
Notes:
1990
H J Schlitt, R Schwinzer, K Wonigeit (1990)  Different activation states of human lymphocytes after antibody-mediated stimulation via CD3 and the alpha/beta T-cell receptor.   Scand J Immunol 32: 6. 717-726 Dec  
Abstract: BMA031 is an IgG2b antibody directed towards the human alpha/beta T-cell receptor that is able to induce proliferation of peripheral blood mononuclear cells independent of antibody crosslinking. The proliferative response to BMA031 during the first 3 days of culture is usually of similar magnitude to that induced by the IgG2a CD3 antibody OKT3 but decreases quickly afterwards. Stimulation by BMA031 induces no measurable IL-2 release, very low expression of the IL-2 receptor, and does not trigger cytotoxic effector function. However, cross-linking of the antibody or addition of IL-2 leads to enhanced and prolonged proliferation, strong IL-2 receptor expression, and cytotoxic activity, features that are usually found after stimulation by the IgG2a CD3 antibody OKT3 in soluble form. The stimulatory effect of BMA031 cannot be diminished by IL-2 receptor blocking, whereas stimulation by OKT3 is strongly reduced. Moreover, proliferation induced by BMA031 has lower sensitivity to inhibition by ciclosporin than OKT3. From these results two major conclusions can be drawn: (1) an IL-2-independent way of activation may be important for the short-term proliferation of the T cells stimulated by BMA031 and (2) after stimulation by BMA031, cells reach a state of activation that is different from that induced by OKT3. These differences are most likely related to the different specificities of the antibodies, alpha/beta TcR versus CD3, suggesting that different activation signals are triggered via CD3 and via the alpha/beta TcR.
Notes:
1989
H J Schlitt, R Kurrle, K Wonigeit (1989)  T cell activation by monoclonal antibodies directed to different epitopes on the human T cell receptor/CD3 complex: evidence for two different modes of activation.   Eur J Immunol 19: 9. 1649-1655 Sep  
Abstract: The mouse monoclonal antibody (mAb) BMA031 (IgG2b) has recently been described to be directed against a monomorphic part of the human T cell receptor (TcR) alpha/beta. In vitro analysis of its stimulatory potential for mononuclear cells revealed two patterns of responsiveness. Out of 35 tested individuals only 2 generated a proliferative response to low antibody concentrations (15 ng/ml; "high responders"), the others ("low responders") responded only to high antibody concentrations (1.5 micrograms/ml); the anti-CD3 mAb UCHT1 (IgG2b) stimulated only the two high responders. This response pattern to BMA031 was determined by the accessory cell compartment in the culture. Stimulation by BMA031 in low responders demonstrated some unusual features: (a) high antibody concentrations were required, (b) addition of autologous serum had no inhibitory effect and (c) vigorous depletion of macrophages reduced but did not abolish the proliferative response. These characteristics were shared by two other mAb, BMA032 and BW239/347, presumably directed against the TcR alpha/beta but not by several other antibodies to the TcR/CD3 complex. Thus, the results demonstrate unusual stimulatory properties of three anti-TcR alpha/beta mAb, inducing a proliferative response without antibody cross-linking. This suggests that the stimulatory effect of anti-TcR/CD3 complex mAb is not only determined by their isotype, but also strongly depends on their epitope specificity.
Notes:
J S Bleck, H J Schlitt, U Christians, C Thiesemann, S Strohmeyer, R Schottmann, K Kohlhaw, K Wonigeit, K F Sewing (1989)  Urinary excretion of ciclosporin and 17 of its metabolites in renal allograft recipients.   Pharmacology 39: 3. 160-164  
Abstract: Renal elimination of the immunosuppressant ciclosporin is virtually unknown. Therefore, in 17 renal allograft recipients under steady-state conditions we studied the urinary excretion of ciclosporin and 17 of its metabolites in blood and 24-hour urine. Patients with liver dysfunction or treated with drugs potentially influencing the metabolism and elimination of ciclosporin were excluded from the study. Ciclosporin and its metabolites were measured by HPLC. Metabolite but not ciclosporin excretion was strongly correlated with creatinine clearance. Metabolites 18 and 26 (beta, epsilon-cyclic metabolite) were rarely found in blood but were excreted in considerable amounts in urine. Approximately 3% of the administered dose of ciclosporin per day undergoes renal elimination in unchanged form or as metabolites investigated. The data suggest glomerular filtration of ciclosporin metabolites, a difference in the rate of elimination between ciclosporin and the metabolites and some kind of metabolism or active transport mechanism for metabolites in the kidney.
Notes:
1988
1987
Powered by PublicationsList.org.